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Natural toxins and artificial toxicants are abundant throughout our environment 
and may play an integral role in remodeling our epigenome and in the development of 
neural diseases.  Exposure to heavy metals and organic pollutants, such as DDT and its 
derivatives, have been linked to neural disease.  Additionally, there are links between 
direct exposure, in both adults and children, to short-lived pesticides and neural diseases.  
While the link has been established, understanding the root cause has yet to be elucidated.   
One increasingly relevant field offering promise in achieving this goal is epigenetics. 
Epigenetic remodeling is one potential mechanism by which environmental exposures 
may lead to human disease.   Epigenetic remodeling events have been increasingly 
implicated in the underpinnings of a variety of brain disorders including 
neurodegenerative disorders and cancer.  We hypothesize that environmental exposures 
and associated epigenetic remodeling events may occur early in life during the critical 
development stages and play a role in long term development of many neural diseases.  
We examine the current status of the field and highlight areas in need of attention and 
propose a model toxicant for understanding the effects of early epigenetic remodeling 
events and the impact of disease by examining the ability of the environmental toxicant 
Paraquat to remodel the epigenome both in vitro and in vivo, and investigate whether 




EARLY NEURAL DEVELOPMENT CHANGES MAY AFFECT THE LONG 
TERM HEALTH OF THE NERVOUS SYSTEM. 
 
Introduction 
Neurodegenerative disorders and brain cancers are increasingly prevalent and 
present significant medical and societal problems that are expected to increase as our 
population ages and the onset of these diseases increases.  While the true cost of 
malignant gliomas, including indirect and societal costs has not yet been fully evaluated, 
outdated values of treatment are greater than $100,000 US per patient per year [1]. 
Indeed, the Agency for Healthcare Research and Quality puts a valuation on the direct 
cost of medical treatment in 2011 at 88.7 billion US dollars within the United States 
alone [2].  Alzheimer’s is the most prominent neurodegenerative disease with a 71% 
increase in number of deaths from Alzheimer’s from 2010 to 2013.  The cost of 
Alzheimer’s disease is estimated at 236 billion US dollars in healthcare and long term 
care related costs.  Parkinson’s disease is another prominent neurodegenerative disease 
with an economic burden on the United States of approximately 14 billion US dollars in 
2010 [3].  The economic burden of disease is one factor that is more easily quantified 
than other burdens induced by neural diseases.  Each of these diseases has a specific set 
of symptoms that create undue burden on these patients.  Mean survival from 
glioblastoma multiforme is approximately 12 months and current therapies extend life by 
6 months over standard chemotherapy and radiation [4, 5].  Other less aggressive gliomas 
that offer better prognosis for survival with treatment still retain the burden of cognitive 
deficit and loss of function depending on the brain region affected [6, 7].  Alzheimer’s 
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and Parkinson’s have their own unique symptoms with some crossover including 
cognitive deficit.  These diseases are almost all progressive and as of yet they are 
incurable largely because the root causes have not been elucidated.  While these diseases 
are often considered multifactorial the epidemiological data implicates an environmental 
component in these diseases. 
Epidemiological Links Between Environmental Exposure and Disease 
Epidemiological evidence implicates a role for toxic environmental exposure in 
the development of neural disease.  Exposure to commercial pesticides increases the odds 
ratio of childhood onset gliomas with greater odds ratio if exposed during the gestational 
period [8].  A study conducted in China for children exposed to pyrethroid pesticides 
determined that children with high levels of pesticide metabolite in the urine had the 
highest odds-risk ratio of 3.26 with a 95% confidence interval of 1.73 to 6.14 in having a 
childhood brain tumor [9].  In the same study, the parents that had been self-reported to 
be exposed to mosquito and cockroach killing pesticides had an increased odds-risk ratio 
for their children developing childhood brain tumors.   Meta-analysis of epidemiological 
studies indicate an increased risk of childhood brain tumors if either parent is exposed 
during or before pregnancy with a higher risk from prenatal paternal exposure to 
agricultural pesticides [10].  Prenatal exposures to lead and p,p’-DDE (a metabolite of 
DDT, a persistent organic pollutant) have a higher risk for behavioral abnormalities in 
children [11].  Chlorpyrifos exposure in adolescent Egyptian pesticide applicators show 
decreased function in neurobehavioral tests as compared to their controls [12].   In the 
same study, the control group show greater levels of chlopyrifos metabolite in urine 
samples than that of US adolescents indicating ready availability from environmental 
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exposure.  Acute exposure risk in children as well as assessment of the field of 
environmental toxicants in high level exposure has been detailed in a recent review [13].  
The authors highlight a growing need to understand the full impact of toxicants on the 
health of children, highlighting a need for work in low dose chronic exposures.   
Adult exposure to pesticides presents its own set of risks to the exposed 
individual.  Adults having high urinary levels of organochlorine pesticides increases the 
odds-risk ratio for cognitive decline [14].  In adults exposed to pesticides for ectoparasite 
control, used in sheep farming, there was an increased risk of neurodegenerative disease 
including parkinsonism, dementia, and neuropathy [15].  Often there is an increased risk 
of neurodegenerative disease associated with living in a rural environment, and often this 
has been attributed to pesticide exposure [16-18].  A detailed examination in California 
examined the links between specific pesticides and Parkinson’s disease.  Utilizing 
pesticide use reporting system data, mandated by California law, the authors were able to 
examine pesticide interactions with specific genetic variants offering insight into 
susceptibility of specific populations to Parkinson’s disease [19].  This study offered a 
unique perspective into the length of exposure not commonly available to 
epidemiological data.    These studies implicate pesticide exposure in an increased risk 
for neurodegenerative disorders or cognitive decline in adult exposure. 
There appears to be a delineation of effect according to exposure period in these 
epidemiological studies; prenatal and early childhood exposure may increase risk of 
childhood brain tumors as well as neurobehavioral impairments, whereas adult exposure 
may lead to an increased risk for neurodegenerative disease.  This may be the result of 
the developmental period versus the matured brain, and it may be an artifact of how these 
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studies were designed, but this hypothesis merits additional investigation.  Oxidative 
stress, produced by many environmental toxicants, has been implicated in 
neurodegenerative disease and in adult neurons the ability to compensate for increased 
stress may be reduced from compensatory capability in development [20].  Oxidative 
damage has been linked to increased risk of cancer as well [21, 22].  It may be likely that 
early development may be prime for toxicant disruption of normal differentiation 
pathways leading to the development of a cancerous phenotype.  Alternatively, this may 
be an effect of the focus of epidemiological studies and the lack of longitudinal exposure 
studies.  This calls to our attention the need to develop longitudinal studies of high risk 
for toxicant exposure cohorts to understand fully the critical exposure windows for 
developing neural disease and if early exposure versus late exposure may be the deciding 
factor for increased risk of neural cancer or neurodegenerative disease (figure 1).  Our lab 
is interested in focusing on the early development exposures and the effect on future 
disease generation.  
Barker Hypothesis of Disease 
The idea that an early development stress leads to disease later in the life of the 
affected individual is not new.  The Barker Hypothesis was originally proposed by David 
Barker in 1990 where he hypothesized that intrauterine growth retardation, low birth 
weight, and premature birth have a causal relationship to the origins of health disparities 
in later life including cardiovascular disease and insulin resistant diabetes [23].  The 
supporting evidence for the Barker Hypothesis, alternatively known as the Thrifty 
Phenotype Hypothesis, comes from both epidemiological and animal studies and 
primarily focuses on metabolically oriented diseases [24].  Animal studies allow for the 
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carefully controlled environment without other confounding variables inherent in 
epidemiological studies.  Male and female mice that have been immune challenged prior 
to mating have been shown to sire larger, faster growing offspring conferring a potential 
fitness advantage [25].  Other studies have shown that male rats with reduced protein 
intake developed a diabetic phenotype which abated after reconditioning with normal 
protein diet indicating there is a critical window for reprogramming [26].  Neonate rats 
can be preprogrammed in a thrifty phenotype response with corticosterone exposure in 
early life that leads to more severe diabetic phenotype when rendered diabetic [27].  All 
of these studies indicate that there is a window of opportunity during which 
environmental events can impact disease and health state later in life. 
The Barker hypothesis, however, is not limited to metabolic diseases; early 
exposure of cohorts to famine increased risk of gastrointestinal cancers with the youngest 
cohort having the greatest risk when compared to later adolescent stage cohorts [28].  We 
can expand this hypothesis based upon epidemiological evidence to include other early 
development perturbations and their effect on disease.  This hypothesis is especially 
attractive as many neural diseases do not have a clear origin and may be attributable to 
such early events not previously considered.  A review of literature focusing on early life 
exposures and DNA methylation, an epigenetic mark, hypothesizes that DNA 
methylation may be a mechanism by which the Barker Hypothesis may work [29].  
Indeed, with the expansion of the epigenetics field and how critical epigenetics is to the 
study of the brain; there is cause to investigate early exposure events in addressing the 





Neuroepigenetics is a newly emerging field that focuses on how epigenetic 
mechanisms can impact neuronal and neuroglial function.  Being that epigenetics 
involves the study of heritable, reversible modifications that control gene function, the 
focus on neural epigenetics only began emerging after the realization that some of the 
epigenetic control mechanisms need not be inherited to be altered and have an impact 
[30].  J. D. Sweatt even highlights that the field of neuroepigenetics has helped to 
redefine the epigenetics field as a whole for this reason. This includes DNA methylation 
which was once thought to be an inherited epigenetic mark.  Considering that neurons are 
post mitotic; their DNA methylation profile should have a stable DNA methylation 
signature.  The field has since shown that the methylation profile is dynamic and 
incorporates other cytosine markers. 
Currently, the focus of neuroepigenetics is largely on neurons and the 
transcriptional control that epigenetics allows in these post-mitotic cells which allows 
them the ability to adapt to current environments.  There is increasing evidence that 
neuroepigenetics is involved in development, learning and memory and environmental 
stress response in neurons.  There is some evidence that astrocytes, a critical support cell 
within the nervous system, are also utilizing some of the same mechanisms and impacting 
neuronal epigenetics.  Here we will briefly overview the major epigenetic components 
and their relevance in the neural system. 
DNA modifications 
DNA methylation is a hallmark epigenetic mark that is probably the most well 
understood mark in terms of function.  DNA methylation is the addition of a methyl 
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group to the 5’ carbon in cytosine bases.  This mark is typically associated with cytosine 
guanine pairs (CpG) and has knownregulatory function in association with regions of 
DNA 200 base pairs or larger that contain greater than 50% CpGs termed CpG Islands 
and have an observed over expected ratio of cytosine and guanine greater than 60% [31].  
The importance of CpG islands first emerged within the context of cancer and 
understanding that hyper-methylation led to inactivation of tumor suppressor genes [32].  
However, it is evident that the regions 2000 or 4000 base pairs up and downstream, 
termed CpG shores and shelves respectively, are important in gene regulation [33, 34].  
These regions may also be important in the differentiation of tissues and cell types and 
therefore important in identifying the cells of origin of cancer [35].  Research has shown 
that when an island region is heavily methylated and within or near a promoter region, 
there is a strong correlation with down regulation of the associated gene [32, 36-38].  The 
presence or absence of DNA methylation can also alter binding sites of transcription 
factors which plays a role in the impact of DNA methylation [39]. 
In the mammalian brain, the majority of DNA methylation changes occur outside 
of CpG islands during development [40, 41].   In fragile X syndrome the methylation 
outside of CpG islands in the FMR1 gene can predict anatomical structure of the brain 
[42].  Neural Progenitor cells exhibit a strong correlation between DNA methylation and 
histone mark changes compared to embryonic stem cells which have poor correlation 
[43].  This may be due to the differentiation of the neural progenitor cells being further 
along in the differentiation process, as the highest correlation exists between increased 
DNA methylation and the loss of open chromatin marks.  This suggests that some of the 
previously available genes are being “closed” off for neural progenitor cells.  There may 
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be interplay with proteins capable of recognizing and binding the methylation marks as 
well. 
There are a number of methyl binding proteins, but one protein of known 
significance in the human brain is methyl-CpG binding protein 2 (MECP2), as the 
absence or mutation of this protein produces Rett Syndrome [44].  Rett syndrome 
produces severe cognitive deficits as well as craniofacial deformities and cranial 
neuropathy.  Females with Rett syndrome are heterozygous for the non-functional 
MECP2 and mouse models have been established to evaluate the development of 
abnormalities [45].  The deficits associated with non-functional MECP2 can be rescued 
in an animal model with the reintroduction of functional MECP2 [46].  MECP2 is also 
capable of recognizing other cytosine modifications such as 5-hydroxymethylcytosine 
[47].  This emphasizes the importance of evaluating other DNA modifications in addition 
to 5-methylcytosine. 
DNA methylation is a stable mark and was originally thought to be semi-
permanent epigenetic mark, erasable only though DNA damage and repair mechanisms 
[48].  However, with recent advances, DNA methylation has been discovered to be more 
dynamic in the context of a single cell.  With the discovery of Tet enzymes and their 
ability to hydroxylate the methyl group, new research has our understanding of potential 
molecular mechanisms by which the methyl group can be removed [49].  5-
methylcytosine is hydroxylated to form 5-hydroxymethylcytosine and subsequently 
converted to a number of other intermediaries and replaced with an un-methylated 
cytosine in a base excision repair pathway [50].  This implies that 5-
hydroxymethylcytosine is only intermediate and plays no particular role as an epigenetic 
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mark.  In the human brain however, there is evidence that 5-hydroxymethylcytosine is 
itself and epigenetic mark and can be associated with increased gene expression [51, 52].  
This is thought to be an important feature in the post mitotic neurons as a mechanism 
with which to regulate gene expression and may play a critical role in synapse formation 
and memory function [53]. 5-HMC is more prevalent the brain and is developmentally 
correlated, as the mark wanes as aging occurs [47, 54]. 
Another important finding is that DNA methyltransferase 1 (DNMT1) cannot 
recognize the 5-hydroxymethylcytosine form and subsequently will not add a methyl 
group to the daughter strand during replication [55].  It may also play a role in altering 
the methylation profile as DNMT1 is required to maintain DNA methylation [56].  
DNMT1 has been shown to be recruited during gene transcription to maintain the 
methylation profile as it exists [57].  If DNMT1 is unable to recognize 5-
hydroxymethlcytosine, the methylation mark may be ultimately removed during normal 
replication.  Interestingly, DNMT1 may not be the only protein unable to recognize 5-
hydroxymethylcytosine, raising the possibility of inhibiting recruitment, an idea that 
deserves more attention.  Case in point is the correlation between 5-HMC presence and 
MECP2 occupancy; such a correlation might suggest that MECP2 does not recognize 5-
HMC [47].  In contrast, MBD3, part of the Nucleosome Remodeling and Deacetylase 
complex (NURD), requires 5-HMC to be present to bind chromatin and the loss of this 
function alters gene expression profiles [52].   
We are now beginning to assess the effect of environmental influences on changes 
in DNA methylation, especially in regards to pesticide exposure.  Using a stress model in 
mice, physical restraint for a period of 30 minutes, investigators found changes in 5-
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hydroxymethylcytosine in adult hippocampus [53].  The majority of these changes 
exhibited increased levels of 5-hydroxymethylcytosine with approximately 20% being 
loss of the mark.  Oxidative stress influences DNA methylation levels of cells exposed in 
vitro to hydrogen peroxide with a global reduction of 5-methylcytosine [58].  While this 
study did not evaluate the global levels of 5-hydroxymethylcytosine, they were able to 
assess a loss in TET activity.  In contrast to this another group evaluated global 5-
hydroxymethylscytosine levels in the presence of redox-active quinones and found an 
increased TET function and increasing levels of 5-hydroxymethylcytosine [59].  The 
authors found that redox active quinone induction of 5-hydroxymethylcytosine was iron 
dependent.  This offers a potential window of understanding duringwhich environmental 
toxins may be the most prominent in altering the epigenome.    Exposure to long lived 
pollutants such as organochlorines shows an increased association with hyper-
methylation of MGMT, a DNA repair enzyme often hyper-methylated in glioblastoma 
multiforme [60].  Of the two pollutant groups assessed, organochlorine pesticides and 
polychlorinated biphenyls, the association curve was dependent upon the group assessed.  
Organochlorine pesticides group has a decreasing association of MGMT hyper-
methylation with higher serum concentrations, while polychlorinated biphenyls exhibited 
a peak of MGMT hyper-methylation in midlevel serum concentrations.  Additional in 
vitro evaluation of pesticide exposure has shown that some pesticides are capable of 
inducing DNA methylation changes after a 12 hour exposure utilizing chip arrays 
originally designed for cancer epigenome measurements [61].  This study highlights both 
that pesticides are capable of inducing DNA methylation changes in vitro but also 
highlights the limitations of utilizing chip arrays.  Chip arrays offer a glimpse into the 
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methylation status after testing experimental variables, however they are limited in the 
sites they can query.  As these arrays were initially set up for cancer analysis, the 
majority of sites queried are near CpG islands limiting the capability to study regions 
outside of the CpG islands.  As CpG islands are often a protected structure from DNA 
methylation changes, these are least likely to be impacted immediately in an 
environmental exposure model [62].  This also raises the question of what may be 
potentially missed by conventional use of the arrays; which may include non-CpG 
methylcytosine or hydroxyl-methylcytosine marks. 
Additional cytosine modifications may be playing an influence in gene regulation 
and deserve more attention.  Among those marks are halide methylcytosines such as 5-
chlorocytosine and 5-bromocytosine.  Both of these marks are irreversible marks and can 
be recognized as a methylated cytosine by DNMT1 [55].  These marks can be introduced 
through reactive species such as hypochlorous acid and once initiated are capable of 
silencing gene expression [63, 64].  There is some evidence that these marks may play a 
role in cancer, but have not been evaluated within the mammalian brain [65, 66].  
Another mark that may have bearing on the gene expression profile are methylation of 
non-CpG cytosines [67].  The evidence indicates that these marks are prevalent in the 
brain but their effect is unclear [68, 69].  However, there is some indication that non-CpG 
methylation are critical in gene expression as MECP2 requires methylated CpA 
dinucleotides to be present in order to localize and regulate gene expression [70] With the 
advancing field of neuroepigenetics, these marks and others deserve more attention and 




Polycomb Repressive Complexes 
Polycomb repressive complexes are large multimeric protein complexes that bind 
DNA and are often associated with repressing gene expression [71].  There are two main 
polycomb complexes: Polycomb Repressive Complex 1 (PRC1) and Polycomb 
Repressive Complex 2 (PRC2).  The distinction between the two main complexes is in 
their function.  PRC1 operates in a maintenance capacity, keeping repressed regions in a 
closed conformation in the removal or replacement of other repressive marks and 
ubiquinates histone tails [72].  PRC2 is often associated with dynamic gene repression 
and methylates histone tails [73, 74].  Each complex incorporates a defined set of 
proteins, but the composition of the complex does not require all of the defined set being 
present and often homologs of a particular protein fill in for specific roles [75].  PRC1 is 
often identified by major constituents: B Lymphoma Mo-MLV Insertion Region 1 
(BMI1) and RING1 A/B, while PRC2 is often identified by major constituents:  Enhancer 
of Zest 2 (EZH2), Suppressor of Zeste 12 (SUZ12) and Embryonic Ectoderm 
Development (EED) proteins [76, 77]. 
PRC1 maintains the ability to ubiquitinate histone tails through the RING1 A/B 
subunit [78].  PRC1 subunit BMI1 stabilizes the RING1 A/B complex and facilitates 
ubiquitination [79, 80].  BMI1 contains a ubiquitin-like pocket with which it can 
oligomerize or bind polycomb subunit PHC2 enhancing the ability of PRC1 to 
ubiquitinate H2A [80].  BMI1 is often studied in the context of gliomas, especially 
Glioblastoma Multiforme as BMI1 plays a critical role in cancer maintenance and is 
hypothesized to play a role in maintaining glioblastoma stem cells [81].  This hypothesis 
is supported as BMI1 maintains neural stem cells in their stem cell phenotype, and may 
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be the crux of the cancer stem cell phenotype [82].  PRC1 also plays a significant role in 
other functions as well, evidenced by the finding that BMI1 can confer resistance to 
oxidative stress [83].  In the same study, the authors describe that BMI1 expression is 
reduced in an aging brain.  This may tie back into the idea that late life exposure to 
environmental toxicants induce neurodegeneration as opposed to cancer. 
PRC2 is a critical complex in the differentiation and function of 
neuroectodermally derived cells.  PRC2 functions by introducing H3K27me3 marks onto 
the histone tails where the complex associates.  These marks are critical for the 
differentiation of neurons and the loss of these marks leads to a dedifferentiated state of 
the neuron and ultimately neurodegeneration [84].  The loss of this repressive mark 
increases gene expression of those genes marked by H3K27me3 [84, 85].  EZH2 is the 
primary component of PRC2 that catalyzes the H3K27me3 mark [86].  For EZH2 to be 
functionally active it must be incorporated into the complex and another PRC2 
component, PHF1, is required for EZH2 to efficiently catalyze the mark [87].  PRC2 
components are critical to the function of PRC2 in the development of the neurectoderm; 
removing a single component can have severe consequences.  Knocking out EZH2 in the 
midbrain alters the differentiation profile of midbrain neurons to a forebrain phenotype 
[85].  EZH2 is necessary for proper radial migration of pyramidal neurons [88].    EED is 
the chromatin binding protein of PRC2 and removal of EED induces a failure of PRC2 to 
assemble and function in maintaining repressive marks [89, 90].   EED knockout models 
prevent the development of normal brain structure as neural progenitor cells are 
prevented from astroglial differentiation [91].  EED is regulated in its stem cell 
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maintenance paradigm through transcription factors STAT3 and OCT-3/4 which control 
expression of the EED gene [90].   
Polycomb repressive complexes are critical for proper neural development from 
progenitor cells to differentiating and migrating neurons.  As we have seen, disruptions in 
these complexes can lead to deleterious or cancerous effect and begs the question, are the 
polycomb complexes susceptible to environmental influence?  As previously mentioned, 
oxidative stress can be induced by a number of pesticides, and in the case of polycomb 
complexes; oxidative stress causes a shift in polycomb group proteins to DNA damage 
regions and EZH2 as well as EED are more tightly bound to the DNA [92].  In this same 
study the authors found that DNMT1 would translocate to CpG islands with another 
polycomb member SIRT1 indicating the potential to alter DNA methylation.  Cigarette 
smoke extract was able to induce an increase in EZH2 protein in human broncho-
epithelial cells, a model system for understanding cigarette induced lung cancer [93].  In 
a mouse model of lung cancer, urethane was able to induce increases in EZH2 and 
consequently global levels of H3K27me3 [94].  Each of these studies highlight that toxins 
can influence polycomb proteins, however, these studies affect mature models and also 
show limitations in the breadth of toxins explored.  A study in drosophila, the model 
system where polycomb complexes were discovered, examines the epigenetic inheritance 
in exposing an F1 generation to an antibiotic and the resultant decreases of polycomb 
gene expression that were carried out to F3 generation [95].  If reductions in polycomb 
expression are capable of crossing transgenerational lines, then they may also be 
affecting an organism throughout its lifetime.  In another model, examining the links 
between breast cancer and Diethylstilbestrol and Bisphenol-A exposure, the authors were 
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able to identify increases in adult mice of EZH2 expression and H3K27me3 marks after 
having been exposed during gestation [96]. These studies highlight the potential to alter 
polycomb complex response in an early development environment.  What effect such an 
alteration might have, has limited direct study, but might be inferred from knockout and 
over expression models, an area that needs further investigation.  In addition, pesticide 
exposure is prevalent in society and little is known about the effect of these 
environmental exposures on polycomb complexes composition or localization. 
Histone Modifications 
Histones, proteins that package DNA, have highly modifiable tails that are subject 
to methylation, acetylation, ubiquination, phosphorylation and other modifications [97].  
Histone modifications are incorporated through enzymes that covalently modify the 
amino acid residue in histone tails [86, 98, 99].  These enzymes offer a means of 
regulating the chromatin landscape and can be incorporated into transcription complexes 
and repressive complexes [86].  These complexes are often a target in therapies as they 
have few side-effects in treatment and are effective in their treatment paradigm [100].  
Cancers targetable through histone deacetylase inhibitors are thought to be epigenetically 
addicted and often respond well to their treatment.  Such targets are attractive enough that 
there has been investigation into their use in treating neurodegenerative diseases [99, 101, 
102]. 
Histone modifications play a role in gene regulation as some marks are associated 
with an open chromatin feature such as methylation of H3K4 and acetylation of H3K27 
tails [103, 104].  Open chromatin is thought to be more available for gene transcription 
allowing for the occupation by RNA polymerase II [105].  RNA polymerase II is also 
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thought to play a role in maintaining the open chromatin state [106].  In opposition, 
methylation of H3K27 is associated with a closed chromatin state, as is methylation of 
H3K9 [107].  Interestingly H3K27 tri-methylation plays an integral role in development 
by its incorporation into bivalent domains [108].  Bivalent domains are those regions of 
chromatin that exhibit both closed and open chromatin marks and have low gene 
expression in early progenitor cells [109].  It is thought that these regions allow for the 
stem cell to enter a differentiation pathway and increase expression of key genes while 
turning off those other bivalent domains not necessary in the differentiation pathway.   
Histone modifications play a significant role in neurodevelopment as they are 
immediate moderators of gene expression.  Caspase 3 is down-regulated in mature brains 
due not to changes in transcription factors, but to increased DNA methylation and 
decreased histone acetylation, reducing the accessibility of the chromatin [110].  This is 
biologically important as a mature brain will require less pruning of unneeded neurons 
that usually occurs during development requiring less apoptotic activator.  Also in 
development, AF9, of the AF9/MLLT3 translocation in leukemia, controls TBR1 gene 
through demethylation of H3K79 at the TBR1 promoter preventing gene expression 
[111].  TBR1 suppression allows for the development of the six layer cortex as TBR1 is 
the last expressed transcription factor in a sequential set of transcription factors in 
differentiation cortical neurons [111].  H3K4me2 differentially marks the gene body of 
tissue specific genes and is acquired during differentiation of progenitor cells in the 
mouse brain [112, 113].  These marks are associated with genes that are being expressed 
in a tissue specific manner and as would be expected, are dynamic through development 
as gene expression profiles change during differentiation [114].  These studies highlight 
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the importance of histone modifications during development and off site histone 
modifications may present developmental abnormalities.  In humans with spina bifida, 
histone H3K79me2, which has shown to be important for cortical development, is 
globally down regulated [115].  This study does not evaluate at which locations 
H3K79me2 is down regulated and such an evaluation would help to determine if the 
modifications absence is causative or correlative.  A study that highlights the need for 
appropriate levels and composition of histone acetylation in the development of a healthy 
brain is the knockout of BRPF1 in mice; BRPF1 interacts with a histone acetyltransferase 
complex enhancing its function [116].  The knockout of BRPF1 reduces brain structure 
with thinner cortical layers and a reduction in the available progenitor cells, these mice 
are also behaviorally abnormal and have a short lifespan of less than 30 days [117].  
These studies indicate the importance of proper covalent histone modifications for proper 
brain development. 
Histone tail modifications are dynamic and play a role in gene regulation. As a 
result, researchers have hypothesized that there might be shifts in the levels of these 
marks in response to environmental cues or toxins.  Developmental arsenic exposure 
alters the histone marks in adult mouse brain tissues and these marks are differentially 
affected based upon the sex of the animal [118].  Two important considerations arise 
from this study: that sex alters the impact of the toxicant, and that epigenetic changes are 
observed in adult animals long after the exposure event.  The study focused on global 
H3K4me3 and H3K9Ac marks and found that arsenic exposed females experienced a loss 
in these marks while their male counterparts experienced a gain.  Another heavy metal, 
cadmium, has been shown  to reduce global levels of repressive mark H3K27me1 in 
18 
 
mouse embryonic stem cells [119].  While this study did not identify the specific location 
of the changes in the genome, global loss of a repressive mark suggests that there may be 
persistent changes in gene expression.  Exposure to ethanol in neural stem cells and the 
fetus induce changes in H3K27me3 and H3k4me3 marks that persist after the acute 
exposure [120].  The effects of the ethanol exposure were also greater after the acute 
exposure window implying that these remodeling events may be slow to develop a 
phenotype, an important consideration when designing exposure studies.  Histone 
modifications are also subject to pesticides and other environmental exposures.  Rat 
dopaminergic neurons exposed to Paraquat for 24 hours exhibited a loss of histone 
deacetylase protein expression and subsequently a gain in histone acetylation [98].  
Dieldrin exposure also increased histone acetylation in both rat dopaminergic neurons 
and mouse models [121].   Dieldrin is a pesticide that has been discontinued in use since 
the late 1980’s but persists in the environment and has a strong association with 
Parkinson’s disease [122].  Increased acetylation in response to both Paraquat and 
Dieldrin might suggest a common mechanism in response to pesticide exposure.  What is 
needed is a detailed examination of where the acetylation events occur both in terms of 
specific histone residues and whether these changes occur in specific regions in the 
genome.  Reactive quinones have been shown to form a histone modification at a number 
of sites both on the tails and within the histone body.  These modifications, while 
unknown how they might react with the epigenetic machinery, have been shown to 
produce reactive oxygen species within the nucleus, raising the potential for mutagenesis 





Micro-RNAs (miRNA) are a subset of non-coding RNA, ranging from 15-30 
nucleotides, which bind target sequences and inhibit translation of the bound mRNA 
through the RISC (miRNA Induced Silencing Complex) complex.  The production of 
miRNAs has recently been reviewed and involved a multistep enzymatic and 
translocation from the nucleus process [124].  The study of miRNAs is an emerging field 
and the details of how they regulate gene expression are beginning to emerge, and also 
indicate that miRNAs play a crucial role in development of the central nervous system.   
In a zebrafish dicer knockout model, dicer cleaves precursor miRNA stands into miRNA 
that bind the RISC complex, there is agenesis of the brain which can be rescued with 
miRNA-430 [125].  MiRNAs are locally expressed in distinct regions of the brains and 
can evade detection with standard techniques [126]. The distinct localization of miRNAs 
indicates that specific cell types require different miRNAs in their function and 
development.  Finding that miRNAs require specialized detection methods could mean 
missing information in interpreting the importance of miRNAs in specific brain regions.  
Indeed a recent review of the miRNAs in the adolescent life stage highlights that there is 
a need for further investigation into miRNAs not only in specific brain regions but also in 
developmental stages [127]. 
MiRNAs exhibit differences in the sexes, a recurring theme in epigenetic 
mechanisms and an important consideration in evaluating the context of differential 
epigenetic marks [128].  Similar to thesex differences described above, arsenic exposure 
in pregnant dams differentially affected male and female offspring, with several miRNA 
being downregulated in males and no impact in females.  REST, a transcription factor in 
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part responsible for differentiation of neural stem cells, is affected by the expression of 
miRNA-9; one of the down regulated miRNAs in the male mice [129, 130].  Complete 
loss of REST during development allows for DNA damage events to go unchecked and 
knockout mice are susceptible to developing gliomas  [131].  In contrast, late stage loss 
of REST induces a neurodegenerative phenotype in mice [132].  This distinction may 
hearken back to epidemiological studies as to why there is a demarcation in developing 
brain tumors versus neurodegeneration based on age of exposure.  Paraquat exposure in 
neural progenitor cells prevents differentiation and upregulates a number of miRNAs 
[133].  This study did not evaluate the specific effects of the differentially expressed 
miRNAs, however, miRNA-34 was among the highest in differential expression, and is 
implicated in cellular senescence and as a biomarker of multiple system atrophy [134, 
135].  
Paraquat as a model toxicant 
Paraquat has been used in agricultural practices for a number of years since its 
introduction to mainstream agriculture in the 1960’s.  Paraquat is an effective 
nondiscriminatory herbicide that functions through inhibition of the chloroplast electron 
transport chain [136].  The use of this herbicide is still prevalent throughout the world, 
including in the United States.  Accidental and intentional ingestion is often fatal and 
there is no known antidote [137, 138].  Patients who have had a high dose exposure 
expire from multi-organ failure and develop pulmonary fibrosis in moderate to severe 
poisonings [139].  Paraquat has some ability to cross the skin in small doses but has 
otherwise not been reported to be mutagenic [140].  However, levels of Paraquat have 
been reported in meconium of fetuses from mothers where Paraquat is heavily used, 
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indicating the exposure of fetuses to Paraquat [141].  Some patients that initially survive 
ingestion of large quantities of Paraquat exhibited and die from seizures thereafter, 
identifying a neurologic component to Paraquat poisoning [142].  Epidemiologic data in 
adult humans does indicate Paraquat increases the risk of Parkinson’s disease in certain 
populations with specific genetic variants, including dopamine transporter variants and 
other comorbidity factors such as traumatic brain injury and behavioral stressors [19, 143, 
144].   
Paraquat Mechanism of Action 
Paraquat has been  studied as a model toxicant for the etiology of Parkinson’s 
syndrome[145].  Initial use of Paraquat in research was due to similar chemical structure 
as that of another Parkinsonian inducing toxicant MPP+, a well-established parkinsonian 
inducing agent [141, 146].  Paraquat inhibits the electron transport chain in animal cells 
through either Complex I or Complex III (figure 2) [147, 148].  Inhibition of the electron 
transport inhibits the production of ATP [149].  Paraquat is also capable of redox cycling, 
which leads to the production of superoxide radicals that can readily pass through the 
mitochondrial membranes [150, 151].  Outside of the mitochondria, the superoxide 
radicals are capable of entering a Fenton reaction with available sources of iron and 
ultimately becoming hydroxyl radicals [152, 153].  Additionally, superoxide dismutase 
converts superoxide radicals into hydrogen peroxide which can dissociate and become 
hydroxyl radicals [154].  At high concentrations, Paraquat disrupts the mitochondrial 
membrane potential, reducing the ability of mitochondria to produce ATP [155].  The 
inhibition of mitochondrial function is reported to have multiple downstream effects 
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including the release of Cytochrome C. This may induce apoptosis, lead to the production 
of superoxide radicals, and lead to an increase in the miss-folding of proteins [156-161].   
Paraquat in Model Systems 
Studies have introduced evidence that Paraquat may be taken up in the intestines 
and eventually enter the brain from the environment.  Caco-2 cells, a  model for intestinal 
uptake in humans, uptake Paraquat through amino acid and choline transporters  [162].  
Paraquat has been shown to cross the blood brain barrier via arginine and lysine amino 
acid transporters [163].  In the brain, dopaminergic neurons are sensitive to toxicant 
stress [164-166].  Dopaminergic neurons uptake Paraquat through dopamine transporters 
and amino acid and ion transporters [167].  Dopamine facilitates an increased uptake of 
Paraquat, increasing the availability of toxin within the dopaminergic neuron [167].  Glial 
cells, including astrocytes and microglia, uptake of Paraquat as well [160].  Microglia 
convert Paraquat into a monovalent cation increasing uptake through dopamine 
transporters [167].  The quantity of Paraquat within the central nervous system after 10 
mg/kg Paraquat injections peaks initially at 0.6 uM and wanes after several hours to 0.2 
uM concentrations [163].  These concentrations are much lower than concentrations 
required to reduce cell viability directly at in vitro testing conditions [148, 160, 162, 167, 
168].   
Discrepancies in the Paraquat Model System 
Many experimental studies use in vitro concentrations ranging from 5 uM to 5 
mM with much work being done at 250 uM to 1000 uM range in vitro.    In this 
concentration range, many cell types lose viability above 200 uM, however, some cell 
types can lose viability in concentrations as low as 50 uM [133].  Many of these viability 
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studies involve the use of mitochondrial function as a proxy for viability, a potential 
problemin a model system where Paraquat acts by inhibiting mitochondrial function.  As 
introduced above, these concentrations are much higher than what is proposed to be 
found available to the neural systems.  This would indicate that there needs to be a frame 
shift in concentrations used in in vitro work, as concentrations in the brain are found to be 
less than 1uM in mouse models. 
There are also discrepancies in the mouse model as to the effect of Paraquat on 
the dopaminergic system.  There are multiple dosing models used with a 1 injection per 
week exposure to 10mg/kg intraperitoneal injection over three weeks being among the 
most common.  Some studies have suggested that the methodology for assessing 
dopaminergic cell loss are inaccurate.  However, utilizing stereoscopy as the gold 
standard, studies have both shown significant loss and no loss in dopaminergic neurons 
[159, 169].  The discrepancy does appear to have some relationship to the age of the mice 
used in the experiments.  Those that argue against dopaminergic cells loss often utilize 
young mice usually starting at 7-10 weeks of age and sacrifice shortly after exposure and 
find no significant loss of dopaminergic neurons [169].  However, other groups utilizing 
older animals (ranging from 2-3 months to 18 months of age) have observed significant 
dopaminergic cell loss [145, 170].  This may be in part due to the loss of compensatory 
capability of older brains to deal with oxidative stress [171].  Still others use models with 
a longer and increased dosing schedule and find reductions in dopaminergic neurons up 
to 30-40% in the longest dosing group [172].  What may be missed in most of these 
studies, however, is the implication that Paraquat may not be a fast acting toxicant like 
MPP+.  Paraquat exposure at postnatal days 5-9 leads to significant dopaminergic cell 
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loss at the age of 6.5 months [170].  Additionally, with a secondary injection of Paraquat 
at the end point of the study, the effect of Paraquat was exacerbated.  It may be that 
Paraquat is priming the model system for deficit with a second stressor a stronger 
correlation with epidemiological data.  Additionally, if epigenetic components are at play 
those effects may not be measured immediately and may take additional time to develop.  
This discrepancy needs to be evaluated as there are a number of research groups that 
show evidence of dopaminergic cell loss [170, 172, 173].  However, dopaminergic cell 
loss may be just a facet of Paraquat as a model toxicant. 
While there may be some discrepancy in how Paraquat effects dopaminergic 
neurons, most studiesagree that Paraquat is able to cross the blood brain barrier [163, 
169, 174].  The concentration at which Paraquat crosses the blood brain barrier appears to 
be a fraction of the total amount given to the animal.  The majority of Paraquat is 
excreted in urine and feces, but at low concentrations Paraquat is available to neural 
systems [175].   
Paraquat at Sub-Lethal Concentrations  
Many studies focus on Paraquat at high concentrations and their effect on the 
dopaminergic system.  However, there are groups that are investigating a more 
environmentally relevant level of Paraquat.    In the c. Elegans model, Paraquat has been 
observed to induce an inverted U-shaped curve in longevity with a maximal 1.5 fold 
increase in longevity [176].  Paraquat is lethal in c. Elegans at 4 mM and above as the 
organism cannot compensate for the increased oxidative stress.  However, at 
concentrations from 100 to 1000 uM, c. Elegans display an increase in longevity with a 
peak at 100-200 uM, while ultra-low doses below 100 uM have limited effect.  The 
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increase in longevity is thought to be part of an reactive oxygen species signaling 
mechanism and indeed longevity is also affected in models with mutations in metabolic 
processing such as Nuo-6 and Isp-1 that affect the through low level oxidative stress by 
interruption of the electron transport chain which electron transport chain [177].  
Additional studies have linked a paraqaut-like mechanism to induced longevity in c. 
Elegans while simultaneously retarding development [178, 179].  Inhibiting the electron 
transport chain or inducing mitochondrial stress can increase the longevity in d. 
Melanogaster models as well [178].  However, where a discrepancy lay is in the 
mammalian models.  Disrupting superoxide homeostasis in mouse models has a 
deleterious or no effect on longevity [178].  However, longevity can be induced by 
decreasing H2O2 levels by overexpressing a catalase, Mcat [180].  This model survives 
past wild type models due to reduced overall reactive oxygen species and associated 
damage and is enhanced with additionally overexpressing super oxide dismutases.  The 
residing difference between the two models may be the incapability of C. Elegans to 
replace cells and the need to adapt to increased oxidative stress [178].  This has been 
proposed as a model for neurogenic stress as neurons cannot be easily replaced and may 
therefore require stress adapting mechanisms.  Additionally, even at these longevity 
inducing levels, Paraquat is able to induce oxidative damage [177].  However, little is 
known about the oxidative damage to other constituents such as DNA and lipids, nor do 
we fully understand the effect on epigenetic machinery at these low levels.   
Epidemiological evidence indicates the possibility of low level exposure to 
Paraquat during fetal development in those mothers who have been exposed to 
environmental levels of Paraquat [141]. The levels of Paraquat detected in the meconium 
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of fetuses is similar to levels detected for in vivo brain exposures.  The effect of 
developmental exposure in the developing brain is only recently being examined.  To 
affect longevity in the c. Elegans model mitochondrial stress is required during a critical 
developmental window, outside of which no effect on longevity from mitochondrial 
stress can be induced [181].  Additional evidence to the effect of low level Paraquat 
exposure in the developing brain comes from a study of embryonic derived 3D-rat brain 
cultures [182] .  In this study, Paraquat was used at much lower than typical 
concentrations: 0.1, 0.5 and 1 uM.  These levels are more akin to the levels found in the 
brains of in vivo treated animals and may offer insight into how low levels of Paraquat 
affect development.  This study showed that initial loss of neuronal proteins could be 
recovered after several days out of exposure, however, not all proteins were able to 
recover full expression, indicating a long lived down regulation of the proteins.  mRNA 
of the proteins assessed also exhibited similar patterns.  Another important finding of this 
study is the continued astrogliosis after removal of Paraquat, as well as a delayed 
activation of microglia.  From the studies in c. Elegans and developmental models it is 
clear that environmental influence through mitochondria may need further consideration 
for environmental exposures. 
Mitochondria as the Environmental Influence Gateway 
Mitochondria have been increasingly implicated in playing a significant role in a 
number of diseases, while our understanding of their interaction within the cellular 
systems is beginning to emerge [183].  Inhibition of the electron transport chain can 
induce neural progenitor cells to overcome growth restrictions by inactivating p53 
providing a potential gateway for oncogenesis [21].   Mitochondrial inhibition appears to 
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have a role in neurodegenerative diseases as well through increased reactive oxygen 
species and reduced mitochondrial function [184].  Several environmental toxicants 
inhibit the electron transport chain including Paraquat, Rotenone, and MPP+ (a derivative 
of MPTP) [148].  Mitochondrial stress can have an impact on reactive oxygen species 
levels within a cell and lead to DNA damage and ultimately apoptosis or cell cycle 
deregulation [185].   
Mitochondria play a significant role in disease states and can communicate with 
the other components of the cell to regulate function.  In the longevity models mentioned 
above, mitochondria communicate with the nucleus and activate histone demethylases 
specific for H3K27me3 increasing gene expression of H3K27me3 associated genes 
[179].  Additionally longevity activating mitochondrial stress increases MET-2 activity 
and H3k9me1/2 marks in the chromatin [186].  The mitochondrial DNA itself may act as 
a chromatin regulator as the interactions between nuclear and mitochondrial DNA have 
been found to be significant although the functional purpose is not yet known [187].  
Disruption of mitophagy can lead to DNA damage and cellular senescence in stem cells; 
evidence of the importance for proper mitochondrial regulation [188].   
Mitochondrial Epigenetics 
Mitochondria are considered the frontline sensors for environmental exposure and 
one hypothesis by which this may occur may be through epigenetically modifying the 
mitochondrial DNA; specifically DNA methylation and hydroxymethylation.  There is 
some controversy regarding the concept of mitochondrial DNA methylation.  This in part 
stems from the much lower presence of DNA methylation or 5-Hydroxymethylation in 
the mitochondrial DNA versus nuclear DNA [189].  There also does not appear to be a 
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consensus on the functional relevance of such modifications as of yet, but this may be a 
byproduct of the infancy of the field [190].  There are technical limitations in measuring 
DNA modifications in the mitochondrial epigenome, one being the repetitive nature of 
the mitochondrial DNA sequence making mapping techniques difficult.  In addition, 
limitations are present in the assay technology as it has been used, requiring careful 
consideration of appropriate controls [191].  There has been an overestimation of the 
level of mitochondrial DNA methylation due to the circular nature of mitochondrial DNA 
as well as non-specific binding with antibody sequestering technologies [189, 191].  
However, there are independent DNA modification machinery within the mitochondria 
and the utilization of more sensitive techniques have shown the levels of mitochondrial 
DNA modifications are significant [192-194].  One study has even been able to link 
mitochondrial DNA methylation to environmental exposure of metal rich particulates 
[195].  Another study has been able to identify an inverse correlation of mitochondrial 
DNA methylation at two loci and the age of the subject indicating a potential aging 
biomarker [196].  What is also unclear is if histones and their marks play a significant 
role in mitochondrial epigenetics.  While histone proteins have been found in 
mitochondria, to date no known histone modifying mechanisms have been identified in 
the mitochondria [197].  Additionally, histones are not known to associate with the 
mitochondrial DNA.  However, recent evidence has found Mof, a histone 
acetyltransferase, within the mitochondria which binds mitochondrial DNA and plays a 
role in mitochondrial transcription [198].  It is clear that there is much work to be done in 
the field of mitochondrial epigenetics to elucidate the functional relevance of any 
epigenetic marks including the effect on mitochondrial gene expression as well as the 
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interplay between mitochondrial and nuclear epigenomes. The advent of these needed 
advances may bring about a greater understanding in how the mitochondria relay 
environmental information into the development and maintenance of living cell systems.  
Paraquat may offer an opportunity, as a known mitochondrial disruptor, to examine if 
there are epigenetic remodeling events as a direct result of exposure and if those changes 
lead to any functional relevance. 
Developing an Early Exposure Model 
The etiology of neural disease remains elusive as many of these diseases are considered 
multifactorial.  Neuroepigenetics provides an opportunity to evaluate how environmental 
influence over time can impact these neural diseases.  There is a clear need to understand 
how environmental influence impacts neural disease as evidenced by the epidemiological 





Figure 1.  Environmental exposure in early development may drive future disease 
events.  We propose that an early development environmental toxicant exposure, such as 
Paraquat, can alter the normal differentiation pathway in epigenetic remodeling events.  
Epigenetic remodeling events may be the key to later disease states in a Barker 








Figure 2.  Current understanding of the mechanism of action for Paraquat.  
Paraquat enters redox cycling producing superoxide radicals and also inhibiting electron 
transport chain components.  Superoxide radicals pass through the mitochondrial 
membrane through pores and are converted to hydrogen peroxide chemically through 
available iron in a Fenton reaction or enzymatically through superoxide dismutase.  
Hydrogen peroxide can form hydroxyl radicals which can then lead to DNA damage, 







C57bl6 mice (Harlan labs), were treated with 10mg/kg Paraquat or saline with 
intraperitoneal injection.  Paraquat was made fresh prior to each injection time point, 1 
mL of injection stock was collected for mass spectrometry.  Mice were treated twice 
weekly for six weeks.  Mice were bred after 1 week of injections.  Gravid mice were 
allowed to reach gestational term.  Pups were collected and brains removed for mass 
spectrometry or glial cell cultures.  Pup brains for mass spectrometry were snap frozen 
and pulverized to homogeneity.  Pup brain cultures are as described later.  Blood samples 
were taken from pups after decapitation.   
Adult mice were treated for a total of 12 injections and six weeks.  Mice were 
euthanized with CO2.  Mice were then trans-cardiac perfused with saline and calcium 
chloride.  In second study blood was collected prior to trans-cardiac perfusion. Blood 
samples were collected with heparin sulfate tubes and centrifuged to collect sera. Sera 
was then frozen for mass spectrometry.  In the initial study, mice were then perfused with 
4% paraformaldehyde and hemispheres retained for histology.  Remaining hemisphere 
was reserved for later DNA and RNA extraction.  Histology hemisphere was immersed in 
4% paraformaldehyde for 72 hours.  In second study mouse brains were removed and one 
hemisphere immersed in 4% paraformaldehyde for 72 hours.  The remaining hemisphere 
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was snap frozen and pulverized for later RNA and DNA extraction as well as mass 
spectrometry.   Two 30% sucrose exchanges were performed on histology sections.  
Initial study brains were then paraffin embedded and cut at 7-10 micron sections.  Second 
study brains were frozen in OCT freezing medium and cut with a cryostat at 20 micron 
thickness.  Tissue sections were then stained for tyrosine hydroxylase. 
Assay for Transposase Accessible Chromatin (ATAC-seq) 
Astrocytes were cultured as described above for 48 hours prior to treatment in T-
25 culture flasks.  Cells were treated with Paraquat at 0.5, 5 and 50 uM concentrations for 
24 or 72 hours.  ATAC-seq protocol was used as described by Buenrostro et. al.  [199].  
Cells were collected by trypsin mediated release and centrifuged at 200 x g for 5 minutes.  
Cell pellet was re-suspended in 1 mL complete medium and 20 uL was diluted into 200 uL 
final volume.  10 uL of final volume dilution was counted on a hemacytometer.  25,000 
cells from dilution were centrifuged at 500 x g for 5 minutes at 4o C.  Cells were washed 
in 50 uL 1 X Dulbecco’s Phophate buffered saline (DPBS).  Cells were centrifuged at 500 
x g at 4o C for 5 minutes in 0.2 mL PCR tubes.  Supernatant was removed and 50 uL Lysis 
buffer (10 mM Tris-HCl, pH 7.4, 10mM NaCL, 3 mM MgCl2, 0.1% IGEPAL CA-630) 
was added to each sample.  Each sample was gently re-suspended by pipette.  Samples 
were centrifuged at 500 x g for 10 minutes at 4o C.  Supernatant was removed and 50 uL 
of transposase mixture (25 uL 2x reaction buffer (buffer TD from Illumina Nextera Library 
Prep Kit), 2.5 uL tranposase (TN5 transposase from Illumina Nextera Library Prep Kit) 
and 22.5 uL of sterile RNase and DNase free water) was added to each sample, now nuclei.  
Samples were gently re-suspended by pipette and then incubated at 37o C for 30 minutes.   
Samples were then immediately purified with Minelute PCR purification kit from Qiagen.  
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Briefly, 250 uL of buffer PB without pH indicator was added to each sample and 
centrifuged in provided spin columns.  700 uL of buffer PE with ethanol added was added 
to the column and centrifuged as a wash step.  An additional drying step of 1 minute 
centrifugation was performed.  Samples were eluted after a 1 minute incubation in 10 uL 
buffer EB.  Samples were then frozen at -80o C until primer indexing was performed. 
Samples were thawed and 35 uL PCR mastermix was added (10 uL nuclease free 
water, 25 uL NEBNext High-Fidelity 2x PCR Master Mix) and indexed primers were 
added according to Table 1 at 2.5 uL per primer.  Samples were PCR amplified as per Table 
2.  5 uL of sample was removed after last cycle of PCR amplification and qPCR amplified 
to determine the remaining number of cycles, N.  9.5 uL qPCR master mix was added to 
each sample (4.4 uL nuclease free water, 0.09 uL SYBR Green I, and 5 uL NEB Next 
High-Fidelity 2x PCR Master Mix).  0.25 uL forward and reverse primer were added to 
each sample as indexed in Table 1.  qPCR was performed in cycles as per Table 2.  
Remaining N cycles were determined by plotting reaction fluorescence by cycle number 
and using ¼ of maximal fluorescence of linear function of the graph (figure 3).  The 
remaining 45 uL of original PCR amplified library was continued in PCR cycles as per 
Table 2 and Table 3.  PCR reactions were purified with Qiagen Minelute PCR purification 
kit as described previously.  Samples were then sequenced. 
Cell Culture 
Astrocyte Paraquat Exposure (Chapter III) 
Primary human astrocytes were obtained from Sciencell.  Cells were cultured on 
corning T75 cell culture flasks with 2 ug/cm2 Poly-D Lysine (Sigma-Aldrich) for 
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adherence in Astrocyte Medium (Sciencell) with provided supplements.  Cells were 
cultured for at least 24 hours prior to treatment with Paraquat (Sigma-Aldrich).  Paraquat 
exposures of length 24 hours and 72 hours were of a single exposure of concentrations 
indicated in results.   
Long Term Cell Culture (Chapter IV) 
Astrocytes, brain vascular pericytes, and Schwann cells (Sciencell) were cultured 
as recommended by the manufacturer in Human Astrocyte, Human Brain Vascular 
Pericyte, and Human Schwann Cell media, respectively (Sciencell).  Culture dishes were 
coated with 2 ug/cm2 Poly-D-Lysine (Sigma) and incubated at least 1 hour prior to use at 
37o C.  Dishes were then washed once and medium added prior to seeding with cells.  
Cells were seeded at a density of 5,000 cells/cm2.  Cells were passaged at 90% 
confluence and plated on Poly-D-Lysine coverslips for immunofluorescence as well as 
new culture dishes for subsequent passages.  Cells were passaged by 0.25% trypsin 
digestion with EDTA and quenched with complete medium.  Cells were centrifuged and 
pellets suspended in complete medium.  Cells were plated at 5,000 cells/cm2 for each 
subsequent passage. DNA and RNA were collected from the remainder cell population. 
Maternal Paraquat Exposure (Chapter VI) 
1-3 day old pups were collected and euthanized; pup heads were dipped in 70% 
ethanol and decapitated.  Brains were immediately excised in a sterile environment.  Skin 
was pulled from the nose to the back of the cranium.  Cranium was peeled away with a 
forceps to expose brain tissue.  Cortex of the brain was immersed in dissection medium 
(1mM EDTA, 1mM EGTA stock 100uM, 1X PBS, 1mg/mL glucose).  Cortex was 
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dissected from brain with forceps by applying pressure at bregma and pushing forward to 
peel cortex.  Corti were minced by individual brain for individual pup cultures or pooled 
in groups of 3 or 4 pups and minced together in dissection medium.  Minced tissue was 
aspirated from dissection medium and collected at the bottom of a pipette.  Tissue was 
submerged in 4 mL of 0.25% trypsin with EDTA and incubated at 37oC for 20 minutes.  
Tissue/trypsin was inverted approximately every 3-4 minutes to mix.  10 mL complete 
medium (DMEM/F12, 10 mL antibiotic/antimycotic, 10% FBS, 5% Horse Serum) was 
prepared in a new conical tube.  Tissue was aspirated and collected at the bottom of 
pipette.  Tissue alone was added to previously prepared complete medium conical tube 
and incubate for 2 minutes.  Tissue was aspirated and transferred to 10 mL of new 
complete medium.  Tissue was triturated 30 times or until homogeneous mixture of tissue 
and medium was present.  Triturated tissue was transferred to culture flasks (3-4 brain 
cultures into a t-75 flask; 1 brain culture into a t-25 flask) and incubated for 24 hours at 
37o C.  Spent medium was removed and 15 mL fresh complete medium was added.  After 
7 days approximately half of medium was removed and 7.5 mL complete medium was 
added.  At 10 to 14 days cultures were assessed for total microglia by observation and 
cultures were harvested for plating or RNA and DNA extraction. 
Microglia were collected by flask shaking at 200 rpm for 45 minutes at 37oC.  
Culture medium was aspirated and flasks were washed with cold dissection medium.  
Dissection medium was aspirated and collected with culture medium.  Fresh culture 
medium was added to flasks and replace into incubator at 37oC for adherent cultures.  
Microglia were centrifuged and suspended in fresh culture medium.  Suspended 
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microglia were aliquoted for RNA and DNA collection and seeding for subsequent 
experiments. 
Adherent cultures were trypsin digested with 0.25% trypsin with EDTA for 5 
minutes at 37oC and collected in complete medium to quench trypsin.  Cells were 
centrifuged and pellet suspended in complete medium.  Cell suspension was aliquoted for 
DNA and RNA collection or seeding for subsequent experiments. 
Cell Viability 
Cell Mitochondrial Viability Assays 
96 well plates were prepared for primary cell cultures by incubating wells in 50 uL 
of 15 ug/ml Poly-D-Lysine solution for at least one hour prior to subculture.  Poly-D-
Lysine solution was aspirated prior to seeding with cells in culture medium.  Cells in culture 
medium were plated at seeding density of 5000 cells/well and 200 uL/well of culture 
medium.  Culture dishes were then incubated overnight prior to treatment to allow cells to 
adhere and acclimate.  Preparation of Paraquat treatment included preparing a 1 mM stock 
solution of Paraquat dichloride into complete medium and performing 2 fold dilutions until 
minimal concentration of 0.5 uM was achieved.  For human Microglia and murine viability 
assays, Paraqaut was prepared at 1mM and diluted to subsequent concentrations.  Cells 
were incubated in 200 uL of indicated concentration for 72 hours.  3 hours prior to end 
time point 100 uL of medium was aspirated and 10 uL of 5 mg/mL 3-(4,5-Dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) was added.  At end time point all 
medium was aspirated and 100 uL of isopropyl alcohol was added to solubilize formazan.  
96 well plate was read on epoch plate reader and results were compared as a percentage of 
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control.  Each concentration was tested in 6 wells of each 96 well plate and plates were 
replicated 4 times with different lots and passages of cells for astrocytes.  Statistical 
significance was determined with a one-way ANOVA followed by Dunnet’s post-test.  * 
indicate p-value less than 0.05 
Cell Viability Assay 
Triple stain method was used to assess live/dead cell count in concentrations at 0.5, 
5.0, 50.0, and 1000.0uM Paraquat in primary human astrocytes as previously described 
[200].  500uM H2O2 was used as positive control.  Cells were cultured in 35mm Poly-D-
Lysine coated glass bottom dishes for at least 24 hours prior to treatment.  Cells were 
treated with indicated concentrations of Paraquat for either 24 or 72 hours.  Cells were 
counted and imaged on a Zeiss Axiovert 200M.  Total cell numbers were assessed with 
hoescht 33342 stain to stain nuclei.  Calcien is cell permeable and metabolized by 
mitochondria producing a green fluorescent substrate if mitochondria are still functioning.  
Ethidium Homodimer is not cell permeable under normal physiological conditions and 
staining of nuclei with Ethidium Homodimer indicate loss of membrane integrity.  Calcien 
and ethidium homodimer were added 1 hour before end point at concentrations of 
0.5mg/mL and 8uM respectively.  Hoescht 33342 was added 30 minutes prior to end point 
at 10mg/mL.  Cells were considered alive if there was no red nuclear staining and had some 
indication of green fluorescence.  Each condition was assessed in 10 fields in the same 
pattern for all conditions.  Each set of conditions was repeated four times for each time 
point.  Statistical significance was determined by a Two-Way ANOVA with Dunnet’s post-





In Vitro Paraquat Treatment 
Cells were cultured on Poly-D-Lysine coated coverslips for 24 hours and treated 
with vehicle, Paraquat (0.5uM, 5 uM,   50 uM, 1000 uM) or 500 uM H2O2 and cultured 
for either 24 or 72 hours.  Cells were then fixed with 0.4% paraformeldahyde and 
incubated at 37oC for 30 minutes.  Cells were washed with 1X PBS with calcium and 
magnesium.  For H2AX immunofluorescence, coverslips were blocked in blocking 
solution consisting of 1X calcium and magnesium PBS, 1.5% donkey serum, 1% natural 
goat serum, 1% BSA and 0.1% Triton X-100 at room temperature for two hours.  
Coverslips were incubated in 1:100 anti-phosphorylated-H2AX antibody and 1:1000 anti-
glial acidic fibrillary protein antibody in blocking buffer overnight at 4oC.  Coverslips 
were washed three times in 1X calcium and magnesium PBS and incubated at room 
temperature in 1:100 anti-mouse alexafluor 488 and 1:200 anti-rabbit alexafluor 555 
secondary antibodies for two hours.  Coverslips were mounted with vectasheild mounting 
medium and sealed with coverslip sealant.  Coverslips were imaged and images were 
quantified with Image J. 
Images were imported into Image J and quantified for total cells, number of positive 
points (as defined below) in each image and number of cells positive for H2AX mark.  
Positive points were defined by setting a threshold based on control images for alexafluor 
488 channel and measured by internal functions to ImageJ.  Set threshold was used for all 
subsequent image analysis for a given experiment.   H2AX positive cells were determined 
if nuclei had a positive mark.  Total positive points for a given image were divided by 
marked positive nuclei to give a ratio of average positive points per affected cell.  Affected 
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cells were divided by total cells to give a ratio of positive cell to total cells.  Data were 
graphed in Graphpad v.6 and statistical analysis was performed with a one-way ANOVA 
followed by Dunnet’s post-test.  * indicate a p-value less than 0.05. 
For 8-oxo-dG immunofluorescence, protocol was followed as previously 
published.  Coverslips were washed in 1X calcium and magnesium free PBS (CMF PBS).  
Coverslips were then incubated in 0.1% Triton X-100 in CMF PBS at room temperature 
for 15 minutes.  Coverslips were washed in CMF PBS and incubated for 1 hour at 37oC 
in TEN buffer (10mM Tris HCL, 1mM EDTA, 400mM NaCl) with 100ng/mL RNase A 
cocktail mix.  Coverslips were washed in CMF PBS and incubated at room temperature 
for 10 minutes in 100 mM Tris HCl, 50uM EDTA with 10 ug/mL proteinase K.  
Coverslips were washed in CMF PBS and incubated in 2 M HCl acid for 5 minutes at 
room temperature followed by quenching with 2.5 volumes 1 M Tris base for 7 minutes 
at room temperature.  Coverslips were washed and incubated in blocking buffer as above 
with the exchange of calcium and magnesium PBS for CMF PBS, for two hours at room 
temperature.  Coverslips were then incubated in CMF blocking buffer with 1:100 anti-8-
oxo-dG antibody overnight at 4oC.  Coverslips were then washed in CMF PBS and and 
incubated for two hours in CMF blocking buffer with 1:100 anti-mouse alexafluor 488 
antibody.  Images were quantified in Adobe Photoshop v.6.0.  DAPI fields were used to 
outline measurements for FITC channel intensities.  Intensities were measured for 16 
cells in each condition for each replicate and average intensity was plotted in Graphpad 
v.6.0.  Statistical analysis was performed with a One-way ANOVA followed by 




Long Term Cell Culture  
 Cells were seeded at 5,000 cells/cm2 on Poly-D-Lysine coated german glass 
coverslips and incubated for 2-3 days.  Cells were then fixed in 4% paraformeldahyde at 
37o C for 30 minutes.  Cells were then washed in 1X Dulbecco’s Phosphate Buffered 
Saline three times.  Blocking solution of 10% FBS in PBS with additional 0.5% triton X-
100 was added and incubated at 37o C for 30 minutes.  Cells were washed 3 times in 
PBS.  Primary antibodies were diluted in blocking solution:  anti-GFAP (Daka), anti-S-
100 (ABCAM), anti-smooth muscle actin (Sigma); and incubated at 4o C overnight.  
Cells were washed in 1X PBS three times.  Secondary antibodies were diluted in 
blocking solution:  anti-mouse Alexafluor (Cell Signaling), anti-Rabbit Alexafluor (Cell 
Signaling); and incubated overnight at 4o C.  Cells were washed 3 times in 1X PBS and 
mounted on slides with vectashield mounting medium.  Coverslips were sealed with clear 
nail polish and imaged at five random fields.  Cell phenotype was assessed by positively 
marked cells over total cells. Cells were considered positive if appropriate cell marker 
was identified as well as nuclear staining.  
Pup brain glial cell culture  
Pup brain tissues were cultured as described above and plated on poly-D-Lysine coated 
coverslips.  Astrocyte cultures and microglia were cultured on coverslips for 48 hours.  
Cells were then fixed with 4% paraformeldahyde for 30 minutes.  Coverslips were washed 
three times in 1X PBS with calcium and magnesium.  Cells were then blocked in blocking 
buffer (3% donkey serum, 2% natural goat serum, 2% bovine serum albumin, 0.1% triton 
X-100 in 1X PBS with calcium and magnesium) for two hours at room temperature.  
Blocking buffer was removed and coverslips were incubated in primary antibody in 
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blocking buffer (1:1000 anti-GFAP for Astrocytes; 1:200 anti-IBA1 for microglia) 
overnight at 4oC.  Coverslips were then washed three times in 1X PBS with calcium and 
magnesium.  Coverslips were then incubated in secondary antibody (anti-rabbit alexaflour-
555 1:200) in blocking buffer for two hours.  Coverslips were mounted with mounting 
medium containing DAPI.  Coverslips were imaged for seven fields in each coverslip.  N=3 
for each condition.  Images were counted by two investigators that were blinded to image 
identities.  Images are false colored green for ease of visualization through Adobe 
Photoshop v6.0.  Intensity of microglia images were performed in Adobe Photoshop v.6.0.  
Intensity was assessed for DAPI and TRITC channels and the ratio of TRITC intensity 
over DAPI intensity were calculated.  Statistical T-test was performed in positive count 
data and intensity data.  * indicates p-value less than 0.05. 
DNA Methylation Arrays and Analysis 
DNA was isolated and an aliquot of 2000ng was submitted to the University of 
North Dakota Epigenomics and Bioinformatics Core for Illumina Infinium 450K DNA 
methylation arrays.  450k methylation array data was imported, controlled for quality, 
and normalized with SWAN normalization through RnBeads R program package [201].  
Data was then exported and analyzed with R program to determine CpG site 
characteristics and associated genes based upon Illumina annotation.  Statistical analysis 
for over/under representation was determined in R with Fisher’s exact test with a cutoff p 





Extraction of RNA and DNA 
          DNA and RNA isolation were performed with manufacturer kits RNeasy and 
DNeasy Blood and Tissue (Qiagen) according to manufacturer protocols.  Briefly, cell 
populations were divided equally into two parts and centrifuged at 200xg for 5 minutes.  
Media was aspirated and cells were washed in DPBS once if isolating DNA.  RNA was 
isolated immediately followed by DNA isolation.  DNA and RNA quantity and quality 
were assessed with a nanodrop 1000 spectrophotometer.  260/280 values for DNA quality 
and RNA quality ranged from 1.8 to 2.1. 
Cell cultures were aspirated of medium and treated with up to 2 mL of .25% trypsin 
with .5 mM EDTA.  Cell suspension was then collected and added to an equal volume of 
5% FBS in Dulbecco’s phosphate buffered saline to neutralize trypsin.  Cell suspension 
was split evenly between two centrifuge tubes and centrifuged at 200xg for 5 minutes.  
Supernatant was aspirated and pellet was washed and centrifuged at 200xg for five minutes 
if DNA extraction was performed or aspirated and 350 uL of Buffer RLT added from 
Qiagen RNeasy Mini Kit. 
DNA extraction was performed with alcohol precipitation as follows.  Supernatant 
was removed from last centrifugation and pellet was lysed in 270 uL DNA Lysis Buffer 
(50mM Tris, 50 mM EDTA, in 2% SDS).  30 uL of proteinase K was added and samples 
were incubated overnight at 60o C.  The following morning samples were heat treated to 
denature proteinase K at 100o C for 10 minutes.  Samples were transferred to a medium gel 
phase lock tube and 300 uL of phenol: chloroform: isoamyl alcohol (25:24:1) was added 
and mixed by inversion.  Samples were incubated for up to a minute and centrifuged at 
13,000 rpm for 5 minutes at 4o C.  Upper aqueous layer was transferred to a new labeled 
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1.5 mL conical tube and 30 uL of 7.5 M ammonium acetate was added, as well as 600 uL 
of ice cold ethanol.  Samples were incubated for 3 hours at -20o C.  Samples were then 
centrifuged for 20 minutes at 13,000 rpm and 4o C.  Supernatant was decanted and aspirated 
off and pellet was washed in 75% ethanol with an additional centrifugation at 13,000 rpm 
for 5 minutes at 4o C.  Supernatant was aspirated and pellet allowed to dry for 5-10 minutes 
before being suspended in 50 uL of DNase free sterile water.  Samples were quantitated on 
Nanodrop 1000 apparatus with 260/280 values ranging from 1.6 to 2.1. 
Extraction of RNA from samples was performed according to the manufacturer’s 
protocol and are briefly described here.   RLT buffer suspended samples were homogenized 
with a sterile 20 guage syringe needle five times.  75% ethanol was added and mixed via 
pipette and transferred to kit included column.  Samples were centrifuged at 8,000xg for 
15 secs and elute discarded.  700 uL buffer RW1 was added to column and centrifuged for 
15 seconds at 8,000xg after which elute was discarded.  500 uL of buffer RPE (with 4 
volumes of ethanol added as described per kit manual) was added with a 15 second 
centrifugation at 8,000xg and elute discarded.  A second wash of 500 uL of buffer RPE 
was performed with centrifugation at 8,000xg for 2 minutes.  A clean elute tube was placed 
on column and a dry centrifugation step at 8,000xg for 1 minute was performed.  50 uL of 
provided RNase free water was added to column and incubated for 1 minute.  Sample 
collection tube was placed in place of elute tube.  Final centrifugation step was performed 
at 8,000xg for 1 minute.  Samples were quantitated on Nanodrop 1000  with 260/280 values 






Injection stock samples were evaluated for Paraquat.  10 uL of sample was 
collected and diluted into 80% methanol with addition of 1 ug of Paraquat standard.  
Samples were then washed twice with 1 volume hexane and centrifuged for 5 minutes at 
2000 x g.  Samples were then submitted for LC/LC-mass spectrometry at UND mass 
spectrometry core. Results are displayed as concentrations of individual injection stocks. 
Approximately 10 mg of tissue and 10 uL of serum were processed for mass 
spectrometry.  For tissue, 10 ng of standard were added to each sample in 80% methanol.  
For sera samples 10 ng of standard was added and samples were dilute to 80% methanol.  
Samples were pulse sonic ated for 7 seconds.  Samples were centrifuged for 10 minutes at 
2000 x g.  Samples were then washed with hexane twice followed by centrifugation at 
2000 x g for 5 minutes.  Samples were then submitted for mass spectrometry.  Tissue 
sample extraction was repeated twice with similar results.  Results are displayed with 
initial results and * indicate statistical significance as per T-test. 
Reactive Oxygen Species Detection 
Whole cell reactive oxygen species assay 
Cells were seeded at 5,000 cells per well and cultured for two days in respective 
complete medium.  Cultures were pre-treated with 1% DMSO and 10uM H2DCFDA in 
HBSS for one hour.  H2DCFDA medium was removed and replaced with Paraquat 
conditioned HBSS with 0 uM, 0.5 uM, 5 uM, 50 uM and 1000 uM concentrations of 
Paraquat.  Hydrogen peroxide was used at a concentration of 500 uM as positive control 
for reactive oxygen species detection.  Cultures were read in 5-15 minutes from initial 
treatment and six hour intervals thereafter until 24 hours.  Cultures were incubated at 37o 
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C with 5% CO2 between reads.  Reads were performed on a Biotek Synergy HT plate 
reader with excitation/emission at 485/528 and a bottom read with sensitivity of 60.  
Results are displayed as fold change over control.  Each concentration was tested in 6-8 
wells of each 96 well plate.  Plates were replicated at least 3 times with astrocytes from 
different lots or passages.  Statistics were performed as Two Way ANOVA with 
Bonferroni’s post-test.   
Mitochondrial Reactive Oxygen Species 
 Astrocytes were cultured as described above for 24 to 48 hours prior to treatment 
in 35 mm poly-d-lysine coated glass bottom dishes.  Cells were incubated in 1 uM 
Mitosox red, 50 nM Mitotracker green and 10 mg/mL Hoescht 33345 for 30 minutes 
prior to initial treatment with Paraquat.  Cells were then treated with Paraquat at 0.5, 5.0, 
50.0, 1000.0 uM concentrations for 0.5 or 16 hours.  Antimycin A was used as a positive 
control at 1 uM concentration.  10 fields per dish were imaged on a Zeiss Axiovert 200M.  
Images were analyzed in Adobe Photoshop version 6.0.  Each experiment was replicated 
a total of 4 times.  Statistical analysis of results were completed with a One-way ANOVA 
with Bonferroni’s post-test. * indicate p < 0.05.  
8-oxo-dG detection 
Astrocyte cultures were seeded at 5,000 cells/cm2 and cultured for 48 hours prior 
to treatment with Paraquat.  Cells were treated with Paraquat at 0.5, 5, 50 and 1000 uM.  
Complete medium was used as control and 500 uM H2O2 was used as positive control.  
Cells were incubated for two hours.  Cells were then fixed in 4% paraformeldahyde for 




RNA Sequencing and Alternative Splicing 
Libraries were created using Illumina Tru-Seq strand specific library preparation 
kits and sequenced on the Illumina HiSeq 2500. The fastq files were aligned against the 
MM10 reference genome using HISAT2 [202]. Reads were assigned to genes and 
counted using Rsubread [203] and differential calls made by DESeq2. Differential gene 
expression lists (tables 5-8) were submitted for gene ontology analysis through Panther 
Gene ontology database, and Ingenuity Pathway Analysis through Qiagen IPA software.   
Sequencing data from second experiment was sequenced with paired end reads 
allowing for alternative splicing analysis.  We used multivariate analysis of transcript 
splicing to find alternative splicing events [204].  Microglia and astrocyte cultures were 





TABLE 1.  ATAC-SEQUENCING SAMPLE LIST AND PRIMER INDEX 
 
Lot [PQ] uM Time (hours) Forward Primer Reverse Primer 
 A 0 24 N502 N701 
 A 0.5 24 N504 N701 
 A 5 24 N502 N702 
 A 50 24 N504 N702 
 B 0 24 N502 N703 
 B 0.5 24 N504 N703 
 B 5 24 N502 N704 
 B 50 24 N504 N704 
 C 0 24 N502 N705 
 C 0.5 24 N504 N705 
 C 5 24 N502 N706 
 C 50 24 N504 N706 
 A 0 72 N503 N701 
 A 0.5 72 N517 N701 
 A 5 72 N503 N702 
 A 50 72 N517 N702 
 B 0 72 N503 N703 
 B 0.5 72 N517 N703 
 B 5 72 N503 N704 
 B 50 72 N517 N704 
 C 0 72 N503 N705 
 C 0.5 72 N517 N705 
 C 5 72 N503 N706 





TABLE 2.  PCR AMPLIFICATION STEPS 
 Initial PCR amplification 
  No. of Cycles Temp (deg. C) Time (s) 
  1 72 300 
  1 98 30 








   
 Amplification Saturation 
  No. of Cycles Temp (deg. C) Time (s) 
  1 98 30 








   
 Finishing Cycles 
 
  No. of Cycles Temp (deg. C) Time (s) 
  1 98 30 











Figure 3.  An overview Assay for Transposase Accessible Chromatin Sequencing 
(ATAC Sequencing).  ATAC Sequencing is a current technology to assess the 
accessibility of chromatin in low numbers of cells.  Nuclei are extracted and DNA tag 
fragments are inserted into open regions of chromatin allowing for sequencing and 

















¼ of linear 
Fluorescence N cycles 
 A 0 24 4000 800 800 7 
 A 0.5 24 4600 1000 900 7 
 A 5 24 4400 800 900 7 
 A 50 24 4400 600 950 8 
 B 0 24 4600 800 950 7 
 B 0.5 24 4400 600 950 7 
 B 5 24 4600 800 950 7 
 B 50 24 4600 600 1000 7 
 C 0 24 4800 800 1000 8 
 C 0.5 24 4600 600 1000 7 
 C 5 24 4800 800 1000 7 
 C 50 24 4600 800 950 7 
 A 0 72 4200 800 850 7 
 A 0.5 72 4600 1000 900 6 
 A 5 72 4400 800 900 7 
 A 50 72 4400 800 900 6 
 B 0 72 4600 800 950 7 
 B 0.5 72 4200 800 850 7 
 B 5 72 4600 600 1000 8 
 B 50 72 4800 800 1000 7 
 C 0 72 4600 600 1000 8 
 C 0.5 72 4600 800 950 7 
 C 5 72 4800 800 1000 6 





PRIMARY HUMAN ASTROCYTES INDUCE DNA DAMAGE RESPONSE AND 
REDUCE OXIDATIVE DAMAGE MARKERS WHILE SURVIVING ACUTE 
LOW CONCENTRATION EXPOSURES OF PARAQUAT 
Introduction 
Many diseases of the human brain are debilitating, progressive, and have limited 
therapeutic options.  The origin of neural diseases have yet to be fully elucidated and recent 
evidence implicates both neurodegenerative and neuro-oncologic diseases to be multifactorial 
[205-207].    Current epidemiological evidence implicates environmental components may be 
involved in the onset of neural diseases [8-19].  The epidemiological evidence also illuminates 
the potential link between early exposure and later onset of disease through an increased risk of 
neural disease after early development exposure.  We hypothesize that this delayed effect of 
environmental stressors on the etiology of neural disease may be attributable to epigenetic 
remodeling events.   
One potential hypothesis in the development of neural disease is that the production of 
reactive oxygen species induced by pesticide exposure lead to irreversible damage events [171].  
There are several agricultural pesticides that work through the induction of oxidative stress 
[148, 151].  Inhibition of mitochondrial function, several of which are studied in the context of 
neurodegenerative disease [148, 158].  One such pesticide that is capable of both, is the 
herbicide Paraquat, which is available throughout the world and currently used in agricultural 
practices. 
Paraquat has been studied in the context of Parkinson’s disease models [172].   
Parkinson’s disease presents with a number of motor deficits including bradykinesia, stooped 
posture, and masklike facial expression resulting from disruption in the basal ganglia pathways 
by the loss of dopaminergic neurons [208].  Cognitive deficits may also be present in cases of 
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Parkinson’s disease which are reflected in a whole brain pathology that can be associated with 
the disease [208, 209].  Patients suffering cognitive deficit are often marked after death by the 
presence of Lewy bodies throughout the brain [210].   Often, the onset of symptoms is 
considered late stage of the disease and irreparable damage has already occurred [208].  The 
disease itself and its origin might start much earlier in life than previously predicted.  
Etiology of Parkinson’s disease has yet to be elucidated as there are limited genetically 
heritable influences that have been found to play a role in Parkinson’s disease.  Genetic 
mutations in genes such as LRRK2 and PARK2 have been linked to cases with a family history as 
well as sporadic cases but do not account for the majority of Parkinson’s disease cases [211, 
212].  Studies focused on pesticide exposure and agricultural links have also shown a strong 
correlation with development of Parkinson’s disease [18, 19].  Parkinson’s disease is prominent 
among epidemiological reports that find correlations between exposure of toxins and onset of 
neurodegenerative diseases.   One factor not accounted for regularly in Parkinson’s disease 
models is the potential presence of pesticides in early life.  It may be possible that early 
pesticide exposure alters the response of normal cells to later stressors and can lead to a 
neurodegenerative response.   
Here we examine the role of pesticides in normal human astrocytes.  Astrocytes are a 
critical support cell within the central nervous system and have potential to influence the loss of 
more sensitive neurons [213].  Our model system is based on primary fetal derived human 
astrocytes and their exposure to low concentrations of Paraquat.  Low concentrations of 
Paraquat may be more representative of concentrations present in the neural systems of in vivo 
models. Our primary focus is on the changes that occur in surviving astrocytes.  We examine the 
capability of primary human astrocytes to survive and the reactive oxygen species response to 
Paraquat.  We further examine chromatin accessibility of treated cells to identify potential 
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epigenetic remodeling events.  We find that primary astrocytes are capable of surviving low 
concentrations of Paraquat and also do not exhibit a detectable sustained change in reactive 
oxygen species.  We also find that Paraquat induces a reactive state in primary astrocytes that is 
concentration dependent. 
Primary human astrocytes can survive low concentrations of Paraquat  
Cell viability of primary human astrocytes to determine sub-lethal concentrations 
was first assessed using a 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide 
(MTT) assay.  The MTT assay has been used as a standard for cell viability in Paraquat 
exposure models and works through the conversion of MTT to formazan in the 
mitochondria.  In these experiments, astrocytes were exposed for 72 hours to 
concentrations of Paraquat ranging from 1000 uM to 0.5 uM.  Our data is consistent with 
other groups that show that high concentrations of Paraquat induce a loss of formazan 
signal, and is also consistent with other primary cell types in having a greater sensitivity 
than immortalized counterparts (figure 4A).  Astrocytes significantly lose viability at 62.5 
uM and higher concentrations of Paraquat.  There does appear to be a slight increasing 
trend in low concentrations of increased viability, but is not statistically significant.  The 
MTT assay has been a gold standard in Paraquat studies to assess cell viability and 
effectively measures mitochondrial function.  Our data indicate that at concentrations 
below 62.5 uM Paraquat, there is no significant effect on mitochondrial function.  While 
the MTT assay has been used a proxy for cell death and or proliferation we sought to 
assess cell survival using a triple stain live/dead assay to confirm our results. 
Using the mitochondrial function data, three concentrations were chosen below 
the significant loss in cell viability: 0.5, 5 and 50 uM.  These concentrations offer a range 
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to assess the impact of sub-lethal concentrations of Paraquat, and mirror what is found 
physiologically in in vivo studies for brain Paraquat concentration.  Also chosen was a 
relatively high concentration of 1000 uM Paraquat as concentrations similar to this value 
have been previously reported to have detrimental effects on the cell population.  500 uM 
H2O2 was chosen as a positive control due to the reactive oxygen species producing 
nature of Paraquat.  In the cell viability assays, primary astrocytes were exposed at the 
above mentioned concentrations for 24 and 72 hours.  Cell death was assessed by the 
uptake and nuclear staining of ethidium homodimer (red) and cell viability was assessed 
with calcein metabolism (green).  Hoescht staining demarcated nuclei of all cells.  
Survival results are reported as a ratio of calcein positive cells over total cells (hoescht 
stained nuclei).  Cell viability is significantly reduced in cells exposed to 1000 uM 
Paraquat and 500 uM H2O2 at 24 and 72 hours (figure 4B).  A discrepancy exists between 
the live/dead and mitochondrial viability assays in that at 1000 uM Paraquat there is 
about 50% cell survival (approximately 65% of control) and mitochondrial viability 
shows about 10% viability.  To differentiate the difference we assessed the total number 
of cells assayed at 24 and 72 hours as a percent of control and have a significant 
reduction in the total number of cells at these time points for both 1000 uM Paraquat and 
500 uM H2O2 indicating that some of the mitochondrial viability loss is from the reduced 
number of cells (figure 4C).  Of note is that the sub-lethal concentrations are indeed not 
lethal when considering the number of cells and survival of the cells are not statistically 




Sub-lethal Paraquat exposure in primary astrocytes fails to induce cytosolic 
Reactive Oxygen Species (ROS) above levels of control but transiently increases 
mitochondrial ROS. 
Paraquat is known to produce reactive oxygen species through Electron Transport 
Chain (ETC) complex inhibition.  We evaluated the effect of sub-lethal Paraquat on 
reactive oxygen species production in the whole cell by H2DCFDA, a fluorogenic 
compound that reacts indiscriminately with all reactive oxygen species.  At sub-lethal 
concentrations Paraquat is unable to exhibit reactive oxygen species levels above control 
levels.  However, in the lethal concentration, 1000 uM Paraquat, reactive oxygen species 
levels are significantly increased, although not to the same level as H2O2 (figure 5A).  We 
also sought to evaluate the levels of reactive oxygen species in the mitochondria as 
Paraquat is reported to produce superoxide radicals within the mitochondria.  Primary 
astrocytes were incubated in mitosox red, a fluorescent probe more specific to superoxide 
radicals, and mitotracker green as well as heoscht to demarcate cellular localization.  
Astrocytes were then exposed for 0.5 and 16 hours as an initial response and to define the 
mitochondrial Reactive oxygen species contribution after significant increase in total cell 
reactive oxygen species in the lethal dose.  Antimycin A, an inhibitor of the ETC, was 
chosen as a positive control.  There is a significant increase in level of mitochondrial 
reactive oxygen species at 0.5 hours for 0.5 uM Paraquat that is not present in the 
remaining concentrations including 1000 uM Paraquat (figure 5B,C).  At 16 hours, other 
than the increase in total cell reactive oxygen species for 1000 uM Paraquat, no Paraquat 
treatment condition has significant reactive oxygen species signal in comparison to the 
control.  The reactive oxygen species signal in primary astrocytes is only transient in the 
mitochondria for the lowest concentration and the highest concentration induces an 
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reactive oxygen species signal without significant reactive oxygen species signal in the 
mitochondria.   
Acute Paraquat exposure induces significant DNA damage response in primary 
human astrocytes at higherconcentrations 
 
We next evaluated the DNA damage response at sub-lethal concentrations by 
immunostaining for phosphorylated H2AX, an established DNA damage response marker 
(Figure 6).  Cells were also stained for Glial Fibrillary Acidic Protein (GFAP) as an 
astrocyte marker (figure 6A).  H2AX staining was significantly present in more cells at 
50 uM Paraquat despite not having a greater H2AX signal in each positive cell in both 24 
and 72 hour time points (figure 6B,C).  Additionally, H2AX signal was detected in more 
cells than control for both 1000 uM Paraquat as well as 500 uM H2O2.  The H2AX signal 
in each positive cell was no greater than control for 1000 uM at 24 hours, however, at 72 
hours there was a significant increase in signal per cell.  The opposite was found for 
H2O2, with the signal per cell at 72 hours no longer being significantly greater than 
control.  Additionally the signal at 72 hours for 1000 uM Paraquat was greater than the 
24 hour signal for 500 uM H2O2.   
Gene expression analysis in acute Paraquat exposure of primary human astrocytes 
displays a batch effect among experiments 
Our initial gene expression analysis of acute Paraquat exposure in primary human 
astrocytes (figure 7) indicated a significant batch effect in samples more dependent on 
replicate than experimental conditions.  Additionally, replicates clustered out independent 
of time in culture suggesting that the replicate samples are from very distinct groups of 
astrocytes potentially masking any measurable effect from acute Paraquat exposure.  In 
subsequent experiments, we repeated the acute exposure paradigm and assessed control 
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conditions based on the number of GFAP expressing cells and the ability to maintain a 
consistent population. 
Loss of Glial Fibrillary Acidic Protien (GFAP) in control conditions indicate acute 
exposure experiments need to be better controlled and repeated 
 
We initially assessed the number of GFAP positive cells in the H2AX data set 
from the initial experiments and in GFAP labeled cells from the repeat experiment (figure 
8).  In the initial acute Paraquat exposure experiments there is a loss in GFAP positive 
cells over the 72 hour window that occurs in lower concentration Paraquat conditions.  In 
the 1000 uM Paraquat 24 hour condition, there is a significant increase in GFAP positive 
cells, however, at 72 hours 1000 uM Paraquat is not significantly different than 24 hour 
control conditions.  With 500 uM H2O2 exposure the response is similar to the low 
concentration Paraquat exposures as well as control conditions.  This appears to indicate 
that the initial experiments may not be as well controlled as they could be.   
When we repeated the acute Paraquat exposure experiments, careful consideration 
was taken to control for as many variables as feasible.  Three separate donors were used 
as replicates to allow for biological variability, but the repeat experiment was performed 
on all three donor cell groups simultaneously with the same reagents to reduce technical 
variability.  We also used the earliest passage possible without sub-culturing to reduce 
potential differences in these cells which may have been induced by variability in sub-
culturing technique.  Previous experiments were performed in cells that had been sub-
cultured once.   
GFAP positive cells were assessed in the repeat experiment for all three donor 
types.  In control conditions, the 72 hour time window no longer induces a drop in the 
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percent of GFAP positive cells.  Additionally we see a concentration dependent increase 
in GFAP positive cells at 24 hours for all concentrations of Paraquat and for 500 uM 
H2O2.  The increase in GFAP positive cells is transient in Paraquat treated cells while 500 
uM H2O2 treated cells maintained higher numbers of GFAP cells.   
Nuclear oxidative damage marker is reduced in low concentration Paraquat 
exposure but not in high Paraquat concentrations 
To reaffirm and compliment initial studies we assessed reactive oxygen species 
response in primary human astrocytes using an oxidative damage marker 8-oxo-dG.  We 
assessed nuclear 8-oxo-dG staining as nuclear damage events would be most likely to 
drive apoptotic events or may generate mutations that drive oncologic events.  Primary 
human astrocytes were exposed to Paraquat (0.5, 5, 50 and 1000 uM) or 500 uM H2O2 for 
two hours in order to characterize an early astrocyte response which complements our 
mitochondrial reactive oxygen species studies.  In 8-oxo-dG nuclear staining at two 
hours, there was reduced staining in 0.5 and 5 uM Paraquat conditions from control, 
while 50 uM and 1000 uM Paraquat were unchanged as compared to vehicle treated cells 
(figure 9). .  500 uM H2O2 induced an increase in nuclear 8-oxo-dg staining.   
Initial results may be skewed by reactivity of the cell populations as indicated in 
figure 8; nuclear 8-oxo-dG staining does confirm a response to Paraquat in low 
concentration acute exposure.  In seeing a reduced intensity at the two lowest 
concentrations, we might expect that these cells have initiated a DNA damage response 
or reactive oxygen species mediating response that confers protection of the nuclear DNA 
from oxidative damage.  However, this response is itself ablated at higher concentrations 
and returns to control condition levels.  This may implicate that the stress response is 
overwhelmed and we are beginning to see nuclear oxidative damage return to normal 
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levels.  However, at 1000 uM Paraquat there is no significant increase in oxidative 
damage implicating that Paraquat induced oxidative damage is limited.  Another 
possibility remains that low level Paraquat exposure induces a stress response that ablates 
natural oxidative DNA damage better than control conditions but at higher Paraquat 
concentrations this condition is lost as the cell is beginning to respond to mitochondrial 
dysfunction. 
Discussion 
We set out to understand the impact of low Paraquat concentrations in primary 
human astrocytes as we expected that the astrocytes will alter their epigenetic profile and 
survive toxicant exposure.  We assessed basic parameters of survival in astrocytes 
exposed to Paraquat and found that acute exposure of 50 uM Paraquat and below the 
astrocyte cultures are capable of surviving.  We further assessed reactive oxygen species 
response in low concentrations and have found that only the lowest concentration, 0.5 uM 
Paraquat was able to induce a transient mitochondrial reactive oxygen species response.  
However, the total reactive oxygen species response over a 24 hour period was not 
significantly different than control conditions in the low concentrations.  Yet without a 
significant reactive oxygen species response we were able to detect DNA damage marker 
H2AX in 50 uM Paraquat treated cells at 24 and 72 hours.  The DNA damage response 
we detect is in the absence of a significant reactive oxygen species response.  H2AX 
demarcates double stranded DNA breaks.  In our exposure model the significant H2AX 
response may be attributable to a change in transcription as opposed to DNA damage 
repair [214, 215].   The other possibility remains that our measurement methods are not 
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sensitive enough to detect reactive oxygen species with lower concentrations of  Paraquat 
exposures. 
When we assess nuclear 8-oxo-dG, a marker for oxidative DNA damage, in the 
replicate experiment, we report a decrease in nuclear 8-oxo-dG signaling for the lowest 
Paraquat concentrations which may indicate an activation of DNA repair mechanisms or 
suppression of oxidative stress by Paraquat.  However, at higher concentrations nuclear 
8-oxo-dG returns to control levels ablating any protective effect.  The effect on nuclear 8-
oxo-dG signaling may be in part to a response seen in other organisms that increases 
viability and lifespan [216].  We hypothesize that we may be inducing a mild stress state 
that allows for repair mechanisms to work without creating additional burdens.  One 
potential investigational pathway for the reduction of nuclear 8-oxo-dG staining would be 
to examine the protein expression and translocation of transcription factors involved with 
oxidative stress pathways.  Additionally, we may be able to check transcription of targets 
for oxidative stress transcription factors to verify downstream effects of oxidative stress 
pathways.  In the event that oxidative stress pathways are not activated we would pursue 
mechanisms of reactive oxygen species suppression including investigating activity of 
electron transport chain members.  Electron transport chain activity has been linked to the 
production of reactive oxygen species, with both increased and decreased activity 
inducing higher reactive oxygen species levels. 
While we have yet to report significant gene expression changes, the replicate 
experiment proves to be encouraging in that the astrocytes clearly respond to Paraquat 
exposure at sub-lethal concentrations.  Future studies are planned pending results from 
the ATAC-seq experiments and would include first evaluating changes in gene 
62 
 
expression associated with Paraquat exposure followed by evaluating the DNA 
methylation changes that might be associated with acute Paraquat exposure.  With 
changes in gene expression data and DNA methylation we may be able to pinpoint 
specific epigenetic remodelers to target in our assessment of the effect of Paraquat in 
epigenetic remodeling.   An additional future direction is to target chronic long term 




Figure 4.  Primary human astrocytes can survive low concentrations of Paraquat.  
A)  MTT viability assay of primary human astrocytes exposed to a two-fold dilution from 
1000 uM Paraquat to vehicle.  Significant loss in viability begins at 62.5 uM and 
continues at higher concentrations, below 50 uM no significant loss of viability exists.  B)  
Survivability results from primary astrocytes exposed to vehicle, Paraquat (0.5, 5, 50, and 
1000 uM) or 500 uM H2O2 as determined by triple stain viability.  Significant loss of 
survivability exists at 24 and 72 hours in both 1000 uM Paraquat and 500 uM H2O2.  C)  
Total cells surveyed as percent of control in triple stain results.  At 72 hours, 1000 uM 
Paraquat and 500 uM H2O2 exposed cells exhibit significantly fewer cells than that of 
control counterparts.  D)  Fluorescent images of triple stain assay at tested concentrations 
and time points.  Hoescht 33345 (blue) indicate nuclei; Calcien (green) indicates 
fluorescent product of mitochondrial respiration, and ethidium homodimer (red) indicates 
nuclei of dead cells as ethidium homodimer is not cell permeable. The cell images also 
indicate that the primary astrocytes appear to be thriving in the presence of Paraquat as at 
5 and 0.5 uM Paraquat the morphology appears the same as the controls (figure 1D).  
However, at 5 uM there does appear to be some differences in morphology.  1000 uM 




Figure 5.  Sub-lethal Paraquat exposure in primary astrocytes fails to induce 
cytosolic Reactive Oxygen Species (ROS) above levels of control but transiently 
increases mitochondrial ROS.  A)  H2DCFDA non-discriminate measurement of 
reactive oxygen species at six hour intervals in primary astrocytes exposed to Paraquat 
(0.5, 5, 50 and 1000 uM) or 500 uM H2O2.  1000 uM Paraquat is the only concentration 
with significant detection of reactive oxygen species.  500 uM H2O2, used as a positive 
control initiates a much higher response than that of the highest concentration of Paraquat 
tested.  B)  Measurement of mitochondrial reactive oxygen species with 1 uM mitosox 
red, 50 nM mitotracker green and 10 mg/mL Hoescht 33345 in primary astrocytes 
exposed to Paraquat (0.5, 5, 50, 1000 uM) or 1 uM antimycin A as a positive control.   
Antimycin A, an electron transport chain inhibitor, induces significant increase over 
control of mitochondrial reactive oxygen species.  0.5 uM Paraquat significantly 
increases mitochondrial reactive oxygen species at 30 minutes but is attenuated at 16 
hours compared to control.  The remaining concentrations do not induce significant 





Figure 6.  Acute Paraquat exposure induces significant DNA damage response in 
primary human astrocytes in high sub-lethal to lethal concentrations.  A)  
Fluorescent images of primary astrocytes exposed to vehicle, Paraquat (0.5, 5, 50, and 
1000 uM) or 500 uM H2O2.  DAPI (blue) indicate nuclei; GFAP (red) indicate glial acidic 
fibrillary protein, a cytoskeletal protein found in astrocytes; and H2AX (green) indicate 
phosphorylated H2AX histones, a marker for DNA damage.  B)  Ratio of H2AX positive 
cells over total cells (left) and total signal per positive cell (right) at 24 hours of exposure.  
H2AX positive cell ratio indicates 50.0 uM and 1000 uM Paraquat and 500 uM H2O2 
have significantly greater number of DNA damage responding cells.  H2AX signal per 
H2AX positive cell is significantly more in only positive control, 500 uM H2O2.  C)  
Ratio of H2AX positive cells over total cells (left) and total signal per positive cell (right) 
at 72 hours of exposure.  H2AX positive cell ratio is significantly more than control in 50 
uM, and 1000 uM Paraquat as well as 500 uM H2O2, with 1000 uM Paraquat having a 
higher ratio than 500 uM H202.  H2AX signal per H2AX positive cell is significantly 




   
Figure 7.  Gene expression analysis in acute Paraquat exposure of primary human 
astrocytes displays a batch effect among experiments.  RNA was collected from 
primary human astrocytes exposed to Paraquat (0.5, 5, and 50 uM) for 24 or 72 hours.  
RNA sequencing was performed on collected samples and results are indicated in 
distance clustering plot.  Clustering indicates that data seperates into clusters of 




Figure 8.  Loss of Glial Fibrillary Acidic Protein (GFAP) in control conditions 
indicate acute exposure experiments need to be better controlled and repeated.  The 
number of GFAP positive cells were counted in the first series (A) and the second series 
(B) of experiments.  Cells were cultured on coverslips for 48 hours prior to treatment 
with Paraquat (0.5, 5, 50, and 1000 uM) or 500 uM H2O2.  Cells were treated with an 
acute exposure for 24 or 72 hours, fixed in 4% paraformaldehyde, and stained for GFAP.  
In control conditions there is a drop in the number of GFAP expressing cells for 
experiment 1 (A) over 72 hours, which is not present in experiment 2 (B).  This indicates 
that experiment 2 was better controlled as the cells are stable over the 72 hour period.  
Additionally in experiment 2, there is a transient, concentration dependent increase in 




Figure 9.  Nuclear oxidative damage marker is reduced in low concentration 
Paraquat exposure but not in high Paraquat concentrations.  Primary human 
astrocytes were cultured on poly-D-lysine coated coverslips for 48 hours prior to 
treatment.  Astrocyte cultures were treated with Paraquat (0.5, 5, 50 and 1000 uM), 500 
uM H2O2, or complete medium for two hours. Cells were then fixed with 4% 
paraformeldahyde, and stained with anti-8-oxo-dG antibody.  Images were captured for 
seven fields in each condition in each astrocyte donor type and intensity of 8-oxo-dG 
staining was measured for the nuclear area as defined by DAPI stained nuclei.  Results 
indicate average intensity per nuclei.  0.5 and 5 uM have reduced intensity in nuclear 
staining of 8-oxo-dG compared to control  while 50 and 1000 uM remain at control 
levels.  500 uM H2O2 positive control has significantly more nuclear staining for 8-oxo-
dG than that of control.  Statistical differences were determined by One-way ANOVA 




GLIAL CELL MITOCHONDRIAL FUNCTION AND REACTIVE OXYGEN 
SPECIES RESPONSE TO PARAQUAT IS DEPENDENT ON CELL TYPE  
Introduction 
The human nervous system is comprised of a heterogeneous mix of cell types 
(figure 10) with multiple origins.  Neurons, astrocytes and oligodendrocytes all arise from 
neural progenitor cells while brain vascular pericytes and microglia arise from cell 
lineages outside of the central nervous system [217-221].  The cell lineage of brain 
vascular pericytes is not clear. Brain vascular pericytes can arise from the same neural 
progenitors as astrocytes and neurons and integrate in non-neural lineage brain vascular 
pericytes, generating a mixed origin population of brain vascular pericytes [220, 221].  
Microglia are considered myeloid in origin and migrate into the central nervous system 
during development [222].  Schwann cells are myelinating cells of the peripheral nervous 
system, and these cells arise from neural progenitor cells but migrate outside of the 
central nervous system conferring a difference in accessibility to environmental toxicants 
[223, 224].   
Each of these cell types have unique functions in the nervous system.   Neurons 
vary in function and morphology that is entirely dependent upon the context of the region 
of the brain in which they are found.  The primary function of neurons are to 
communicate signals in circuits established during development.  Astrocytes are a 
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ubiquitous cell type found throughout the nervous system.  Their function is primarily to 
support neuronal function and do so by secreting trophic factors and facilitating neuronal 
synapses [225].  They also maintain an immune capacity and function in the event of 
trauma to develop glial scarring preventing further neuronal death [226].   
Microglia are the primary immune cell of the central nervous system and can 
recruit additional immune mediating cells in the event of disease [227, 228].  Microglia 
interact closely with astrocytes to facilitate the immune response [229].  Microglia also 
act to clean up the neural environment [230].  Oligodendrocytes and Schwann cells act in 
a similar capacity but in two distinct locations [231].  Both cell types act to myelinate 
axons and facilitate neuronal signaling, but oligodendrocytes are limited to the central 
nervous system while their counterparts, Schwann cells inhabit the peripheral nervous 
system.  Brain vascular pericytes are a major component of the blood brain barrier [232].  
Brain vascular pericytes facilitate communication between microglia and the immune 
cells outside of the central nervous system [233].  Considering many of these cell types 
have different cell lineages and functional significance we propose that different cells 
will respond differently to the same stimulus. 
We chose Paraquat as our stimulus to assess the effect in different primary cells 
types because of the links between environmental exposure and neurodegenerative 
diseases [8-19].  Others have reported in vitro effects of Paraquat on neurons and other 
immortalized cell lines [98, 149, 156, 157, 162].  Our study examines the effect of 
Paraquat in primary glial cell types in two species.  We examine human microglia, brain 
vascular pericytes and Schwann cells and murine astrocytes and microglia to address that 
different cell types respond differently to the same stimulus.  We assessed mitochondrial 
71 
 
viability and reactive oxygen species response, two parameters reported to be affected by 
Paraquat.  We found that Paraquat exposure differentially affects mitochondrial function 
dependent on cell type.  However, we found that in human cells Paraquat induced a 
similar reactive oxygen species response while in murine cells there was a differential 
response.  Additionally we found that an immortalized microglia cell line, BV2, had a 
differential reactive oxygen species response than the primary microglia counterparts.   
Mitochondrial Viability 
Mitochondrial viability is cell dependent in Paraquat exposure 
Mitochondrial viability was assessed in fetal derived primary human Brain 
Vascular Pericytes (BVP) (figure 11 A), Schwann cells (hSC) (figure 11 B) and 
Microglia (hM) (figure 11 C, D) primarily to assess the effect of Paraquat on cells and 
secondarily as a proxy for cell viability.  All cell types were cultured for 24 to 48 hours 
prior to treatment and subsequently treated with Paraquat for 72 hours.  Mitochondrial 
viability was assessed through MTT assay.   
BVP exhibit a significant decrease of about 65% in mitochondrial viability at 125 
uM Paraquat.  Concentrations below this value do not show a significant decrease in 
mitochondrial viability.  Concentrations above 125 uM show the most reduced viability 
at approximately 90% loss in mitochondrial viability.   
hSC exhibit a significant loss in mitochondrial viability at 125 uM Paraquat with 
approximately 50% of the population remaining viable.  At 250 uM Paraquat, 25% of the 
hSC population remain viable.  Although not statistically significant, there also appears to 
be a downward trend in viability at 16 uM Paraquat on up to 62.5 uM Paraquat.  
Concentrations below 16 uM are not different from the control population.   
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IL1B stimulates growth in hM [234] and also stimulates an inflammatory 
response in hM [235].  hM do not actively divide without stimulation, requiring the 
addition of IL1B in hM cultures to prolong culture conditions.  In an effort to assess 
chronic Paraquat exposure over multiple population doublings in vitro we first sought to 
characterize the effect of IL1B in the response of hM to Paraquat mitochondrial viability 
(figure 11 D).  We also sought to address the effect of Paraquat on mitochondrial viability 
in unstimulated hM (figure 11 C).  Cells were treated with the same paradigm as above 
with reduced number of different concentrations to account for the limited availability of 
hM.  Unstimulated hM exhibit a significant loss with the addition of Paraquat with 65 to 
75 percent remaining viable in concentrations of Paraquat at 64 uM and below.  At 1000 
uM, unstimulated hM retain 10 percent viability.  In the hM viability assays, 500 uM 
H2O2 was used as a positive control to induce cell viability loss.  In unstimulated hM, 500 
uM H2O2 retain viability at 10%.  Stimulated hM also have a significant decrease in 
mitochondrial viability in all Paraquat treatment conditions with the exception of 32 uM 
Paraqaut.  The decrease is less than that of unstimulated hM with a gain of 10 to 15 
percent in viability between matched concentration sets in unstimulated versus stimulated 
hM.  The exception to this is at 1000 uM Paraquat where no gain is observed and 
potentially a decrease may be observed.  In the H2O2 treated stimulated hM, viability is 
significantly decreased from the control stimulated hM but only reduced to 60 percent 
viability compared to a 10 percent viability in unstimulated hM. 
We also sought to assess the effect of Paraquat storage in sterile water at 4o C for 
a period of 3 months.   We used BVP as the cell type to screen with as these cells grow 
quite well.  Cells were treated with the same paradigm as above, with fewer conditions 
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centered around the potential cutoff point of 50 uM Paraquat. 72 hours exposure to 0.5 
uM and 5 uM Paraquat had no difference from control in either freshly prepared or 3 
month old Paraquat preparation.  50 uM Paraquat was significantly reduced in fresh 
Paraquat preparation and reduced but not significant in the 3 month old preparation.  The 
50 uM Paraquat conditions were not significantly different from one another in the both 
preparations.  The 1000 uM Paraquat was significantly reduced from control conditions 
in both preparations and the conditions were not significantly different from one another.  
500 uM H2O2 was also significantly reduced in both preparations that were not 
significantly different from one another. 
Murine glial cells have a differential mitochondrial response to acute Paraquat 
exposure. 
We also sought to assess the effect of Paraquat on mitochondrial viability in 
primary murine neonate derived astrocytes (mA) and microglia (mMG)  in vitro.  mA and 
mMG were derived from 1 to 3 day old pups on the C57bl6 background.  Cells were 
cultured from mixed brain cultures and incubated for 24 to 48 hours prior to Paraquat 
treatment.  Cells were then exposed to Paraquat for 72 hours and mitochondrial viability 
was assessed with MTT. 
mA mitochondrial viability at 0.5 and 5 uM Paraquat conditions is unchanged 
from control (figure 12 A).  At 32 uM Paraquat and above there is a significant loss of 
mitochondrial viability to 25% remaining or less as the concentration increases.  500 uM 
H2O2 also has a significant loss in mitochondrial viability with nearly all viability lost.   
mMG showed an increase in mitochondrial viability at 0.5 uM Paraquat with 
approximately 25% increase over control.  5 uM Paraquat was not significantly different 
than the control condition, while 32 uM Paraquat and above all exhibit a significant loss 
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in viability with less than 20 percent remaining in each of the higher concentrations.  500 
uM H2O2 also showed a significant loss in mitochondrial viability remained with more 
mitochondrial viability than that of the 1000 uM Paraquat.   
 
Reactive Oxygen Species Response 
Paraquat induced reactive oxygen species response is similar in different human 
glial cells. 
Paraquat has been reported at high concentrations to have a significant reactive 
oxygen species response in many cell types.  We sought to assess the levels of reactive 
oxygen species in BVP and hSC at concentrations below the significant loss in 
mitochondrial viability (figure 13).  Cells were cultured for 48 hours prior to treatment 
with Paraquat or H2O2, a positive control.  Reactive oxygen species levels were assessed 
with H2DCFDA pretreatment followed by Paraquat exposure.  Reads were conducted at 6 
hour intervals.  At concentrations of 0.5 uM, 5 uM, and 50 uM Paraquat; there was no 
measurable difference from control conditions in either BVP or hSC.  At 1000 uM 
Paraquat there was a significant and sustained reactive oxygen sspecies signal measured 
at 6 hours in both BVP and hSC.  500 uM H2O2 had a significant signal that was 
sustained from six hour read onwards in both BVP hSC.  The reactive oxygen species 
response in both cell types is similar at 500 uM H2O2 at 2.5 to 3 fold increase over 
control.  The 1000 uM Paraquat shows some difference in respect to cell type with BVP 
showing a 1.4 fold increase over control (figure 13 A) and hSC showing a 1.6 fold 




Paraquat induced reactive oxygen species response in murine glial cells is cell 
dependent. 
We also sought to assess murine glial cells in reactive oxygen species response to 
Paraquat at sub-lethal and lethal concentrations.  Primary murine cells were isolated from 
neonatal pups as described above and cultured for 48 hours prior to treatment.  Cells were 
pretreated with H2DCFDA and then treated with Paraquat at 0.5, 5, 50 and 1000 uM 
Paraquat.  500 uM H2O2 was used as a positive control in primary murine cells.  There is 
a distinct reactive oxygen species response between the mA (figure 14 A) and the mMG 
(figure 14 B). 0.5, 5 and 50 uM Paraquat in mA and mMG were not detectable above 
control conditions and 500 uM H2O2 showed a 2.5 to 3.0 fold change over control 
conditions.  However, the cells differed in their response to the lethal concentration of 
1000 uM Paraquat.  mA showed an increasing trend above control conditions which was 
only significant at 18 hours.  mMG showed an increased reactive oxygen species level 
that initiated and was significant at 6 hours and continued to climb up until 18 hours.  mA 
only showed at 18 hours a 1.2 fold increase over control conditions while the mMG 
showed as high as 1.8 fold increase over control conditions. 
Published literature which includes data assessing whole cell in vitro reactive 
oxygen species find reactive oxygen species production at lower concentrations than we 
are reporting here with primary cells.  We sought to verify our conditions against a 
published cell line with a H2DCFDA protocol and selected BV2 microglia, a C57bl6 
neonatal derived immortalized cell line reported to be similar in function to primary cells 
[236].  BV2 microglia were cultured for 48 hours prior to treatment.  Cells were then 
subjected to the same protocol as above.  BV2 microglia show a reactive oxygen species 
response similar to the published results but different than that of primary cells (figure 14 
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C).  BV2 microglia have a robust and sustained response at 3 hours with 1000 uM 
Paraquat; earlier than that of the primary counterpart.  The maximal reactive oxygen 
species response to 100 uM Paraquat is at 2.5 fold over control much higher than the 
maximal primary cell response.  In 50 uM Paraquat treatment the reactive oxygen species  
response is significant at 5 hours and continues to climb until 18 hours nearly matching 
the 1000 uM Paraquat response.  5 uM Paraquat response becomes significant at 18 hours 
at approximately 1.3 fold above control conditions.  Both of these concentrations in the 
mMG primary cells did not have a response above control conditions.  0.5 uM Paraqaut 
did not elicit a response above control conditions matching the primary mMG cells.   
Discusssion 
In our study evaluating different glial cell types and their response to direct 
exposure to Paraquat we found that the different glia respond differently in two basic 
parameters:  mitochondrial function and reactive oxygen species response.  
Mitochondrial function is completely dependent on cell type as human glial cells respond 
differently than the murine counterparts (figures 4A, 11 and 13) and differently from one 
another.  Schwann cells and brain vascular pericytes survive acute Paraquat exposure at 
higher concentrations than that of other neuroglia including astrocytes.  Schwann cells 
offer the capacity to provide a protective function to neurons in biologically averse 
environments.  This function might provide for internal mechanisms allowing schwann 
cells to compensate for toxicants.  This may apply to brain vascular pericytes as well, as 
blood brain barrier function is maintained in the presence of Paraquat [163].  Blood brain 
barrier maintenance is critical for protection of the neural environment.   
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Interestingly microglia mitochondrial response is different in the two species as 
murine microglia have increased mitochondrial function at 0.5 uM while the human 
counterpart exhibits the opposite with reduced mitochondrial function.  This study is 
limited in the interpretation that can be drawn as our mitochondrial assay measures the 
ability of cells to convert MTT to formazan which can be a function of increased 
mitochondria through increased cells or mitochondrial biogenesis or increased 
mitochondrial efficiency.   
There remains a possibility that murine microglia have been activated by Paraquat 
stimulus and the activated microglia survive and proliferate in low Paraquat 
concentrations.  Activation status may play a role in microglial response to Paraquat as 
the human microglia lose mitochondrial function without IL1B but regain mitochondrial 
function at 32 uM Paraquat in the presence of IL1B.  This may reflect a threshold that 
must be reached before mitochondrial function is ramped up that is lower in murine 
microglia.   
One significant difference in the microglia is the difference in 500 uM H2O2 
exposed cells.  IL1B treated human microglia show much reduced mitochondrial function 
compared to untreated human microglia and primary murine microglia.  Microglia have 
the potential to survive reactive oxygen species in an inflammatory state but the murine 
microglia are reduced to levels similar to high Paraquat exposure. This is in contrast to 
activated human microglia.  Two potential explanations exist; that the murine microglia 
in our model are not activated in the culturing method, or human microglia have unique 
adaptive responses for oxidative stress environments.  In either case there is a significant 
difference in how human versus murine microglia respond to insults.  This warrants 
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further investigation as microglia have been implicated in the development and 
progression of both cancer and neurodegeneration.  
While high Paraquat is reported to induce reactive oxygen species in the 
microenvironment, the IL1B treated microglia don’t show a different response than that 
of untreated human microglia, indicating that at high concentrations, the mechanism that 
exists to preserve mitochondrial function in the presence of H2O2 cannot compensate for 
Paraquat loss in mitochondrial function.  This may offer a clue as to the protective 
mechanism in human microglia.  One critical piece of information that is necessary for 
better understanding the impact of Paraquat on human microglia is the reactive oxygen 
species response.  We can see in the murine microglia that the reactive oxygen species 
response is significant in the highest level of Paraquat, much earlier and higher as  
compared to the murine astrocytes response.  Understanding the human microglia 
reactive oxygen species response, especially at 32 uM Paraquat might offer insight into 
potential stress response pathways.   
BV2 microglia have been reported as a good proxy for microglia as they are 
proliferative and display many of the same qualities as primary microglia making them 
easier to propagate and use in experiments.  Our data shows, however that BV2 microglia 
respond differently to similar  levels of reactive oxygen species than their non-
immortalized primary cell counterparts.  Not only do the BV2 respond earlier than the 
primary counterpart, they also respond at much lower concentrations.  Some Paraquat 
literature is based on reactive oxygen species work in BV2 microglia which may 
arbitrarily raise attention to reactive oxygen species damage and response mechanisms 
[160].  Our data also shows primary cells having reduced mitochondrial function at much 
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lower concentrations of toxicant exposures than that of published literature on many cell 
lines [148, 160, 162, 167, 168].  We also show that murine astrocytes have lower 
threshold of mitochondrial inhibition than human astrocytes, but the reverse is true for 
microglia.  Human microglia have reduced mitochondrial function at the lowest Paraquat 
concentration we tested.  Two conclusions can be made from this; cells can survive low 
acute exposures of Paraquat, but mitochondrial function of these cells is impacted at 
much lower concentrations in glia than previously reported [160].   
A caveat to the data presented here exists in the in vitro nature of the cells.  With 
monotype cell cultures we ignore the impact other cells have in Paraquat exposure.  
Microglia are reported to convert Paraquat to a monovalent cation, the only form that can 
traverse the dopamine transporter [167].  Astrocytes have been reported to express the 
dopamine transporter [237].  This might be affecting the bioavailability of Paraquat to 
astrocytes.  Additionally, astrocytes may play a role in activating microglia [238]. This 
could fundamentally change the microglia response to Paraquat.  However, despite these 
points, in vitro culture is necessary in the study of epigenetics as each cell type has a 
distinct epigenetic profile and mixed populations can mask epigenetic remodeling events. 
Our data begins to assess that different cells respond differently to the same 
environmental stimulus, further investigation is warranted into how each of these cell 
types are responding.  Further work is necessary in understanding the genetic response of 
the different glial cells to Paraquat exposure.  Additionally we need to assess if Paraquat 
is unique in its effect on the different glial cells or if there is one programmed response in 
each cell type to a range of environmental toxicants.  Additional co-culture studies would 
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be necessary to determine some of the interactions between the cells and how that plays a 





Figure 10.  Heterogeneity of the nervous system.  Schematic of the main cell types 
within the nervous system.  The heterogeneity of the human nervous system indicates the 
need for assessing other cell types considering the interactions that can take place 





Figure 11.  Mitochondrial viability is cell dependent in Paraquat exposure. 
Mitochondrial viability in the presence of Paraquat in additional glial cell types: A) brain 
vascular pericytes, B) Schwann cells, and microglia in the C) absence or D) presence of 
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Figure 11 Cont.  IL1B.  E)  Paraquat still affects mitochondrial function equally well 
after 3 months in water.  Cell types were exposed to single concentration of Paraquat for 
72 hours and results were determined by quantification of metabolized MTT.  * indicate 




Figure 12.  Murine glial cells have a differential mitochondrial response to acute 
Paraquat exposure.  Mitochondrial viability of murine A) astrocytes and B) microglia 
after 72 hours of Paraquat exposure as determined by metabolized MTT.  Murine 
astrocytes have a significant loss in viability at 32 uM Paraquat and higher 
concentrations.  Concentrations at 5 uM and below show no significant loss in 
mitochondrial viability.  Murine Microglia exhibit a loss in mitochondrial viability at 32 
uM and higher concentrations of Paraqaut. However, at 0.5 uM Paraquat, microglia 
mitochondrial viability is significantly higher than that of control conditions. * indicate p 





Figure 13.  Paraquat induced reactive oxygen species response is similar in different 
human glial cells.  Reactive oxygen species were assessed over 24 hours at six hour 
intervals in A) brain vascular pericytes and B) Schwann cells exposed to Paraquat.  
Reactive oxygen species were assessed with H2DCFDA and fluorescence was measured.   
1000 uM Paraquat induces a sustained reactive oxygen species response in both cell types 
whereas concentrations at 50 uM and below have no significant impact on reactive 
oxygen species response.  * indicate p < 0.05as determined by two-way ANOVA 





Figure 14.  Paraquat induced reactive oxygen species response in murine glial cells 
is cell dependent.  Reactive oxygen species were assessed over 18 hours at three hour 
intervals in murine A) astrocytes and B) microglia exposed to Paraquat.  Reactive oxygen 
species response in C) immortalized BV2 murine microglia to Paraquat assessed over 18 
hours with 3 hour intervals up to 9 hours and a final read at 18 hours.   Reactive oxygen 
species were assessed with H2DCFDA and fluorescence was measured.   Primary murine 
astrocytes have a significant reactive oxygen species response to Paraquat at 1000 uM 
and 18 hours of exposure.  All other Paraquat concentrations tested in primary astrocytes 
have no significant impact.  Primary murine microglia have a significant reactive oxygen 
species response that initiates between 3 and 6 hours at 1000 uM Paraquat.  All other 
Paraquat concentrations tested in primary microglia show no significant impact.  BV2 
immortalized microglia have a significant reactive oxygen species response in 
concentrations as low as 0.5 uM Paraquat.  Higher concentrations tested have an earlier 
initiation of reactive oxygen species response as well as a greater fold change over 






LONG TERM CULTURE INDUCES DNA METHYLATION CHANGES 
PREVENTING STUDY OF LONG TERM PARAQUAT EXPOSURE IN VITRO 
IN PRIMARY NEURAL CELLS 
Introduction 
          Primary samples are critical to our understanding of environmental exposure driven 
epigenetic reprogramming. Cell lines often have altered molecular machinery that allows 
for the continued propagation of the cell line which allows immortalized cell lines to 
respond differently to treatment conditions [239-242].  The use of primary samples has 
driven the field of developmental biology as a natural state to study molecular machinery 
[41, 243, 244].  A field that has increased the understanding in both disease and 
development fields is the field of epigenetics [245, 246].  As mentioned in the 
introductory chapter, epigenetic modifications target a number of unique gene regulatory 
elements including histone modification and polycomb repressor complexes [247, 248] as 
well as DNA base modifications specifically 5-methylcytosine and 5-
hydroxymethylcytosine [249, 250].   
DNA base modifications are often the first measure of epigenetic changes in a cell 
because they are considered to be stable and are easy to quantitate using various loci 
specific and genome wide techniques.  DNA base modifications facilitate gene 
expression control through a number of mechanisms that can increase or decrease gene 
expression with the former being more often the case [251].  5-methylcytosine 
modifications are facilitated through enzymes that directly covalently modify cytosine 
residues with in DNA structure.  DNMT1 facilitates the maintenance of appropriated 
methyl modifications as cells replicate [252, 253].  DNMT3a and DNMT3b facilitate de 
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novo methylation and are may function in concert with other known epigenetic regulatory 
complexes including the polycomb group [254-256].  DNA demethylation events are 
indirect as currently no known direct DNA demethylase exists [257].  TET family 
proteins oxidize the methyl group forming an intermediate form; 5-
hydroxymethylcytosine [258].  Subsequent degradation events occur in the conversion 
through 5-formylcytosine to 5-carboxylcytosine [259].  The resultant product has been 
proposed to be removed through base excision repair or enzymatically [260, 261].  The 
inability of DNMT1 to recognize 5-hydroxymethylcytosine as a substrate also prevents 
the propagation of a cytosine modification thereby providing a second avenue for 
demethylation [55].    
Recent work has been established to evaluate the differences in epigenetic profiles 
of primary cell populations induced in culture.  Much of this work resides in stem cell 
populations in understanding how better to expand these populations for therapeutic 
purposes or in the context of understanding how to improve in vitro fertilization success 
rates [262, 263]. Mesenchymal stem cells are perceived to be of high therapeutic 
potential in their ability to differentiate into numerous cell types [264-266].  
Mesenchymal stem cells exhibit decreased overall DNA methylation in long term culture 
[267].  Mesenchymal stem cells also contain specific DNA methylation sites termed CpG 
clock sites that can be utilized to identify culture passage of tested mesenchymal stem 
cells [268, 269].  Hematopoetic stem cells (HSC) and their progenitors have been shown 
to gain methylation in short term culture, illustrating that different cell types display 
different responses to long term culture [270]. 
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Little is known about the effects of long term culture on the epigenome in 
differentiated primary cell types.  The importance of understanding how long term 
culture affects primary cell populations is implicit in the evaluation of the difference 
between disease points and the corresponding cell of origin when comparing epigenetic 
marks.  Of particular interest to our and other groups is the role of epigenetic remodeling 
events that occur in the neural environment and the long term ramifications of these 
changes [271, 272].  As with other cancers; neural cancers exhibit greatly altered 
epigenetic profiles with DNA methylation when compared to normal primary cells [155, 
273, 274].  Additionally neural cell populations in patients with neurodegenerative 
diseases also exhibit altered DNA methylation profiles [275, 276].  Understanding the 
etiology of these diseases from an epigenetics perspective requires a baseline of 
epigenetic profile from the native state of the cell type.  Here we evaluate the effects of 
long term culture in primary human astrocytes, brain vascular pericytes, as well as 
schwann cells on DNA methylation to better evaluate the best baseline cell population for 
comparison.  We find through Illumina 450k beadchip arrays significant differences in 
DNA methylation between initial culturing and subsequent passages in all three cell 
types. 
Prolonged cell culture induces phenotype changes in primary cells 
To evaluate the effect of long term culture we cultured primary human astrocytes, 
brain vascular pericytes, and schwann cells for 21 days collecting representative samples 
at each subculture point (figure 15 A).  We first sought to evaluate cellular phenotype 
across passage points.  Astrocytes are commonly identified by cytoskeletal marker glial 
fibrillary acidic protein (GFAP) which was used for initial assessment of purity [277].  
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As the astrocyte cell population are cultured across passages GFAP expression is less 
prominent and few cells express detectable levels of GFAP at passage 4 (figure 15 B).  
Brain vascular pericytes are marked by immunostaining of α-smooth muscle actin (α-
SMA) a cytoskeletal filament specific to pericytes [278].    The expression of α-SMA is 
retained throughout the latest passage observed (figure 15 B) in all cells imaged 
indicating a single cell type present in culture.  However, at passage 4 brain vascular 
pericyte morphology has shifted from small stellate cells to a flat amoebic morphology.  
Schwann cells can be marked by a number of cytological markers.  S100 is a common 
marker for Schwann cells, but not specific to Schwann cells exclusively [279, 280].  To 
uniquely identify Schwann cells, GFAP expression in conjunction with S100 was used as 
multiple neural cell populations express GFAP [281].  The expression of GFAP and S100 
in the cultured cells appears to be heterogeneous among cells but each cell expresses 
either protein to some degree.  Overall GFAP expression appears to decrease over 
passaging while S100 increases in expression in later passages.  Schwann cells also 
appear to undergo a morphological shift in passage 4 exhibiting a more flattened 
morphology then preceding passages. 
Prolonged culture induces DNA methylation changes in primary human cell types 
Utilizing the Illumina 450K beadchip array we examined DNA methylation in 
astrocytes, brain vascular pericytes, and Schwann cells from the earliest passage available 
(p.2) to a later passage (p.5).   Data represent sites that are differentially methylated 
between early and later passages (figure 16 A).  For all three cell types the majority of 
differences include losses of methylation across passage points.  The majority of 
differential methylation shifts from hypermethylated or hypomethylated to 
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hemimethylated, with few sites shifting from one extreme to the other.  Astrocytes 
exhibit differential methylation in intermediate passage 3 which is exacerbated and 
propagated in passages 4 and 5.  However, there is no clear distinction between passage 4 
and 5.  This indicates that there are two shifts in methylation status of Astrocytes with the 
more dramatic being the shift between passage 3 and 4.  The sites that exhibit differential 
methylation at the early passage are further exacerbated in the shift in methylation at later 
passages.  Brain Vascular Pericytes hold their initial methylation pattern out to passage 4 
before the appearance of a large shift in sites that are differentially methylated.  Schwann 
cells exhibit a shift at passages later than passage 3, however, with the passage 4 data not 
present no distinction about when this shift occurs can be made. 
We next characterized the persistence of these changes across the passage points 
for astrocytes, brain vascular pericytes and Schwann cells (figure 16 B).  In each of the 
cell types there are a number of differentially methylated sites that are retained 
throughout the passages.  Of the earliest initiation in differential DNA methylation, 
astrocytes retain 73% and 97% of increased and decreased methylation respectively 
whereas pericytes retain 12% and 61% increased and decreased methylation respectively.  
Schwann cells retain 43% increased and 61% decreased of the initiating differential 
methylation.  After passage 4 of both astrocytes and brain vascular pericytes, the 
differential methylation is altered across greater number of sites and the retention of those 
sites holds at 97% and 67% increased and decreased for astrocytes and 37%and 77% 
increased and decreased for brain vascular pericytes.  Of note there are a number of sites 
that are dynamic between passages, likely reflecting a dynamic role for DNA 
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methylation.  To further understand the importance of these sites we examined where 
these sites occur. 
Changes in DNA methylation occur outside of CpG islands and transcription start 
sites but occur more frequently on specific chromosomes 
We were interested in the implications of changes in DNA methylation across 
passages and their significance in location.  To examine the differential methylation we 
examined those sites that exhibited increased or decreased methylation with a delta beta 
value greater than 0.2 or less than -0.2 from P2 to P5.   Utilizing beadchip array 
annotation we first sought to characterize sites more susceptible to change at the 
chromosomal level (figure 17 A).  Here we note that there are a number of chromosomes 
that have over and under representation as determined by fisher’s exact test in both 
increased and decreased methylation.  Astrocytes have 4 chromosomes that are 
overrepresented in increased methylation; less than that of brain vascular pericytes and 
schwann cells with 5 and 7 respectively.  In chromosomes underrepresented for increased 
methylation; astrocytes have 7 chromosomes which is similar to that of brain vascular 
pericytes and schwann cells at 9 and 8 respectively.  While a number of chromosomes are 
differentially methylated similarly between cell types there are clear and distinct 
differences between cell types in 9 of the 23 chromosomes.  At each of these 
chromosomes there is a difference in over/under representation as well as the magnitude 
of the observed over expected ratio.  One caveat to this data is the lack of equal 
representation on the 450K array.  While the results were weighted by the number of sites 
available, some chromosomes are only represented by low numbers of sites such as the Y 
chromosome with only 93 sites available on the array.  In these cases however, the 
sampling was too low to be determined significant.  Decreased methylation has similar 
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representation in several of the chromosomes that display over or under representation in 
increased methylation.  Chromosomes 2, 5 and 13 are overrepresented in both increased 
and decreased methylation suggesting that these chromosomes are particularly vulnerable 
to differences in methylation in long term culture.  Additionally chromosomes 19, 20 and 
X are significantly underrepresented in both increased and decreased methylation 
indicating greater stability in long term culture.  Notably, the number of chromosomes 
that are significantly over and underrepresented in decreased methylation sites, is more 
than that of increased methylation in all three cell types; likely reflective in the much 
greater number of sites that have decreased methylation.   
We next considered the representation of these differentially methylated sites in 
relation to the transcription start site (figure 17 B).  Each site is capable of representing 
more than a single gene which is reflected in the annotation.  To address the crossover, 
sites that were representative of more than one position relative to the start site were 
counted if the relationship was for an independent gene.  Increased methylation is 
overrepresented in sites annotated with the gene body for all three cell types and within 
the 3’ untranslated region for astrocytes.  The remaining regions, including the promoter 
region and 1st exon displayed fewer than expected sites of increased methylation.  In sites 
that exhibited a decrease in methylation much of the 5’ region of the gene body was 
under represented in all three cell types.  The 3’ untranslated region and gene body were 
overrepresented for decreased methylation in brain vascular pericytes as well as Schwann 
cells.  Astrocytes only exhibit overrepresentation of the gene body in decreased 
methylation.  This would suggest that the area around the transcription start site is stable 
and likely to be unaffected by the differences in DNA methylation attributable to long 
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term culture.  The latter halves of annotated gene bodies are more susceptible to change 
in long term culture. 
Another regulatory feature in DNA methylation that we sought to characterize 
were CpG islands and adjacent regions called shores and shelves. Our goal was to further 
characterize these sites and determine if such changes may have implications in long term 
studies (figure 17 C).  CpG Islands associated with promoters are often hypermethylated 
in cancers [282, 283].  Long term culture of primary cells has been proposed as a model 
for inducing a cancerous phenotypes [284].  Here we show that in the neural associated 
cell types studied, CpG islands actually have less than expected numbers of CpG 
dinucleotides demonstrating increased methylation with long term culture, regardless of  
cell type.  Additionally, long term culture of these neural associated cells only show 
higher than expected increased methylation in open sea regions.  In examining decreased 
methylation across these primary cells, the loss in methylation is more than expected in 
regions outside of the CpG Island and its shores.  CpG shores are indicative of cell of 
origin as well as play a role in driving gene expression [35].  However, CpG shelves also 
play a role in driving gene expression; low island methylation and high shelf methylation 
has greater correlation with gene expression than that of island methylation or shelf 
methylation alone [33].  In all three cell types we exhibit loss of methylation in the shelf 
regions at a greater than expected ratio which may indicate a role in gene expression 
control over the long term culture of these primary cells.  Additionally the stability of the 
CpG Island in both decreased methylation and increased methylation changes indicates a 




Cellular proliferation and metabolic function gene ontologies are over-represented 
in long term culture induced methylation changes  
           We also assessed differential methylation in the context of gene ontology to 
address unique ontology groups that arise in long term culture of primary human cells.  
To address gene ontologies we identified genes that had at least one site differentially 
methylated between the earliest passage P2 and the subsequent passages P3, P4, P5.  
Gene lists were analyzed using Panther.  Data shown represent ontologies that had over 
representation with a p-value less than 0.05.  Panther offers a number of ontology groups 
with which to analyze gene lists; we examined biological processes and pathway 
analysis. 
Among all cell types, as we would expect from the retention of differentially 
methylated sites, there are a number of ontologies describing changes in these cells that 
appear initially and are retained across passage points.  There are increased numbers of 
overrepresented genes and ontologies that appear in later passages due to more 
differential methylation in later passages.  In each cell type there are changes in DNA 
methylation that are over-represented in notable ontologies.   Astrocytes have changes in 
DNA methylation over-represented in a number of developmental ontologies that appear 
in P3 (figure 18 A).  The astrocyte population is fetal derived. This may be reflected in 
the genes that are among the first to be affected in long term culture of primary human 
cells.  Primary cells become senescent with multiple passages, however, this typically 
occurs at later passage points [269].  Changes in DNA methylation are over-represented 
that may be reflective of this phenomenon, including those that focus on cell death and 
apoptosis; which is first observed in P3. Additionally changes in DNA methylation are 
over-represented in induction of apoptosis ontology which appears in later passages 
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(figure 18 A,B).  DNA methylation changes are also over-represented by biological 
process ontologies in late passage that involve cell adhesion to matrix and other cells 
(figure 18 B).  Analyzing changes in DNA methylation by pathway ontology finds over-
representation of genes in WNT signaling, Integrin signaling, and cadherin signaling 
pathways (figure 18 C).   Each of these ontologies include genes that have been 
implicated in regulating cellular growth, senescence and cell interactions with cellular 
environment and other cells.   
Brain vascular pericytes ontology analysis reveals that the majority of genes 
impacted by changes in DNA methylation are over-represented in ontologies in both 
early and late passages that involve regulation (figure 18 D, E).  While the over-
representation is similar to astrocytes, the lack of gene representation in development or 
apoptotic feature ontologies in the brain vascular pericytes is notable.  Brain vascular 
pericytes also exhibit changes in methylation of CpG sights associated with genes known 
to play a role in adhesion (figure 18 E).  Genes impacted by changes in DNA methylation 
are over-represented in the WNT signaling pathway as well as cadherin and integrin 
signaling pathways (figure 18 F).   
Schwann cells cultured for multiple passages exhibit changes in genes which are 
associated with gene over-representation in a number of gene ontologies including 
development related ontologies (figure 18 G).  Genes impacted by changes in DNA 
methylation that are over-represented in apoptotic or cell death ontologies are few in 
number.  Similarly to brain vascular pericytes and astrocytes, Schwann cells have a 
number of genes over-represented in ontologies representative of cell to cell interactions 
and matrix adhesion (figure 18 G,H).  Analysis of genes impacted by changes in DNA 
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methylation finds over-representation in WNT, cadherin, and integrin signaling pathways 
(figure 18 I).  Of note is the over-representation of genes in the apoptosis signaling 
pathway in an earlier passage that is not retained through to P5.  The same holds true of 
genes over-represented in the biological process: induction of apoptosis (figure 18 G,H).   
Discussion 
We report that primary human astrocytes, brain vascular pericytes, and Schwann 
cells demonstrate changes in cellular morphology and expression of cell markers during 
subsequent sub-culturing events.  In addition to phenotypic changes, we also report 
changes to DNA methylation in all three cell types.  The culturing conditions for these 
cells were without treatment and indicate that sub-culturing events or prolonged culture 
can induce changes in DNA methylation in the absence of an experimental manipulation.  
Most of these changes are demethylation events, which may have implications for 
increased chromatin accessibility.  While this data does not address the question of how 
chromatin accessibility changes, it can offer insight into the relevance of such changes. 
An important aspect of the culture induced changes arises with regard to the 
location of the genome in which the changes occur.  Many of the changes are outside of 
key gene regulatory regions, with the exception decreased DNA methylation of island 
shelves.  Shelf regions have been implicated in altering gene expression [33].  Shelf 
regions have also been implicated in playing a role in cellular identity [35].  However, 
despite the changes to the shelf regions, the islands and associated shores have few 
changes. Many of the changes occur outside of gene regulatory regions in what is termed 
as open sea DNA.  Changes in DNA methylation outside of the regulatory regions may 
have no bearing on gene expression and the significance of these changes is unknown.  
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Investigation into gene expression may highlight the role culture induced DNA 
methylation may play in gene expression.  We would expect that many of these changes 
have no direct impact on gene expression, but we have not performed RNA seqencing on 
these samples. 
Changes in culture induced DNA methylation changes may have a significant 
impact on chromatin accessibility.  DNA methylation plays a role in recruiting members 
of the polycomb repressive complexes and with a significant loss of DNA methylation 
many of the impacted regions may be now accessible.  With current methods such as 
ATAC-sequencing, we may be able to define chromatin accessibility shifts.  These shifts 
may be important in exposing DNA to damage events.  Future investigations are 
warranted in understanding the DNA damage response and damage events that occur in 
prolonged culture.  This has important implications in expanding in vitro cultures for 
therapeutic purposes.  If expanding in vitro cultures induces significant changes in 
methylation and alters the chromatin accessibility, therapeutic uses may be limited as the 
cells may not respond correctly in a new host.  We may also be introducing cells that 
have potential DNA damage and could lead to future cancer events.   
Another consideration in expanding cultures relates to genes affected by culture 
induced changes in DNA methylation.  The changes we report in DNA methylation affect 
genes associated with multiple distinct and overlapping gene ontologies, but significant 
among them are WNT signaling and cellular adhesion ontologies.  Genes over-
represented in WNT signaling and cellular adhesion ontologies can play a role in cellular 
senescence [285].  Culturing primary cells often induces replicative senescence and the 
DNA methylation changes we report may be the initiating stages of replicative 
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senescence [286]. To address if prolonged culture induces cellular senescence in primary 
human astrocytes, brain vascular pericytes and Schwann cells, we suggest looking at 
cellular senescence markers throughout the passages.  It is important to identify if these 
cells are entering senescence, as we can use the associated DNA methylation changes to 
determine the maximal number of passages for expanding cultures.   
          In our environmental toxicant exposure studies, we find that culture induced DNA 
methylation changes provide enough of a barrier that prevents using a chronic exposure 
long term culture model.  We see significant changes in approximately 4% of 
interrogated CpG sites.  This represents a significant portion of the sites we can assay and 
may mask a number of changes induced by environmental exposure.  A potential 
alternative would be to use whole genome bisulfite sequencing to identify all CpG sites.  
However, our data does not represent the whole genome and a repeat study of culture 
induced changes would be necessary to identify sites that change with culture.  Again this 
may prevent identifying critically changed sites from environmental exposure.  The 
culture induced changes we report here warrant utilizing in vivo models despite technical 





Figure 15.  Prolonged cell culture induces phenotype changes in primary cells.  A)  
Schematic of protocol for long term culture of primary human cell types, astrocytes, brain 
vascular pericytes and schwann cells. Primary cell types were cultured for 21 days 
through 4 passages and samples collected at each passage point for DNA methylation 
analysis and immunocytochemistry. B)  Cells cultured at each passage were fixed in 4% 
paraformeldahyde and immunolabelled for astrocytes (GFAP), brain vascular pericytes 
(a-SMA) and schwann cells (S100, GFAP).  Immunolabelling indicates phenotypic 





Figure 16.  Prolonged culture induces DNA methylation changes in primary human 
cell types.  Primary human cell types were cultured through P5 and DNA was collected 
at each sub-culture point.  DNA methylation was assayed with Illumina 450k Beadchip 
Array.  Data are represented in heatmap (A) for all differentially methylated sites 
between passage points and venn diagrams (B) of differentially methylated sites common 
between passage points. + Δβ indicates an increase in methylation at CpG sites, and – Δβ 
indicates loss of methylation at CpG sites.  Primary cell types include Astrocytes, Brain 
Vascular Pericytes and Schwann cells.  Methylation data were SWAN normalized and 




Figure 17.  Changes in DNA methylation occur outside of CpG islands and 
transcription start sites but occur more frequently on specific chromosomes.  
Differential methylation was determined with a cutoff with absolute Δβ value of 0.2 and 
characterized based upon Illumina annotation of 450k Beadchip array.  Data represent the 
number of observed sites over expected sites based upon total sites assayed.  
Characterization of sites include chromosome representation (A), relationship to 
transcription start site (B), and relationship to CpG island (C). + Δβ sites indicates sites 
that gained methylation, whereas - Δβ  indicates sites of loss in methylation.  * indicates 




Figure 18.  Cellular proliferation and metabolic function gene ontologies are over-
represented in long term culture induced methylation changes. 
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Figure 18 cont. 
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Figure 18 cont.  Differentially methylated sites were characterized by genes that had at 
least one site differentially methylated.  Gene lists for each passage and cell type were 
subjected to gene ontology analysis through the Panther database.  Ontologies that were 
significantly overrepresented are represented.   Data also represent gene ontology 
analysis through each passage point, which display retention of ontology categories to 
late passages in each cell type.  Biological process gene ontology represented by genes 
differentially methylated in early and late passages for astrocytes (A,B), brain vascular 
pericytes (D,E) and Schwann cells (G,H). Over-representation in pathway gene ontology 
of genes differentially methylated for astrocytes (C), brain vascular pericytes (F), and 
Schwann cells (I).  Astrocytes, Brain Vascular Pericytes, and Schwann Cells have unique 
changes in DNA methylation but are over-represented in similar ontologies.  There are 





MATERNAL PARAQAUT EXPOSURE INDUCES PERSISTENT GENE 
EXPRESSION CHANGES IN NEONATE GLIAL CELLS THAT MAY DRIVE 
FUTURE DISEASE EVENTS 
Introduction 
Neural diseases that lack a clear genetic origin have been linked to being multifactorial 
diseases [287-289].  Few mutations exist that explain neurodegenerative diseases and the 
mutations that do exist fail to explain the majority of the disease pool [211, 290, 291].  Neural 
cancers are often low mutational load cancers and reside in a privileged environment protected 
by the blood brain barrier preventing effective treatment [292, 293].  Despite a clear genetic 
influence there does appear to be an influence from outside sources. 
Environmental factors appear to have an epidemiological impact on both 
neurodegenerative disease and neural cancer [8-19].  There is a clear increase in risk of 
childhood brain tumors after maternal pesticide exposure [294].  However, adult exposure 
seems limited to an increased risk of neurological disorders and neurodegenerative diseases 
[295, 296].  There appears to be a critical window in which pesticide exposure can drive 
cancerous events after which only neurodegenerative events occur. 
One such pathway that may define if such a window of susceptibility exists is 
epigenetics.  Epigenetic remodeling events have been linked to environmental influence.  We 
propose that pesticide exposure in utero will lead to significant transcriptional changes that may 




In this study we used a current Paraquat induced parkinsonian model to assess the 
effect of early development pesticide exposure on progeny neuroglia.    Here we show that 
Paraquat is retained in the adult brain tissue but not in the brain of pups (figures 20 and 21).  
Despite the absence of detectable Paraquat, we show that pup astrocytes and microglia have 
sustained differential gene expression after maternal Paraquat exposure.  We also show these 
changes are cell type specific. 
Intraperitoneal Paraquat exposure prior to and during gestation does not affect 
dam mass, gravidity or pup number 
To effectively address chronic exposure of an environmental toxicant during 
development we utilized an in vivo model system where female mice are treated with 
Paraquat just prior to and during gestation (figure 19 A).  This model allows us to address 
the effect of Paraquat in a naturally developing animal without the caveats of long term 
culture induced epigenetic changes.  Additionally, the animal model allows for normal 
development and cellular interactions not present in in vitro modeling systems.   
In our model system, female mice receive twice weekly injections of 10 mg/kg 
Paraquat for a total of six weeks.  One week into the treatment schedule, the female mice 
were bred and exposures continued throughout gestation.  Brain tissue of 1 to 3 day old 
pups were collected and cultured with the exception being a small subset of pups where 
the brain was retained for mass spectrometry and future histological analysis.  Adults 
were carried out until 6 weeks at which point the animals were perfused and brain tissue 
collected for histological analysis as well as mass spectrometry.  Injections of animals 
were performed intraperitoneally with 1 mg/mL Paraquat saline solutions made fresh 
prior to injections.  Samples of injection stocks were saved and assessed for Paraquat 
109 
 
concentration by mass spectrometry (figure 19 B).  Injection stocks were on average 1.15 
mg /mL, slightly higher than our target concentration.  This may be due to technical 
errors.  However, all animals were treated with the same stock on the same day; any 
discrepancies in Paraquat exposure were across all animals.   
With this injection schedule we assessed the mass of the adults prior to each 
injection to determine a consistent 10 mg/kg Paraquat dosing schedule.  We characterized 
this data to assess the effect on the weight of animals (figure 19 C).  This data indicates 
that non-gravid mice did not lose mass throughout the dosing schedule.  The gravid 
females also did not lose any mass prior to breeding, nor was there a difference in mass 
between Paraquat treated and saline treated gravid females indicating there were no 
obvious or overt gross changes on the adult mice. 
Additionally we recorded the number of mice that were gravid (figure 19 D) and 
the pup yield for each gravid mouse (figure 19 E).  In both of these characteristics there 
was no significant difference between control and treatment groups.  In the percent of 
gravid mice there does appear to be a negative trend in the number of gravid mice in the 
Paraquat treatment group, however the p-value is 0.117 indicating the reduced number of 
gravid mice is not significant.   
The characterization of the mice indicates no change in the treated animals 
compared to the control group.  Treatment of animals with a substantia nigra impacting 
compound usually affects some motor and behavioral characteristics not assessed here.  
Anecdotally the Paraquat treated animals appeared healthy and indistinguishable from 
control animals. The Paraquat treated animals did not exhibit any changes that would 
meet the criteria necessary for euthanasia.   
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Dam brains unable to clear Paraquat from intraperitoneal injections. 
Blood samples were collected prior to cardiac perfusion with saline.  Blood 
samples were centrifuged in heparin sulfate and sera collected.  Brain tissue was removed 
after perfusion of approximately 10 mL of saline.  Brains were dissected into 
hemispheres, snap frozen and pulverized to homogenize samples.  Processed samples 
were submitted for mass spectrometry analysis.  Adult brain tissues (figure 20 A) from 
Paraquat treated animals show significant increase in Paraquat levels with in the brain 
tissue compared at approximately 0.5 ng/mg tissue to control group animals with about 0 
ng/mg tissue.  This residual Paraquat is available in the brain tissue approximately 2-3 
days after the last injection.   
Paraquat is water soluble and 95% of Paraquat is cleared from the body in urine 
or feces within the first few hours of injection [297].  This indicates that Paraquat is 
retained within brain tissues after serum levels have cleared and may reflect an inability 
to effectively clear Paraquat from the brain tissue.  However, of note is for the 10 mg/kg 
Paraquat injected, only a small amount of Paraquat is retained.  This is reflected in the 
work of others; Paraquat is able to cross the blood brain barrier but only small amounts 
cross and are retained within the brain tissue [163].  Our study confirms that Paraquat is 
retained in the brain but does not address if brain Paraquat can be cleared over a slower 
time frame [163, 169].   
Pup brains and serum are clear of Paraquat 
We also sought to assess the level of Paraquat in pup tissues.  Brain tissue from 
maternally Paraquat treated pups show no difference in Paraquat levels from control 
group pups (figure 21A).  Pup sera also show no Paraquat availability in either control or 
Paraquat exposed animals.  The lack of Paraquat in the neonate brain is markedly 
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different from the adult brain tissues and may be indicative of either an enhanced ability 
to clearance Paraquat or an inability for Paraquat to access the neonate brain tissues.   
The lack of Paraquat in the neonate tissues indicate that Paraquat is unable to 
maintain a presence in the brain tissue indicating that any effect from Paraquat would 
have to be in single hit responses that correlate to the injection schedule.  To assess if 
such an effect were occurring we assayed astrocytes and microglia cultured from neonate 
brains for changes in gene expression.   
Maternal Paraquat exposure has no apparent effect on astrocyte enrichment or 
Glial Fibrillary Acidic Protein (GFAP) expression  
In order to assess gene expression changes in cultures derived from neonate 
tissues, we first sought to characterize the cultures for astrocyte and microglia presence.  
Pup adherent brain cultures were cultured and assessed for astrocyte number with anti-
GFAP antibody (figure 22 A).  Images indicate that there are a number of positively 
stained cells for GFAP as well as unstained nuclei indicating a mixed population of cells.   
Positively stained cells display a fibrous astrocyte morphology but display no differences 
between treatment conditions in morphology or staining intensity.  Morphology of 
stained cells indicate a fibrous astrocyte type as the GFAP staining is diffuse in a flat 
processes similar in morphology to a fibroblast [298].  Protoplasmic astrocytes exhibit 
spindle shaped processes in a stellate appearance and do not regularly appear in the 
images [299].  Protoplasmic astrocytes do not stain well for GFAP which may reduce the 
yield of GFAP positive cells in our cultures [300].  However, with the number of nuclei 
that do not stain within the images, there is a population of nuclei that cluster and are 
smaller than the stained astrocyte counterparts.  These smaller nuclei indicate a 
completely different cell type and the size of the nuclei are suggestive of microglia.  
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Future co-staining with IBA-1 would be necessary to determine the level of microglia 
contamination in the astrocyte population. 
Image counts were made by two independent and blinded investigators.  The 
average of the results indicates a population of astrocytes enriched to about 55-65 percent 
of the total population.  There is also no statistical difference between the treatment and 
control populations in the number of positively stained cells. 
The similarity in GFAP positive cells in morphology and percentage of the 
population of cells between treatment conditions indicates the astrocyte composition is 
similar between treatment groups and that there is not a significant loss in one population 
over the other.  Examination of the microglia from the same populations indicate a 
marked difference in treatment groups. 
Maternal Paraquat exposure alters pup microglia Ionized Calcium-Binding 
Adaptor Molecule 1 (IBA1) expression 
Microglia were collected from shaken flasks and cultured on poly-D-Lysine 
coated coverslips for 48 hours prior to fixation.  Cells were stained for IBA1, a 
cytoskeletal marker of microglia and macrophages.  Representative images (figure 23 A) 
show amoeboid shaped cells in control and Paraquat conditions.  However, staining 
intensity of IBA1 is noticeably different between the treatment groups.  Indeed the 
number of IBA1 cells is reduced in Paraquat exposed cells (figure 23 B) with 
approximately 25% drop in the percentage of IBA1 positive cells.  Additionally the 
intensity ratio of IBA1 intensity to DAPI intensity in Paraquat treatment group is 
significantly lower than that of control treatment group (figure 23 C).   
The difference in IBA1 is unexpected as IBA1 is present in matured microglia 
and the production of IBA1 is stimulated by macrophage colony stimulating factor, 
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which is secreted by the brain [301].  Microglia are not derived from neural precursors 
but from myeloid precursor cells and migrate to the central nervous system during 
development [302].  The presence of mCSF in the brain stimulates the migrating cells to 
mature into microglia [303].  In having reduced expression of IBA1 for the Paraquat 
treatment group, we raise the possibility that the microglia may not be fully matured.  
Another possibility also remains in that the microglia may be unhealthy and are simply 
dying.  With the limited population of cells cultured from the pup brains we assessed 
gene expression data for changes that might give direction to response to Paraquat 
treatment. 
Gene expression analysis shows experimental batch effect 
In utero exposure treatments were completed in two separate experiments, an 
initial study with fewer animals and a second larger study with age matched animals.  
RNA was extracted from cultured pup brain tissue with adherent and non-adherent cells 
mechanically separated.  RNA sequencing was performed on samples and differential 
gene expression analysis was completed.  Distance clustering of all samples in both 
experiments was completed (figure 24).   
Samples cluster out into two distinct clades based on cell type.  The separation 
based on cell type are expected as different cell types have unique gene expression 
profiles.  This does indicate that the mechanical separation effectively separated out two 
different populations of cells.  However, the samples also cluster into two distinct clades 
based on experimental replicates.  This indicates the two experiments are more dissimilar 
than control and treatment groups.  When examining treatment and control groups within 
each experiment clade, the microglia samples cluster by treatment group while astrocyte 
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cultures cluster indifferently to treatment group.  To assess the difference in treatment 
versus control as well as differences between the experiments we performed differential 
gene expression between Paraquat treatment and Control treatment for differences in 
treatment and differential gene expression between Control group from Experiment 1 and 
Control group from experiment 2. 
Maternal Paraquat exposure experiments are unique from one another 
Differential gene expression analysis of RNA sequencing data for treatment 
versus control conditions in astrocytes and microglia (figure 25A) indicate differentially 
expressed genes that are typically overexpressed in both cell populations.  However, 
comparing control groups between the two experiments shows large differences between 
experiments, far greater number of changes than those attributed to Paraquat exposure.  
This indicates the experiments are very distinct from one another.   
Further examination of the differences between the experiments identifies several 
points on which the two experiments are different from one another and should be 
analyzed separately.  Experiment 1 animals are of varying ages and pups are from mostly 
older adults in the 4 to 7 month at the end of study age range (Table 4).  However, 
Experiment 2 is comprised of age matched animals that are 3.5 months at the end of 
study.  Additionally the representation of pups between treatment and control groups is 
more balanced in experiment 2 as pups were born to several mothers in both treatment 
groups.  In experiment 1 pups were born to several control animals but only two 
treatment animals.  In those treatment animals 6 were born to one female while 2 were 
born to another female.  This disproportionately represents one dam in the treatment 
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group.  Based on these results we analyzed differential gene expression separately for 
each experiment.   
Repeat experiments have different patterns in gene expression changes 
In splitting the analyses between the experiments there is an immediate difference 
in the pattern of differential gene expression.  In experiment 1, the differential gene 
expression is largely overexpressed significantly differential expressed genes for the 
Paraquat treatment group in both astrocytes and microglia (figure 26 A, B); whereas the 
significantly differentially expressed genes are more split between over and under 
expressed genes for astrocytes and microglia in experiment 2 (figure 26 C, D).  However 
the overlap of the genes is minimal between cell type and experiments.  Despite the lack 
of cohesion between cell types or treatment groups in the differential gene expression we 
sought to identify if there were specific patterns to the types of genes affected and 
analyzed these gene sets for gene ontology to provide some insight. 
Independent differential gene expression analysis identifies distinct differential 
gene expression patterns for each experiment.  Experiment 1 shows mostly increased 
gene expression for differentially expressed genes while experiment 2 has both increased 
and decreased gene expression (Tables 5, 6, 7, 8,).  Likely, this may be a reflection of the 
disproportionate representation of Paraquat samples from a single dam.  With the 
understanding that these experiments are different in animal representation and that the 
second experiment has a larger sample population we characterized the differences in 





Gene expression data indicates a response in pup brain cells to maternal Paraquat 
exposure 
We tested the similarity of samples within a cell population type using distance 
clustering methods.  Paraquat samples have a tendency to cluster separately from the 
control groups (figure 27).  Astrocyte clustering identifies a group of pup samples that 
cluster into two unique clades distinct from control clades (figure 27 A).  Additionally we 
find that some pups from Paraquat treated mothers cluster in Paraquat clades while their 
littermates cluster into control clades.  Microglia samples cluster more distinctly than 
astrocyte samples (figure 27 A,B).  In microglia samples there are three distinct clades 
that are highly independent from one another.  Again littermates do not cluster together 
into the same clades and in some cases cluster with control group samples.   
The distance clustering results indicate that maternal Paraquat exposure 
differentially effects offspring.  As some littermates cluster with Paraquat treatment and 
Control treatment, we note that not all samples are representative of a single pup.  Future 
studies will require pups to be analyzed independently as pooling cells from multiple 
pups may mask littermate differences.  Paraquat treatment also appears to generate 
unique clades indicating a unique response from each sample group or unique effects 
from Paraquat treatment on the same population.   
Cellular adhesion and signaling ontologies are over-represented in differential gene 
expression of astrocyte cultures 
 
To give us a general indication of processes and pathways affected by changes in 
gene expression we used Panther Gene Ontology analysis.  Ontology analysis was used 
on differential gene expression lists (Table 7) to identify groups of genes and signaling 
pathways impacted by in utero Paraquaat exposure.  Biological Process-Slim (figure 28 
A) uses a reduced ontology gene list to help identify global changes in gene expression.  
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In astrocytes, the slim biological process identifies a number changed in gene expression 
grouped into categories involved in cell adhesion and signaling. Changes in gene 
expression are over-represented by approximately 2 to 10 fold indicating there are more 
genes identified in the ontology than we should expect.  The top three categories are 
adhesion related ontologies indicating that in utero Paraquat exposure affects astrocyte 
adhesion genes and potentially properties.  
While biological process allows for the overall identification of changes, focusing 
on other ontology characterizations allow us to identify in more detail the effect of 
differential gene expression from in utero Paraquat exposure.  We next identified genes 
significantly over-represented in pathways (figure 28 B).  Genes in the cadherin signaling 
pathway are significantly over-represented by 5.64 fold (Table 9).  Genes in this pathway 
play an important role in cellular adhesion but also in cellular migration, stem cell 
maintenance, and cancer progression.  Analysis of genes in the context of reactome 
pathway ontologies identifies genes over-represented in two pathways:  collagen 
biosynthesis and modifying enzymes and Collagen Formation.  These pathways may be 
important in matrix deposition and in the context of astrocytes; formation of glial 
scarring.  Analysis of genes over-represented in protein classification ontologies (figure 
28 D) identifies cell adhesion molecules and signaling molecules as major constituents in 
our differentially expressed genes for astrocyte cultures.  Together these ontologies begin 
to identify that the astrocyte cultures are different in their ability to communicate and 
adhere to their surrounding cells and matrix.  Identifying other groups of genes with 
similar functions may help define the role that a change in adhesion capabilities and 
cellular signaling may play. 
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Comprehensive biological process ontology identifies additional developmental 
ontologies in astrocyte cultures 
We sought to characterize the differentially expressed gene list for astrocyte 
cultures further with the complete biological process ontology (Figure 29).  Further 
characterization would allow us to identify genes over-represented in additional ontology 
groups clarifying the effect of environmental toxicant exposure. In astrocyte cultures, the 
expanded analysis of differential gene expression identifies additional ontologies being 
related to development.  Genes in the newly identified ontologies are all over-represented 
indicating we are seeing more genes in these ontologies than we should expect.  Our 
differential gene expression list is most over-represented in the hexose biosynthetic 
process with greater than 20 fold over-representation.  Hexose biosynthetic pocess 
ontology involve genes that play a role in forming six carbon monosaccharides.  This 
ontology might be expected with the proposed role of Paraquat inhibiting mitochondrial 
function.  We next sought to characterize the changes in gene expression for microglia. 
Immune function and stimulation response ontologies are over-represented in 
differential gene expression of microglia cultures 
We characterized in utero Paraquat exposure microglia differentially expressed 
genes (Table 8) to identify processes and pathways affected by changes in gene 
expression.  In the slim biological process (figure 30A) genes are underrepresented in  
ontology categories involving immune and sensory related processes.  The under-
representation of immune related genes signifies that genes involved in immune function 
might be protected in their expression as we identify fewer than expected genes in these 
ontologies.  Analysis in the reactome pathway ontologies (figure 30 B) finds 
differentially expressed genes are overrepresented in ontologies being related to 
translation and transcription.  No other ontology characterizations had significant gene 
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representation.  Paraquat exposure impacting some of the translation and transcriptional 
genes, as over-represented here, is in line with in vitro Paraquat studies initiating an 
unfolded protein response and altering translational and transcriptional activity [304, 
305].  As the number of differentially expressed genes in microglia are greater than the 
number in astrocytes we again sought to characterize the differentially expressed genes 
with the Complete Biological Process ontology. 
Comprehensive biological process ontology identifies numerous metabolic ontologies 
in microglia culture differential gene expression 
Further characterization of differentially expressed genes in microglia identifies 
many metabolic and catabolic processes that may be disrupted with Paraquat exposure.  
Genes are over-represented many of the ontology groups (Table 10).  However, genes are 
under-represented in three categories:  neurological system process, G-protein coupled 
receptor signaling pathway, and sensory perception.  The expanded analysis has 
identified a switch from under to over-representation in genes due to the expansion of the 
gene lists for each of ontology group, previous analysis did not incorporate all of the 
possible genes.  The overrepresentation of genes in metabolic ontologies show a clear 
disruption of normal cellular processes in microglia exposed to Paraquat during 
development.  Despite the number of metabolic processes impacted, genes are only over-
represented in one ontology (regulation of cell cycle) that is potentially related to 
apoptosis or cell death.   While the ontology analysis presented here offers a basic 
understanding of what processes and pathways are being impacted, incorporation of gene 





Astrocyte and microglia cultures have different predicted responses in activation of 
pathways 
Gene ontology analysis offers an understanding of potential impact from 
differentially expressed genes, however, this type of analysis does not factor in 
expression patterns.  To incorporate gene expression data we used Ingenuity Pathway 
Analysis which offers a predictive function in identifying pathway ontologies.  Using the 
expression patterns within the gene set the algorithm predicts if the pathway would be 
active (orange, positive z-score), inactive (blue, negative z-score), unchanged (white, 
zero z-score) or no activity pattern available (gray) if activity of interacting genes in a 
pathway can be predicted from differential gene expression.  No activity pattern available 
can be derived from conflicting gene expression data points or insufficient data points to 
make a conclusion. 
Ingenuity Pathway analysis allows us to identify the pathways most likely to be 
involved with our differential gene expression lists and to predict the activation of a 
pathway.  Ingenuity Pathway Analysis of experiment 2 indicates that the two cell types 
vary in the pathways affected by the differentially expressed genes with Ephrin A 
signaling and Circadian Rhythm Signaling being the only common pathways (figure 32).  
Both of these pathways are unpredicted in the pathway analysis.   
In astrocyte pathway analysis (figure 32 A) the Wnt-b catenin signaling, 
Dopamine-DARRP32 feedback in cAMP signaling and glioblastoma multiforme 
signaling are predicted to be activated pathways.  The NF-kB signaling pathway is 
predicted to be inactivated.  Microglia pathway analysis (figure 32 B) displays several 
pathways predicted to be inactivated including:  ETF2 signaling, p53 signaling, ATM 
signaling, and prolactin signaling.  Both mTOR and AMPK signaling are predicted to be 
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activated.  A majority of the pathways in both astrocytes and microglia were unpredicted 
in activity pattern.  This may be due to a lack of consensus on the direction of changes in 
gene expression within the pathway.  However, despite the lack of prediction available 
there are a number of signaling pathways and cancer related pathways that are significant.  
To identify constituents that may be playing a critical role in the response to in utero 
Paraquat exposure we expanded the pathways for select pathway ontologies. 
Ingenuity pathway analysis identifies some potential proto-oncogenic pathways in 
Paraquat exposed astrocyte cultures 
 
IPA analysis of in utero Paraquat exposed astrocyte cultures identified several 
potentially proto-oncogenic pathways with over-represented genes (figure 33).  WNT/ b-
catenin signaling is predicted to be activated (figure 32 A) and expansion of the pathway 
identifies the gene hits in our differentially expressed genes (figure 33 A).  Two Wnt 
members are both increased in expression as well as a key transcription factor in the 
WNT canonical pathway, Lef1.  Frzb, an antagonist of the canonical WNT signaling 
pathway, is also increased in gene expression.  Frzb is reported to be silenced in 
glioblastoma multiforme but contradicting results indicate that Frzb is highly expressed 
in the nucleus of high grade astrocytoma patient samples [306, 307] indicating an 
ambiguous role in mediating the Wnt signaling pathway.  A casein kinase Csnk1g1 is 
increased in expression in Paraquat exposed astrocyte cultures.  Csnk1g1 is involved in 
mitotic spindle location and polarity [308].  Gnao1, encodes for Go subunits in signaling 
cascades [309], is found to be decreased in expression in Paraquat exposed astrocytes.  In 
hepatocellular carcinoma, decreased Gnao1 expression was found in patient samples and 
inhibiting Gnao1 decreased cellular senescence [310].  Critical gene hits in Wnt/  
catenin signaling; Wnt4, Wnt6, and Lef, are also identified in three additional pathways:  
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Role of Wnt/GSK-3b signaling in the pathogenesis of influenza (figure 33 B), Human 
Embryonic stem cell pluripotency (figure 33 C) and Glioblastoma Mutliforme signaling 
(figure 33 D).   
The Role of Wnt/Gsk-3b signaling in pathogenis of influenza pathway (figure 33 
B) identifes Interferon alpha/beta receptor 1 (Ifnar1) which is overexpressed in Paraquat 
exposed samples.  Ifnar1 is involved in the signaling cascade of interferon signaling 
which regulates general immune responses [311].  However, Ifnar1 signaling is also 
important in the ability of glioblastoma cells and glioblastoma stem-like cells to evade 
natural host immunity [312].  While Ifnar1 gene expression compared to normal cells is 
not addressed in the study, the loss of Ifnar1 mediates a loss in the signaling pathway 
down regulating MHC class proteins and increasing the ability of natural killer cells to 
target the glioblastoma cells.   
In Human embryonic stem cell pluripotency pathway, which cannot be predicted 
in activity (figure 32 A), we see the addition of genes Fgfr3 and Fgfrl1.  Fgfr3 has been 
implicated as a marker specific for astrocytes and involved in the regulation of 
morphology in reactive astrogliosis [313, 314].  Reduced Fgfr3 induces a fibrous 
astrocyte phenotype and is associated with a reduced hypertrophic pathological response 
[313]. In our study Fgfr3 has decreased in expression.  Fgfrl1 is also decreased in 
expression in our study.  Fgfrl1 overexpression induces cell adhesion in a transformed 
human embryonic kidney cell line [315], but can induce proliferation in esophageal 
squamous cell carcinoma by preventing cell cycle arrest [316].   
The glioblastoma multiforme signaling pathway in Paraquat exposed astrocyte 
cultures is predicted to be activated.  No new genes are incorporated in this list, but 
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important cell proliferation regulators are identified in the pathway.  Important to note is 
that Fgfr3 is downregulated but in glioblastoma lines Fgfr3 is typically overexpressed.  
Fgfr3 can control differentiation of chondrocytes and neuronal cells and is expressed in 
early astrocyte progenitor cells [313, 317, 318].  This suggests that Fgfr3 signaling may 
play a role in the differentiation of astrocytes and would require further examination.   
Ingenuity pathway analysis identifies some glial scarring and disrupted cellular 
signaling pathways in Paraquat exposed astrocyte cultures 
We next expanded pathways that may have a role in glial scarring and cellular 
signaling.  The Hepatic fibrosis/Stellate cell activation pathway (figure 34 A) could not 
be predicted in activity but, several collagen encoding genes are increased in expression 
as well as CD40.  CD40 is involved astrocyte immune response in neuro-inflammation 
[319, 320].  CD40 has also been reported as a biomarker for better prognosis in glioma 
patients and enhancing expression can increase efficacy of antibody treatments in model 
systems [321].  Igfbp5 is decreased in expression which may play a role in IGF signaling 
mediated inflammation [322].  Increased expression in genes coding for collagen and 
inflammatory mediators indicate a potential for an inflammatory glial scarring 
environment. 
Additional evidence for an inflammatory glial scarring environment arise from the 
Axonal guidance signaling pathway (figure 34 B).  While IPA analysis was unable to 
predict the activity of the axonal guidance signaling pathway, insight can be taken from 
the changes in gene expression of key genes.  Within this data set Robo1 and Sema6a, 
both repulsive cues in axonal guidance, are increased in expression.  Epha7 and Efna2, 
both increased in our study, are members of the ephrin signaling pathway and play a role 
in repulsion in axonal guidance [323, 324].  We also see changes in G-protein signaling 
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members Gnaao1 and Gng11, with increased expression of Gng11; and a decrease in 
Rgs3 which negatively regulates g protein signaling and can play a role in inhibiting 
chemoattraction [325].  One additionally important member of this pathway is Sema3f, 
shown to be decreased in expression.  Sema3f plays a significant role in directing 
neurons, there is also evidence that Sema3f plays a role in mTOR signaling [326, 327].   
Considering that gene expression patterns indicate an increase in chemo-repulsive 
genes and cellular signaling potentially involved in maintaining the axon repulsive 
environment it would appear that the astrocyte cultures are producing an inhibitory 
environment for neurons.  This potential taken into account with the upregulation of 
collagen coding genes and inflammatory modulators would suggest that the in utero 
exposed Paraquat astrocyte cultures are developing a glial scarring environment.   While 
we do not see an increase in GFAP positive cells or intensity as we would expect in such 
an environment (figure 22 A), we must take note of the fact that the expression changes 
are small and may be subtly influencing the astrocytes.   
Indeed, when we examine the NF-kB signaling pathway (figure 34 C), IPA 
analysis predicts an inactivation of the pathway.  NF-kB is a transcription factor that will 
translocate to the nucleus after dissociation from IkB regulating inflammation pathways 
[328].  A predicted inactivation of inflammatory pathways might be responsible for the 
lack of a perceivable difference in in utero Paraquat exposed astrocytes.  Il1rn is an Il1A 
and Il1B antagonist and can deactivate the NF-kB signaling pathway [329].  Il1rn is 
increased in expression for in utero Paraquat exposed astrocyte cultures potentially 
driving down NF-kB signaling.  Irak3 is also increased in expression in the in utero 
Paraquat exposed astrocytes.  Irak3 is primarily expressed in macrophages and 
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monocytes and serves to regulate the IL-1 signaling pathway and can also deactivate 
monocytes [330].  Data on function in astrocytes is limited, however, Irak3 expression in 
glioblastoma tumors is prognostic of recurrence [331].   
Additional signaling pathways are also disrupted.  The dopamine-DARRP32 feed-
back signaling pathway is predicted to be activated by IPA analysis (figure 34 D).  In this 
pathway there are several ion channel genes affected by in utero Paraquat exposure.  
Grin2a which is overexpressed and Grina, under-expressed are both glutamate gated ion 
channels.  Another ion channel Cacna1c, a calcium ion channel has slightly increased 
gene expression.  Changes in ion channel signaling may alter signaling capabilities within 
the cell. 
The glycerol 3-phosphate shuttle pathway is unpredicted in activation through 
IPA analysis but is involved in the shuttling of electrons into the electron transport chain 
by conversion of NADH to NAD+.  Both Gpd1 and Gpd2 are decreased in expression.  
Gpd1 and Gpd2 encode for Glycerol-3-Phosphate Dehydrogenase in the cytosol and 
mitochondria respectively.  The proteins encoded by these genes function to transport 
electrons from the cytosolic NADH into the electron transport chain.  Transcriptional 
control of Gpd2 is under thyroid hormone response elements.  The role decreased 
expression of Gpd1 and Gpd2 in utero Paraquat exposed astrocytes is unclear as there is 
limited evidence for physiologic response to changes in expression of Gpd1 and Gpd2.  
By limiting the main enzymes in the glycerol-3-phosphate shuttle, the availability of 
cytosolic NADH might increase and subsequent ATP production limited, however, the 
malate aspartate shuttle may be able to compensate.  The change in glycerol-3-phosphate 
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shuttle members warrant further investigation as metabolic dysregulation has been 
implicated in a number of diseases. 
Several DNA damage response genes and pathways are down regulated in Paraquat 
exposed microglia cultures 
 
In microglia ingenuity pathway analysis we expanded pathways that play a role in DNA 
damage response.  Several of these pathways were in the top five represented pathways.  Some 
pathways are predictive in the nature of activation.  The p53 Signaling pathway is predicted to 
be inactivated (figure 32 B).  There are several key members in the p53 signaling pathway that 
are also represented in several other pathways (figure 35 A, B, C, E).  Atm is decreased in 
expression in our system.  Atm plays a significant role in the DNA damage repair pathway [332].  
Atm deficient models are prone to cancer development and neurodegeneration [333].  
Additionally Atm silencing in glioma stem cells reduces the glioma stem cell capability to 
proliferate [334] indicating a significant role in the ability of maintaining proliferation.  Indeed 
the Atm signaling pathway is predicted to be inactivated (figure 35 C) based on expression 
changes.  Atr is another DNA damage sensor and can act in concert with Atm [335].  Both Atm 
and Atr are important in regulating apoptosis.   
A confounding factor in the idea that DNA damage is down regulated is the Gadd45 
Signaling pathway (figure 35 B), predicted to be inactive (Figure 32 B). Gadd45b is involved with 
cell cycle check point regulation and cell growth [336] which we found to be increased in 
expression.  This indicates that some cell cycle arrest pathways may be activated while others 
remain inactivated.  However, Gadd45b may play a role in altering the DNA methylation profile 
in the microglia as Gadd45b can induce DNA demethylation [337].  Gadd45b may also play a role 
in proliferation and survival as overexpression has been reported to increase survival in serum 
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starved environments [338].  Additionally Gadd45b overexpressing cells were able to form 
tumors in NOD/SCID mice.   
Additionally within the ATM Signaling pathway (Figure 35C) Mdm2 is a critical member 
of the DNA damage response pathway as Mdm2 inhibits p53 activating apoptotic pathways 
[339].  Mdm2 also plays a role in proliferation of cancer cells [340] We report that Mdm2 is 
increased in expression (Figure 35 A), indicating that there may be down regulation of apoptotic 
pathways in addition to the decreased DNA damage repair pathways. Mdm2, a ubiquitin ligase, 
facilitates ubiquitination of p53 and promotes degradation of p53 [341].  In addition to DNA 
damage repair pathways, Mdm2 is critical in protein ubiquitination pathways [342].   
We also report several genes associated with protein ubiquitination being differentially 
expressed (Figure 35D).  Most differentially expressed ubiquitination genes (USP members) are 
decreased in expression.  We also note that Ubb is increased in expression.  Ubb knockout 
models find that Ubb plays a role in dysregulated differentiation in neural progenitor cells [343].  
In the Ubb knockout models apoptosis was a regular occurrence.  Ubb overexpression is found 
after forebrain ischemia within 24 hours but dissipates thereafter [344].  If Ubb expression 
translates to increased protein expression in the Paraquat impacted microglia Ubb may be 
facilitating a stress response pathway or may simply be targeting proteins for degradation.  
Some clue to the altered Protein Ubiquitination Pathway might be identified by expanding the 
eIF2 Signaling pathway.  eIF2 Signaling is involved in transcriptional control and can facilitate 
apoptotic pathways [345].  The eIF2 Signaling pathway is predicted to be inactivated by 
ingenuity pathway analysis (Figure 32B).  We report several ribosomal protein genes to be 
increased in expression (Figure 35E).  We also report Atf4, a pro-survival factor activated after 
mitochondrial stress [346], to be increased in expression.  Atf5 acts as an anti-apoptotic 
transcription factor and plays a role in regulating mitochondrial dysfunction [347, 348].  We find 
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Atf5 increased in expression in Paraquat exposed mitochondria.  These factors taken into 
account would suggest that the microglia are inducing a survival gene expression profile.  We 
next decided to expand several proliferative and cell survival pathways over-represented from 
ingenuity pathway analysis. 
Several cell proliferation and apoptosis pathways and genes are dysregulated in 
Paraquat exposed microglia cultures 
We expanded several pathways that may have ties to cell survival and 
proliferation in microglia.  mTOR signaling plays an important role in cell metabolism 
and apoptosis [349].   Ingenuity pathway analysis predicts mTOR signaling pathway to 
be activated in maternal Paraquat exposed microglia (figure 32 B).  However, mTOR 
signaling is ambiguous in the effect on apoptotic signals [349] and requires further 
attention to genes affected to gain insight.  One such gene Ddit4, has a significant role in 
the outcome of mTOR activation and function.  In an energy depletion context Ddit4 
inhibits mTOR activation [350] in opposition to the predicted activation of mTOR 
Signaling pathway.  However, high expression level of Ddit4 correlates with poor 
prognosis in of glioblastoma multiforme [351] indicating that the role of Ddit4 may be 
more ambiguous than initially understood.  Indeed, in -cells Ddit4 blocked apoptotic 
signaling mechanisms [352] indicating that Ddit4 mechanism is context dependent.  Two 
additional genes that may have a significant role are Irs2 and Prkd3.  Irs2 is reported to 
be involved in energy homeostasis [353] of the organism while Prkd3 has a role in cancer 
migration and proliferation [354-356].  Prkd3 is decreased in expression while Irs2 is 
increased in expression lending the results to the idea that mTOR activation in the case of 
maternally exposed pup microglia to apoptotic events.  However, Rhod is increased in 
expression in maternally exposed pup microglia.  Rhod is a key member of cell cycle 
129 
 
progression and cell motility [357, 358] indicating that increased expression in the 
microglia could promote cell proliferation.  It is clear that mTOR signaling pathway 
members have been affected, however, further investigation is warranted to establish to 
overall outcome of the differences in gene expression. 
AMPK Signaling is predicted to be activated in microglia in maternal Paraquat 
exposed pups (Figure 36B).  AMPK signaling may be important in our model as AMPK 
signaling has been reported to be upregulated in anti-neuroinflammatory models [359].  
AMPK signaling is also upregulated in mitochondrial dysfunction promoting cell survival 
[360].  A key player may be Adrb1 which is increased in gene expression.  Signaling 
through Adrb1, (Adrenergic Beta Receptor 1) key to norepinephrine signaling, has been 
reported to reduce production of pro-inflammatory signaling cytokines [361, 362].  
Studies in brown adipose tissue show Adrb1 can modulate AMPK signaling.  Activation 
of the Adrb1 signaling pathway can reduce neuroinflammation and restore behavioral 
deficits in an Alzheimer’s mouse model [363].  Modulation of the norepinephrine 
signaling pathways may help explain the difference in Iba1 expression (Figure 23) as 
Iba1 is a marker of microglial activation and inflammation [363, 364].   
Another potentially critical gene identified is the bromodomain protein encoding 
gene Brd7.  Brd7 is critical during development as knockout models are embryonic lethal 
and show growth restriction [365].  Brd7 may is reportedly involved in multiple models 
of senescence with changes in Brd7 expression directly correlating with cellular 
senescence [366].  Brd7 may play a role in modulating inflammation by inhibiting the 
NF-kB pathway [367].  In maternal Paraquat exposed Microglia, the expression level of 
Brd7 is down.  Decreased expression of Brd7 may lead to inactivation of cellular 
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senescence pathways allowing the microglia to continue to proliferate.  As we have 
already discussed Atm and Atf4 are also identified and may be playing a role in promoting 
cell survival in line with Brd7 expression and predicted activation of AMPK signaling. 
We also report two additional categories from IPA analysis: Molecular 
Mechanisms in Cancer and Hereditary Breast Cancer Signaling (Figure 36 C, D).   While 
activity of these pathways was not predicted, it is important to note that several 
constituents from previous pathways are also identified here as well.  Additionally, that 
we are identifying changes in gene expression with ties to cancer is important.  We 
wouldn’t anticipate a microglial based cancer, however we might anticipate a protective 
role in the neural environment.  We also expanded Nitric Oxide Signaling in the 
Cardiovascular System, which is predicted to be inactive (figure 32 B).   
Several members of previous pathway ontologies are present in the Nitric Oxide 
Signaling Pathway in the Cardiovascular System as well.  The production of nitric oxide 
can be detrimental to neurons [368, 369].  Nitric oxide plays a critical role in activation of 
microglia [370].  Activated microglia can overproduce nitric oxide negatively impacting 
neuronal survival [371].  The predicted inactivation of nitric oxide signaling offers 
evidence in support of a protective phenotype.  
The effect on differential gene expression in both astrocyte cultures and microglia 
offers insight into the biological implications of maternal Paraquat exposure.  However, 
changes in transcription levels offers a partial understanding of the impact of maternal 
Paraquat exposure.  Future studies may allow us to examine effects at the protein level 
and potentially in long term ramifications from these changes.  In light of recent advances 
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in sequencing analysis our study does lend itself to evaluating the effect of Paraquat 
maternal exposure on gene splicing events. 
In utero Paraquat exposure alters RNA splicing in astrocyte and microglia cultures 
Lastly we sought to characterize alternative splicing events (figure 37).  Paraquat 
has been reported to induce a caloric restriction phenotype that induces alternative 
splicing.  Considering we show a number of differentially expressed genes in microglia 
that may drive alternative splicing events (Figures 35E and 30B) paired end RNA 
sequencing data was analyzed with rMATs (Multivariate Analysis of Transcript 
Splicing).  rMATs can determine the alternative splicing events based upon two criteria: 
Junction Counts Only that identifies reads that lie across exon splice points; and Junction 
Counts with Reads on Target, which adds the inference of relative reads around a splice 
site to the Junction Counts only.  Alternative splicing events with a p-value significance 
<0.05 are displayed.  rMATs accounts for five different splicing types:  Skipped Exons 
(SE), Mutually Exclusive Exons (MXE), Alternative 5’ Splice Site (A5SS), Alternative 
3’ Splice site (A3SS) and Retained Intron.   
In astrocyte cultures and microglia the majority of alternative splicing events 
occurs in SE events. Maternal Paraquat exposure microglia have more alternative splicing 
events than the astrocyte cultures exposed to Paraquat. In both groups there are a few 
examples of RI which implies that the splicing machinery may be unable to function 
correctly in identifying correct splicing sites. Alternatively this may mean that 
transcription is occurring more quickly than splicing mechanisms can function.  With so 
few significant examples of retained intron, there may be significance to the genes in this 
category.  The MXE, A5SS, and A3SS have fewer significant events than SE in both cell 
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types but together comprise nearly as many events as SE.  Further investigation into the 
splicing machinery may be necessary to determine the effect of Paraquat.  Additionally 
evaluating the gene lists may highlight physiologic relevance for alternative splicing 
events.  To illustrate the changes that are occurring in the individual samples we 
expanded Tensin 1 in astrocyte cultures. 
As an example, tensin 1 in astrocytes is alternatively spliced in in utero Paraquat  
Tensin 1, a focal adhesion molecule [372], has been reported to be alternatively spliced.  
We used Tensin 1 as a representative of alternative splicing in Paraqaut exposed astrocytes 
(figure 38).  Control groups show multiple isoforms of Tensin 1 within a sample set.  Some 
control samples preferentially selecting for only one isoform.  Paraquat exposed samples 
preferentially select for one isoform with one sample present with both isoforms.  This example 
highlights that further investigation is warranted into understanding the biological context of 
the alternative splicing events.  
Tensin 1 is involved in cellular communications and focal adhesions [372, 373].  Cellular 
signaling can be achieved with specific protein domains that interact with tyrosine phosphatases 
present within the protein [374].  Tensin 1 plays a role in regulating proliferation and migration 
and the loss of which prevents migration and proliferation [373].  In our model system we show 
an alternatively spliced version which may impact the appropriate connections between cells.  
Further investigation is warranted for understanding the role one isoform plays over the other 
in cellular signaling as well as adherence capability of the astrocytes. 
Discussion 
We have shown that in utero Paraquat exposure induces changes in gene 
expression of glial cells from neonate tissues.  We, however, also show discrepancies 
between the replicate experiments as we previously addressed.  With the difference in 
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ages of animals giving birth between experiments we do not have true replicate 
experiments.  We might conclude however, that there are differential gene expression 
changes based simply upon the age of the mothers that could warrant further 
investigation.  There is evidence of neurological differences in pups born to advanced age 
mothers [375]. This may also provide an opportune investigation into the effect of 
environmental toxicants based on the age of animals during pregnancy.  With the 
evidence of changes induced by age of the mothers and that the treatment group has 
fewer representative mothers in our initial experiment, we focused on the larger second 
study with younger females for most of our analyses. 
The changes in gene expression are specific to each cell type as little overlap 
exists in differentially expressed genes as well as pathways and ontologies impacted.  
These changes are sustained changes as the cells were cultured for two weeks prior to 
harvest.  The sustainable nature of the reported changes in gene expression imply we may 
have altered the epigenetic landscape.  Additionally we report significant changes in 
splicing patterns in our experiment.  While we do not report epigenetic remodeling 
events, ongoing studies in the laboratory include ATAC-sequencing to address the basic 
question of how we alter the chromatin landscape with in utero exposure to Paraquat.  By 
evaluating the chromatin landscape we may be able to cross reference histone and 
polycomb ChIP data sets to find potential epigenetic remodeling targets.  What remains 
clear is we have impacted these cell types and this impact could have long term 
ramifications. 
The unique gene expression that occurs in each cell type indicates that different 
cells respond differently to Paraquat exposure.  Analysis of differentially expressed genes 
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in astrocytes illustrates that astrocytes are predicted to be activated in glioblastoma 
signaling pathway while also have several pathways that could be tied to glial scarring 
and prevention of axonal growth.  The cooperation of these pathways may signify that we 
may be inducing a precancerous phenotype as glioblastoma and other astrocytomas 
induce a glial scar like phenotype [376, 377].  What is interesting is that the Human 
Embryonic Stem Cell pathway is significant in represented genes but unpredicted in 
activity.  This may also implicate a precancerous phenotype as glioblastoma populations 
typically do not share an identical expression profile with stem cells as they have a more 
differentiated phenotype, but do share proliferative gene expression profiles [378].   
We also reported that the treatment astrocyte cultures are indistinguishable from 
control group astrocyte cultures.  The lack of a phenotype change in the presence of the 
gene expression changes indicate that the altered astrocytes may be masked like normal 
cells and continue to incorporate further changes in gene expression.  To evaluate this 
further we propose future studies to evaluate effects in neural cells of maternally exposed 
pups at later time points in life; for example 6 months, 12 months and 18 months.  What 
might be the most interesting in such a long term study is to evaluate littermates.  We 
report that littermates are unequally affected by maternal Paraquat exposure.  Our data 
indicate that some littermates will cluster with Paraquat treatment groups while others 
cluster into control group.  Additionally, within the Paraquat treatment groups there are 
distinct clades implying that Paraquat does not act uniformly in overall phenotypic 
outcome.  Our current study was not designed to evaluate the condition of littermates as 
some littermates were pooled.  Future studies would limit pooling of samples to evaluate 
specific changes within litters. 
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Microglia have a distinct response to Paraquat exposure as compared to 
astrocytes.  In the astrocytes, gene expression changes suggest alterations to pathways 
which may promote increased proliferation and potential activation, where in the 
microglia the changes in gene expression are more ambiguous.  Our in vitro culture 
staining show much reduced IBA1 staining indicating that Paraquat has had a clear 
phenotypic effect.  One might propose that these cells are dying as the ontologies of 
differentially expressed genes are represented by metabolic functions and translational 
regulation as well as the IBA1 staining.  IPA analysis indicates that DNA damage 
pathways are inactivated which would correlate with breakdown of DNA in cell death 
[379, 380].  However, we also have a predicted activation of the mTOR pathway which 
would indicate that these cells could be actively proliferating [381].  We also note that 
there are additional pathways tied to cancer signaling and activated translation and 
transcription that have been identified in these analyses.  As we continue to delve deeper 
into the specific genes within the expanded pathways, the gene expression changes 
suggest that we have actively translating cells with reduced DNA damage signaling 
pathways and upregulated proliferation pathways.  Indeed some regulators of apoptosis 
are decreased while others are increased.  There is little evidence of microglia based 
cancers, but microglia may play a critical role in facilitating cancer initiation and 
progression [382].  Microglia are already reported to play a significant role in 
neurodegeneration [383-385].  Whether the microglia will play a role in either disease 
pathway is unclear, as is their ability to survive long term, but what remains clear is that 
the microglia are altered in our model and would likely be unable to function in a normal 
capacity.  Future long term studies may help elucidate this function. 
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An interesting caveat to this data is that our study did not find measurable 
Paraquat in pup brain tissues by mass spectrometry. While we do see gene expression 
changes in two separate in vivo in utero Paraquat exposures (discussed later) we were 
unable to detect Paraquat in neonate tissues.  We would not expect serum levels to 
contain Paraquat but we might expect to see Paraquat in the neonate brain tissues.  What 
might explain this is the presence of the blood brain barrier. The blood brain barrier in 
developing organisms is not as leaky as is normally ascribed [386, 387].  Original data 
points to a fully functional blood brain barrier.  Although the blood brain barrier may be 
complete and effective there are marked differences in the expression of transporters in 
endothelial cells of brain microvasculature.  Notably the SLC family of proteins are 
overexpressed in developing embryos and neonates compared to adults [388, 389].  SLC 
family of proteins include organic cation transporters such as OCT3, known to play a role 
in internalization of Paraquat [167].  The absence of Paraquat may be due to the 
developing brain more effectively blocking or effluxing Paraquat from brain tissue.  In 
order to isolate this effect, future studies can identify time of exposure in embryos as well 
as efficacy of blood brain barrier in our model system.  Additionally we may be able to 
evaluate how effective Paraquat is at crossing the placental barrier.  Some work has been 
done in this area which indicates that low levels of Paraquat can cross the placenta in 
monkeys [390].   
It may be that the changes in gene expression in both the astrocyte cultures and 
the microglia is dependent upon the time frame of exposures.  Astrocytes may be more 
protected after development of the blood brain barrier thereby limiting any further 
exposure to astrocytes.  Microglia, however, do not enter the central nervous system 
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immediately as they are humoral in origin and migrate during development [302].  
Consequently microglia may have additional exposure events driving the changes in gene 
expression we report here.  This highlights that while these cells show significant 
difference in the effect of Paraquat, the differences may be a function of the number 




Figure 19.  Intraperitoneal Paraquat exposure prior to and during gestation does 
not affect dam mass, gravidity or pup number.  Schematic of experiment A).  Adult 
female mice were exposed to Paraquat for six weeks with twice weekly intraperitoneal 
injections of 10 mg/kg of Paraquat and bred during exposure.  Pups were carried to full 
term and sacrificed for whole brains as well as astrocytes and microglia.  Injection stocks 
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Figure 19 cont. B) were made to 1 mg/mL for an injection schedule of 10 uL/g of adult 
weight.  Paraquat stocks were assessed by liquid chromatography mass spectrometry.  C)  
Mouse mass during experiment was not significantly different between control and 
Paraquat treated animals in either pregnant or non-pregnant animals (Two-way ANOVA 
with bonferroni’s post test).  D)  Percent of mice that were gravid showed a decreased 
trend in Paraquat treated animals versus control animals although not significant (p-Value 
of 0.177 as determined by T-test).  E) Average pup yield shows no difference between 





Figure 20.  Dam brains unable to clear Paraquat from intraperitoneal injections.  
Female mice were intraperitoneally treated with 10 mg/kg Paraquat for 6 weeks.  Mice 
were sacrificed 3 days after last injection and blood was collected before transcardiace 
perfusion to flush the brain of blood.  Brains were removed, snap frozen and pulverized 
for homogeneity.  10 ng of labelled Paraquat was added and samples were extracted with 
80% methanol and sonication.  Samples were centrifuged, and supernatant was washed 
with hexane twice.  Samples were submitted for LC/LC mass spectrometry and 
normalized against internal standard.   A) Adult brain tissues have a significant presence 





Figure 21.  Pup brains and serum are clear of Paraquat.  Pups were collected 1-3 
days postnatal and sacrificed.  Blood was collected after decapitation and brains were 
removed, snap frozen and pulverized for homogeneity.  10 ng of labelled Paraquat was 
added and samples were extracted with 80% methanol and sonication.  Samples were 
centrifuged and supernatant washed twice in hexane.  Samples were submitted for LC/LC 
mass spectrometry.  A) Pup brains and B) sera had no significant levels of Paraquat (T-




Figure 22.  Maternal Paraquat exposure has no apparent effect on astrocyte 
enrichment or Glial Fibrillary Acidic Protein (GFAP) expression.  Brains from 1 to 3 
day old pups were cultured for two weeks at which point culture flasks were subjected to 
shaking at 200 rpm in an incubated shaker for 45 minutes.  Medium was removed and 
cells were washed once in dissecting medium.  Adherent cultures were treated with 
trypsin and suspended in complete medium.  Cells were then reseeded onto poly-D-
Lysine coated german glass coverslips.  Cells were cultured for 48 hours prior to fixation 
in 4% paraformaldehyde.  Coverslips were washed in PBS and incubated in blocking 
solution (3% Donkey serum, 2% Natural Goat Serum, 2% BSA, and 0.1% Triton X-100 
in PBS with Ca++ and MG++) for two hours.  Coverslips were then incubated overnight at 
4o C in blocking solution with 1:1000 anti-GFAP.  Coverslips were then washed and 
incubated in blocking solution with alexa-fluor 555 secondary for two hours.  Coverslips 
were washed and mounted with vectasheild mounting medium with DAPI.  Coverslips 
were imaged (A) and counted (B) by two individuals for positively stained cells.  The 
results were averaged and are represented in 6.3 B.  A T-test was performed for statistical 




Figure 23.  Maternal Paraquat exposure alters pup microglia Ionized Calcium-
Binding Adaptor Molecule 1 (IBA1) expression.  Brains from 1 to 3 day old pups were 
cultured for two weeks at which point culture flasks were subjected to shaking at 200 rpm 
in an incubated shaker for 45 minutes.  Medium was removed and flasks were washed 
once in dissecting medium.  Medium and Dissection Medium were collected and 
centrifuged to collect suspended cells.  Cells were suspended in complete medium and 
then reseeded onto poly-D-Lysine coated german glass coverslips.  Cells were cultured 
for 48 hours prior to fixation in 4% paraformaldehyde.  Coverslips were washed in PBS 
and incubated in blocking solution (3% Donkey serum, 2% Natural Goat Serum, 2% 
BSA, and 0.1% Triton X-100 in PBS with Ca++ and MG++) for two hours.  Coverslips 
were then incubated overnight at 4o C in blocking solution with 1:200 anti-IBA1.  
Coverslips were then washed and incubated in blocking solution with alexa-fluor 555 
secondary for two hours.  Coverslips were washed and mounted with vectasheild 
mounting medium with DAPI.  Coverslips were imaged (A) and counted (B) by two 
individuals for positive cells.  The results were averaged and are represented in B.  
Intensity measurements (C) were performed for the DAPI and IBA1 channels and are 





Figure 24.  Gene expression analysis shows experimental batch effect.  Distance 
clustering of the RNA sequencing results for microglia (green) and astrocyte (brown) 
samples from experiment 1 (black) and experiment 2 (grey) exposed to Paraquat (pink) or 
Saline (control, blue).  Results indicate samples cluster according to cell type and 




Figure 25.  Maternal Paraquat exposure experiments are unique from one another.  
Differential gene expression between Paraquat and control for astrocytes and microglia 
combined for experiment 1 and 2 (A); and differential gene expression between control 
groups from experiment 1 and 2 (B) for astrocytes and microglia.  Results are shown in 
MA plot format of mean expression versus log fold change.  Each dot indicates the 
results for a gene locus; the further right indicates greater mean expression and away 
from the central axis indicate the greater the difference in expression between the two 
groups.  Red dots indicate statistically significant difference in gene expression with an 
adjusted p-value < 0.05.  Control conditions between the two experiments have 
significant number of differentially expressed genes that are greater in number than 
between the experimental conditions for both experiments combined.  Reexamination of 




Figure 25 Cont.  Dams in first experiment vary in age from 3 to 7 months at the end of 
experiment while the second experiment, dams were aged 3.5 months at the end of 
experiment.  Additionally, pups from first experiment were from varied aged mothers in 
control group while treatment group were primarily from one mother at the age of 6 
months.  One mother in the Paraquat treatment group was aged 4 months at the end of the 
study but generated only two pups compared to 6 pups from the 6 month old mother.  The 




TABLE 4.  DIFFERENCES IN AGE OF MOTHERS AND PUP 
REPRESENTATION OF IN VIVO PARAQUAT EXPOSURE 
EXPERIMENT 1 
DAM Age (end of study) Number of pups 
CONTROL 
  
A 4 Months 9 
B 7 Months 10 
C 6 Months 8 
D 5 Months 8 
PARAQUAT 
  
E 4 Months 2 
F 6 Months 6 
   
EXPERIMENT 2 
DAM Age (end of study) Number of pups 
CONTROL 
  
A 3.5 Months 2 
B 3.5 Months 3 
C 3.5 Months 8 
D 3.5 Months 4 
PARAQUAT 
  
E 3.5 Months 4 
F 3.5 Months 4 
G 3.5 Months 7 
H 3.5 Months 7 
I 3.5 Months 7 
J 3.5 Months 7 
K 3.5 Months 5 




Figure 26.  Repeat experiments have different patterns in gene expression changes.  
Differential gene expression alaysis is displayed in MA plot format for differential gene 
expression between Paraquat and Control groups for Astrocytes in experiment 1 (A) and 
experiment 2 (C); and microglia in experiment 1 (B) and experiment 2 (D).  Each dot 
represents a gene locus with greatest difference between control and treatment group 
furthest right and distal to central axis.  Red dot indicates significant difference in gene 
expression with an adjusted p-value < 0.05.  Experiment 1 has differential gene 
expression that is largely increased gene expression in both cultures whereas the second 






Figure 27.  Gene expression data indicates a response in pup brain cells to maternal 
Paraquat exposure.  Distance clustering of gene expression data sets are separated into 
A) astrocytes and B) microglia from the second experiment.  Pups from Paraquat treated 
dams are differentially clustered with some pups clustered into the control groups in both 
astrocyte and microglia cultures.  Some littermates do not cluster according to treatment 




Table 5. Experiment 1 astrocyte differential gene expression 
Gene Base mean 
Fold 
change 
(log2 ) Lfcse Stat p-value 
Adjusted 
p-value 
A230072C01RIK 195.3009 -0.5321 0.1635 -3.255 0.0011 0.0455 
A630001G21RIK 924.8758 0.5126 0.1553 3.3013 0.001 0.0427 
ABCB10 1218.071 0.2473 0.0712 3.4712 0.0005 0.0306 
ABCB7 2721.595 0.3768 0.1101 3.4238 0.0006 0.034 
ACD 1467.72 -0.2938 0.092 -3.1939 0.0014 0.0495 
ACVR1 1914.492 0.5833 0.1236 4.7205 0 0.0041 
ACVRL1 852.0515 0.7915 0.2116 3.7414 0.0002 0.0199 
ADAM10 16799.99 0.5327 0.1269 4.1968 0 0.0113 
ADAM17 13550.44 0.5387 0.1423 3.7852 0.0002 0.0188 
ADCK4 2674.018 -0.4368 0.126 -3.4671 0.0005 0.0307 
ADH5 6600.139 -0.2266 0.0694 -3.2661 0.0011 0.0446 
ADPRHL2 1198.513 -0.3543 0.1007 -3.5197 0.0004 0.0294 
AGA 1537.543 0.2808 0.0879 3.1955 0.0014 0.0495 
AKIP1 1116.054 -0.3865 0.1205 -3.2084 0.0013 0.049 
AKR1E1 1935.482 -0.345 0.0923 -3.7388 0.0002 0.0199 
ALDH16A1 1782.4 0.2893 0.09 3.2151 0.0013 0.049 
ALG1 1368.435 0.2909 0.0848 3.4298 0.0006 0.034 
ALG11 1440.983 0.3399 0.0956 3.5557 0.0004 0.028 
ALG2 2460.809 0.3112 0.093 3.347 0.0008 0.0387 
AOAH 3480.191 0.876 0.2505 3.497 0.0005 0.0299 
APP 44525.44 0.5073 0.1469 3.4522 0.0006 0.0321 
ARFIP2 2139.4 -0.2924 0.0887 -3.2959 0.001 0.0432 
ARL3 2819.645 -0.2976 0.0922 -3.2266 0.0013 0.0483 
ATF6B 3455.05 0.2322 0.071 3.2713 0.0011 0.0444 
ATP11C 1962.929 0.3982 0.115 3.4609 0.0005 0.0313 
ATP13A1 3089.343 0.3383 0.1021 3.3139 0.0009 0.0417 
ATP2A2 26053.34 0.4474 0.1275 3.5081 0.0005 0.0298 
ATP2B1 11288.16 0.6114 0.1833 3.3358 0.0009 0.0391 
ATP6AP1 18666.66 0.3356 0.1045 3.2101 0.0013 0.049 
ATP6AP2 13597.31 0.4013 0.1225 3.2762 0.0011 0.0439 
ATP7A 4402.727 0.6084 0.1679 3.6231 0.0003 0.025 
B3GLCT 1402.893 0.454 0.1197 3.7942 0.0001 0.0186 
B4GALT1 8795.652 0.4872 0.1217 4.0023 0.0001 0.0152 
BCAP31 6819.807 0.3337 0.094 3.5492 0.0004 0.0285 
BTF3L4 5121.198 -0.2107 0.0563 -3.7417 0.0002 0.0199 
C2CD2 1042.574 0.2686 0.0771 3.4865 0.0005 0.0302 
C3AR1 34789.4 1.0594 0.3244 3.2658 0.0011 0.0446 
C430049B03RIK 139.2193 -0.4529 0.1297 -3.4913 0.0005 0.0302 
C5AR1 16713.56 0.8603 0.2442 3.5231 0.0004 0.0294 
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Table 5. Experiment 1 astrocyte differential gene expression 
Gene Base mean 
Fold 
change 
(log2 ) Lfcse Stat p-value 
Adjusted 
p-value 
CALCRL 1024.469 0.8964 0.2308 3.8842 0.0001 0.0173 
CALU 20149.08 0.5101 0.1483 3.4394 0.0006 0.0334 
CANX 39879.08 0.4137 0.1146 3.6092 0.0003 0.026 
CCDC88B 2981.955 0.6913 0.1736 3.9823 0.0001 0.0154 
CCL3 19161.82 1.3696 0.3629 3.7741 0.0002 0.0195 
CCL4 9547.414 1.5974 0.3337 4.7874 0 0.0041 
CCRL2 794.1884 1.6785 0.4658 3.6034 0.0003 0.0261 
CD40 183.9531 1.2576 0.3528 3.5649 0.0004 0.028 
CD93 8790.698 1.3089 0.4049 3.2328 0.0012 0.0475 
CDK5 1971.101 -0.3076 0.0745 -4.1267 0 0.0124 
CFH 14731.47 1.3322 0.3494 3.8128 0.0001 0.0181 
CHMP5 5878.114 -0.2852 0.078 -3.655 0.0003 0.0236 
CKAP4 3707.037 0.5815 0.1631 3.5649 0.0004 0.028 
CLEC4A2 933.3873 0.8477 0.2641 3.2093 0.0013 0.049 
CLPTM1 9861.658 0.377 0.115 3.2787 0.001 0.0439 
CMKLR1 3021.377 0.7944 0.2112 3.7622 0.0002 0.0199 
CNPY3 3993.837 0.32 0.0875 3.6564 0.0003 0.0236 
COL14A1 3564.542 0.9967 0.2961 3.3659 0.0008 0.0375 
COL15A1 389.0267 1.9925 0.3517 5.665 0 0.0002 
COL18A1 5116.197 1.3278 0.3884 3.4187 0.0006 0.0345 
COL7A1 989.7385 1.4971 0.3811 3.928 0.0001 0.017 
COMMD3 3807.594 -0.2749 0.0779 -3.5275 0.0004 0.0294 
COMMD6 1532.15 -0.3604 0.1095 -3.2914 0.001 0.0434 
COPZ1 8958.451 -0.205 0.0642 -3.1913 0.0014 0.0495 
COX20 1109.286 -0.3893 0.1158 -3.3607 0.0008 0.0376 
CPD 24174.18 0.6776 0.2001 3.3859 0.0007 0.0367 
CRIPT 2717.822 -0.32 0.0852 -3.7547 0.0002 0.0199 
CRTAP 2888.495 0.5213 0.1471 3.5436 0.0004 0.0286 
CTSC 35438.14 0.766 0.1732 4.4223 0 0.0072 
CUTC 309.7578 -0.448 0.1248 -3.59 0.0003 0.0269 
CWC27 1204.131 -0.156 0.0467 -3.3396 0.0008 0.0389 
CYB5RL 311.2579 -0.3769 0.0914 -4.1234 0 0.0124 
CYBA 10220.45 0.5603 0.174 3.2196 0.0013 0.049 
DCHS1 1013.114 0.8995 0.2822 3.188 0.0014 0.0496 
DCPS 1402.558 -0.4135 0.1113 -3.7138 0.0002 0.0213 
DCTN6 2315.876 -0.271 0.0683 -3.9678 0.0001 0.0158 
DDOST 10934.29 0.4269 0.1115 3.8304 0.0001 0.0181 
DERL1 8018.775 0.4006 0.1056 3.7941 0.0001 0.0186 
DGCR2 5137.984 0.3249 0.0924 3.5172 0.0004 0.0294 
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Table 5. Experiment 1 astrocyte differential gene expression 
Gene Base mean 
Fold 
change 
(log2 ) Lfcse Stat p-value 
Adjusted 
p-value 
DHCR7 1649.84 0.4022 0.1095 3.6729 0.0002 0.023 
DIEXF 685.7031 0.2853 0.0893 3.1959 0.0014 0.0495 
DMAP1 900.4709 -0.3192 0.0985 -3.2409 0.0012 0.0466 
DNAJB11 7392.899 0.4047 0.1243 3.257 0.0011 0.0455 
DNAJC7 8110.152 -0.1793 0.0558 -3.2144 0.0013 0.049 
DOCK10 3867.138 0.557 0.1665 3.3455 0.0008 0.0387 
DOLK 1126.045 0.3476 0.0895 3.8863 0.0001 0.0173 
DPH7 564.8091 -0.3512 0.1023 -3.4316 0.0006 0.0339 
DSE 5699.122 0.5911 0.1678 3.5221 0.0004 0.0294 
DYNC1I2 11074.47 -0.1477 0.0458 -3.2213 0.0013 0.049 
E130308A19RIK 500.0205 0.2803 0.0856 3.2765 0.0011 0.0439 
ECE1 1498.967 0.6907 0.1901 3.6324 0.0003 0.0246 
EDEM1 16303.32 0.5362 0.1491 3.5952 0.0003 0.0267 
EDEM3 4587.485 0.5111 0.1392 3.6708 0.0002 0.023 
EHBP1L1 5408.712 0.4034 0.1224 3.294 0.001 0.0432 
EHMT1 2529.755 0.2232 0.0643 3.4723 0.0005 0.0306 
ELF4 3493.626 0.7022 0.1918 3.6605 0.0003 0.0235 
EMC10 5454.196 0.2404 0.0712 3.376 0.0007 0.0372 
EMC2 3596.058 -0.2835 0.0734 -3.8603 0.0001 0.0175 
EMC3 5357.152 0.3346 0.0939 3.564 0.0004 0.028 
EMILIN1 2720.479 1.1828 0.3455 3.4238 0.0006 0.034 
EMILIN2 7921.403 1.2023 0.3106 3.871 0.0001 0.0175 
EMR1 27153.69 0.8778 0.2622 3.348 0.0008 0.0387 
ENG 408.0728 1.0139 0.2631 3.8533 0.0001 0.0175 
ENPP1 2427.951 1.4304 0.2787 5.1324 0 0.0012 
ERLIN1 3048.488 0.4262 0.1328 3.2089 0.0013 0.049 
ERP29 11721.5 0.3548 0.1102 3.2197 0.0013 0.049 
ERP44 4069.614 0.4037 0.0978 4.1284 0 0.0124 
ESYT2 3178.01 0.3792 0.1134 3.3442 0.0008 0.0387 
EXT2 4349.371 0.4552 0.1057 4.3065 0 0.0095 
FAM103A1 2687.899 -0.3078 0.087 -3.5354 0.0004 0.0292 
FAM129A 1042.007 0.7762 0.2421 3.2066 0.0013 0.049 
FAM3C 3017.126 0.3039 0.0768 3.9574 0.0001 0.016 
FASTKD2 1389.962 0.342 0.1052 3.2509 0.0012 0.0458 
FBXW2 3215.126 -0.2123 0.058 -3.6605 0.0003 0.0235 
FCF1 1595.481 -0.336 0.1046 -3.2127 0.0013 0.049 
FES 5227.603 0.5863 0.1812 3.2366 0.0012 0.047 
FNTA 5027.679 -0.2116 0.0587 -3.6026 0.0003 0.0261 
FRG1 2067.485 -0.3112 0.0916 -3.398 0.0007 0.0364 
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Gene Base mean 
Fold 
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(log2 ) Lfcse Stat p-value 
Adjusted 
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FRRS1 2518.767 0.6612 0.207 3.1946 0.0014 0.0495 
FUT8 2082.426 0.3559 0.1065 3.3406 0.0008 0.0389 
GALNT1 10160.44 0.3104 0.0774 4.0084 0.0001 0.0152 
GALNT12 842.2514 0.6795 0.2094 3.2448 0.0012 0.0463 
GALNT2 7107.554 0.3683 0.0931 3.9559 0.0001 0.016 
GALNT4 1730.21 0.38 0.1067 3.5625 0.0004 0.028 
GANAB 12257.23 0.4326 0.1022 4.2349 0 0.0109 
GLCE 1346.104 0.5984 0.1592 3.76 0.0002 0.0199 
GLO1 7175.031 -0.1986 0.0601 -3.3051 0.0009 0.0426 
GM6377 3904.936 1.5563 0.4007 3.8841 0.0001 0.0173 
GPANK1 455.6793 -0.4837 0.145 -3.335 0.0009 0.0391 
GPATCH11 781.2755 -0.2322 0.0707 -3.2832 0.001 0.0438 
GPR180 1113.092 0.2589 0.0762 3.3962 0.0007 0.0365 
GRN 104280.8 0.7218 0.2243 3.2174 0.0013 0.049 
GUSB 31750.72 0.6288 0.1898 3.3124 0.0009 0.0418 
GXYLT1 3039.154 0.5203 0.1483 3.5076 0.0005 0.0298 
H2-M3 980.9927 0.5882 0.1654 3.5556 0.0004 0.028 
H6PD 2492.987 0.699 0.1894 3.6912 0.0002 0.022 
HDAC10 680.952 -0.315 0.0955 -3.298 0.001 0.043 
HIATL1 4518.212 0.2807 0.0855 3.284 0.001 0.0438 
HSPA13 3915.644 0.4053 0.1111 3.6478 0.0003 0.0241 
IDH3B 6113.389 -0.1772 0.045 -3.9392 0.0001 0.0166 
IDH3G 5382.453 -0.2383 0.0619 -3.8526 0.0001 0.0175 
IFNAR1 9678.696 0.4328 0.1238 3.4969 0.0005 0.0299 
IL13RA1 2340.843 0.7033 0.1839 3.8249 0.0001 0.0181 
IL18RAP 118.1133 1.0702 0.3357 3.1878 0.0014 0.0496 
IL21R 3447.091 0.82 0.2566 3.1951 0.0014 0.0495 
IL2RG 1460.285 1.0865 0.2568 4.2316 0 0.0109 
IMPAD1 5495.458 0.4523 0.1414 3.1981 0.0014 0.0495 
ISCA2 1238.617 -0.3537 0.108 -3.2752 0.0011 0.0439 
ITGA4 5130.182 0.9199 0.2803 3.282 0.001 0.0438 
ITGA6 21184.41 0.5762 0.1625 3.5468 0.0004 0.0286 
ITGA8 503.5242 1.7937 0.5144 3.4867 0.0005 0.0302 
ITGA9 1981.366 0.7063 0.2144 3.2947 0.001 0.0432 
ITGAM 24746.32 0.9502 0.2355 4.0342 0.0001 0.0152 
ITGAV 12366.5 0.6432 0.1671 3.85 0.0001 0.0175 
ITPRIPL2 5674.511 0.5019 0.1259 3.9867 0.0001 0.0154 
JOSD2 976.6704 -0.3236 0.1006 -3.2182 0.0013 0.049 
JRKL 520.5603 -0.6055 0.1796 -3.3718 0.0007 0.0373 
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KAT5 2090.07 -0.258 0.0605 -4.2615 0 0.0109 
KCNK13 1822.596 0.776 0.2363 3.2842 0.001 0.0438 
KCNK6 2355.364 0.6456 0.1982 3.2572 0.0011 0.0455 
KCNN4 1300.014 1.2798 0.3944 3.2447 0.0012 0.0463 
KDELR2 4894.537 0.4156 0.1247 3.3329 0.0009 0.0392 
KLHL15 225.8867 0.4846 0.1332 3.6387 0.0003 0.0245 
KREMEN1 2403.113 0.3545 0.0912 3.8862 0.0001 0.0173 
LAMA1 367.8885 2.1206 0.545 3.8913 0.0001 0.0173 
LAMA4 1402.364 1.5817 0.4828 3.2764 0.0011 0.0439 
LAMC1 12371.84 0.8419 0.2254 3.7344 0.0002 0.02 
LCMT1 1100.947 -0.292 0.0917 -3.1851 0.0014 0.0499 
LEMD3 1292.685 0.365 0.0961 3.7988 0.0001 0.0186 
LEPRE1 1333.03 0.5375 0.1454 3.6967 0.0002 0.0217 
LGALS3BP 8398.49 0.752 0.2165 3.4738 0.0005 0.0306 
LHFPL2 12282.17 0.778 0.2271 3.4252 0.0006 0.034 
LMAN2 10273.98 0.4465 0.098 4.5581 0 0.0065 
LPGAT1 5014.969 0.4222 0.1138 3.7113 0.0002 0.0213 
LRP1 47331.02 0.848 0.2222 3.8171 0.0001 0.0181 
LRP10 7731.231 0.3713 0.1093 3.3975 0.0007 0.0364 
LRP5 6046.732 0.5663 0.1775 3.1907 0.0014 0.0495 
LRRC25 2487.824 0.6944 0.1828 3.798 0.0001 0.0186 
LTBR 4483.262 0.2747 0.0784 3.5024 0.0005 0.0298 
LYN 12984.76 0.4525 0.1185 3.8182 0.0001 0.0181 
LYRM2 1341.636 -0.4026 0.1074 -3.7471 0.0002 0.0199 
MAGT1 5500.203 0.4634 0.1235 3.7509 0.0002 0.0199 
MAN1A2 6429.679 0.3107 0.0941 3.3029 0.001 0.0426 
MAN2A1 8285.93 0.984 0.241 4.0828 0 0.013 
MANBA 4460.731 0.6957 0.1991 3.4937 0.0005 0.0302 
MAP3K15 316.4611 0.5917 0.1657 3.5721 0.0004 0.0279 
MED31 610.4451 -0.3774 0.1163 -3.2462 0.0012 0.0463 
MESDC2 4584.407 0.3255 0.0909 3.5828 0.0003 0.0271 
METTL10 960.2092 -0.3818 0.099 -3.8554 0.0001 0.0175 
METTL17 642.2856 -0.3604 0.1012 -3.5607 0.0004 0.028 
MFSD1 20364.69 0.5407 0.1542 3.5069 0.0005 0.0298 
MGAT2 5369.618 0.3587 0.1 3.5881 0.0003 0.0269 
MGAT4A 3240.102 0.5317 0.1527 3.4814 0.0005 0.0302 
MIA3 5095.23 0.4318 0.1072 4.0295 0.0001 0.0152 
MMP14 7945.334 0.6584 0.2003 3.2876 0.001 0.0437 
MRGBP 549.8911 -0.2987 0.0935 -3.1964 0.0014 0.0495 
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Adjusted 
p-value 
MRPS33 2649.029 -0.3677 0.1153 -3.1899 0.0014 0.0495 
MTCP1 311.8406 -0.4286 0.134 -3.1998 0.0014 0.0495 
MTFMT 595.4192 -0.3666 0.0995 -3.6839 0.0002 0.0224 
MTIF3 655.3098 -0.2924 0.0851 -3.435 0.0006 0.0336 
NAE1 2024.557 -0.2724 0.0835 -3.2629 0.0011 0.045 
NAGPA 3508.316 0.4979 0.1469 3.3897 0.0007 0.0367 
NCLN 5196.686 0.3544 0.1006 3.5223 0.0004 0.0294 
NCOR2 8393.79 0.4895 0.1443 3.3917 0.0007 0.0367 
NCSTN 10341.39 0.421 0.1184 3.5551 0.0004 0.028 
NIN 3647.378 0.5307 0.1277 4.1553 0 0.012 
NIPA2 4946.151 0.3115 0.092 3.3844 0.0007 0.0367 
NLRP3 4574.967 1.0899 0.2572 4.2379 0 0.0109 
NPRL2 715.6184 -0.3113 0.0905 -3.4377 0.0006 0.0334 
NRP1 21438.17 0.8646 0.1772 4.878 0 0.0034 
NRP2 15104.98 0.7894 0.2275 3.4706 0.0005 0.0306 
NRROS 12552.96 0.8931 0.2658 3.3596 0.0008 0.0376 
NUCB1 12918.29 0.4492 0.1312 3.4241 0.0006 0.034 
OSM 2739.486 1.753 0.4372 4.0096 0.0001 0.0152 
OSTM1 5618.707 0.3419 0.1072 3.1901 0.0014 0.0495 
OTUB1 4481.877 -0.2309 0.0633 -3.6461 0.0003 0.0241 
P4HB 36182.08 0.5432 0.1321 4.1111 0 0.0124 
PAGR1A 1422.095 -0.5559 0.1428 -3.8934 0.0001 0.0173 
PCGF1 287.4089 -0.3889 0.1151 -3.3779 0.0007 0.0371 
PDIA3 48632.65 0.4068 0.1249 3.256 0.0011 0.0455 
PEF1 2431.798 -0.2495 0.0649 -3.8432 0.0001 0.0178 
PELP1 2692.532 0.2592 0.0812 3.1921 0.0014 0.0495 
PGAP3 307.4509 0.498 0.1153 4.3197 0 0.0094 
PIGK 3666.926 0.3749 0.1172 3.1978 0.0014 0.0495 
PIGN 3716.082 0.4244 0.1146 3.7041 0.0002 0.0215 
PIGS 5057.106 0.3242 0.1012 3.2039 0.0014 0.0492 
PIGT 8942.47 0.3408 0.1008 3.3817 0.0007 0.0367 
PIGU 2159.139 0.3387 0.1026 3.3027 0.001 0.0426 
PIK3R6 640.2297 0.8153 0.2336 3.4896 0.0005 0.0302 
PIN4 930.7954 -0.4076 0.1211 -3.3651 0.0008 0.0375 
PLOD1 11968.77 0.7851 0.1657 4.7392 0 0.0041 
POFUT1 2835.486 0.3434 0.0883 3.8887 0.0001 0.0173 
POFUT2 4048.77 0.3543 0.0866 4.0915 0 0.013 
POLR1C 1527.871 -0.2688 0.0803 -3.3484 0.0008 0.0387 
PPIL2 3733.749 -0.2102 0.0644 -3.2659 0.0011 0.0446 
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Adjusted 
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PRKCSH 6513.871 0.4808 0.1042 4.6133 0 0.0055 
PROKR1 213.2612 0.6461 0.191 3.3828 0.0007 0.0367 
PRSS36 163.599 -0.4516 0.1359 -3.3219 0.0009 0.0407 
PSD4 2735.632 0.5863 0.1733 3.3826 0.0007 0.0367 
PSEN1 5850.226 0.341 0.0951 3.5848 0.0003 0.0271 
PTBP3 18674.18 0.437 0.1097 3.9828 0.0001 0.0154 
PTPRC 10185.11 0.9065 0.2155 4.2062 0 0.0113 
PUS3 567.4557 -0.3629 0.1136 -3.1943 0.0014 0.0495 
QPCTL 920.8176 0.2812 0.0829 3.3931 0.0007 0.0367 
QSOX1 3086.738 0.5552 0.148 3.7523 0.0002 0.0199 
RAP2A 13356.74 0.3054 0.0908 3.3645 0.0008 0.0375 
RBM48 419.9354 -0.3427 0.0983 -3.4854 0.0005 0.0302 
REEP3 10627.55 0.5032 0.1529 3.2908 0.001 0.0434 
REL 980.9194 0.8689 0.2482 3.5003 0.0005 0.0299 
RGS1 7701.269 1.8377 0.4697 3.9127 0.0001 0.0172 
RNF113A2 547.5429 -0.4368 0.128 -3.4111 0.0006 0.035 
RNF149 5370.134 0.5457 0.1311 4.1626 0 0.012 
RPN1 14886.6 0.5032 0.1428 3.5238 0.0004 0.0294 
RRBP1 15760.78 0.4892 0.1305 3.7493 0.0002 0.0199 
SCFD2 694.3512 -0.2418 0.074 -3.2658 0.0011 0.0446 
SCNM1 1156.713 -0.3953 0.1166 -3.389 0.0007 0.0367 
SCUBE1 323.346 1.8724 0.5169 3.6225 0.0003 0.025 
SEC61A1 12593.95 0.4306 0.1126 3.8234 0.0001 0.0181 
SELT 15910.02 0.2542 0.0711 3.5776 0.0003 0.0275 
SEPN1 5584.832 0.3949 0.094 4.203 0 0.0113 
SH3GLB2 2354.215 -0.2099 0.0563 -3.7282 0.0002 0.0202 
SHISA5 8331.439 0.402 0.1153 3.4859 0.0005 0.0302 
SKP1A 16355.09 -0.3139 0.0927 -3.3878 0.0007 0.0367 
SLC16A10 3935.105 0.9064 0.2694 3.3638 0.0008 0.0375 
SLC16A6 2398.814 0.5642 0.1609 3.5055 0.0005 0.0298 
SLC20A2 2315.617 0.3727 0.0978 3.8127 0.0001 0.0181 
SLC27A4 2544.628 0.2537 0.0755 3.3581 0.0008 0.0376 
SLC29A1 2653.751 0.7363 0.1835 4.0117 0.0001 0.0152 
SLC30A7 2964.695 0.4033 0.108 3.733 0.0002 0.02 
SLC35C1 1973.678 0.3348 0.0963 3.4788 0.0005 0.0304 
SLC35E1 4689.348 0.4362 0.1205 3.6191 0.0003 0.0252 
SLC38A1 16627.57 0.4675 0.1387 3.3695 0.0008 0.0375 
SLC38A10 11091.78 0.4208 0.1137 3.7009 0.0002 0.0216 
SLC39A7 7170.347 0.3955 0.0968 4.0858 0 0.013 
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SLC7A8 11644.68 0.7271 0.1766 4.1175 0 0.0124 
SLC9A6 1969.346 0.2992 0.0859 3.4823 0.0005 0.0302 
SMIM11 1006.976 -0.3447 0.1068 -3.2266 0.0013 0.0483 
SNHG3 503.1507 -0.532 0.1591 -3.3439 0.0008 0.0387 
SNW1 5752.968 -0.169 0.0482 -3.5071 0.0005 0.0298 
SNX1 7620.871 -0.2091 0.0637 -3.2833 0.001 0.0438 
SP3 6227.712 0.2062 0.047 4.3906 0 0.0078 
SPAG7 2411.116 -0.3085 0.0741 -4.1645 0 0.012 
SPPL2A 8643.653 0.3622 0.1117 3.2421 0.0012 0.0466 
SPTLC1 3468.398 0.3826 0.1054 3.6318 0.0003 0.0246 
SPTLC2 5668.586 0.3589 0.1117 3.2148 0.0013 0.049 
SRI 6607.079 -0.2311 0.0687 -3.3654 0.0008 0.0375 
SRPR 6653.627 0.3343 0.101 3.3103 0.0009 0.0419 
SSBP1 1501.318 -0.4168 0.1073 -3.8845 0.0001 0.0173 
SSR1 13524.05 0.5052 0.1377 3.6693 0.0002 0.023 
SSR3 21787.28 0.336 0.0866 3.8786 0.0001 0.0174 
STK11 3820.487 -0.1985 0.0611 -3.2501 0.0012 0.0458 
STT3A 11701.76 0.495 0.1263 3.9192 0.0001 0.017 
SUDS3 4986.608 -0.1995 0.0569 -3.504 0.0005 0.0298 
SUMO1 5342.998 -0.2905 0.0905 -3.2089 0.0013 0.049 
SURF4 14765.49 0.4535 0.1011 4.4876 0 0.0072 
SUSD1 896.6106 0.64 0.1918 3.3372 0.0008 0.039 
SYF2 3528.691 -0.2387 0.0675 -3.5345 0.0004 0.0292 
SYPL 8472.742 0.3041 0.0936 3.2504 0.0012 0.0458 
TAGAP1 492.3484 -0.4524 0.1315 -3.4395 0.0006 0.0334 
TGFB1 8369.635 0.6034 0.1631 3.6986 0.0002 0.0217 
TGFBI 8673.343 1.0345 0.287 3.6047 0.0003 0.0261 
TGFBR2 16001.84 0.5502 0.1632 3.3718 0.0007 0.0373 
TLR13 14753 0.8835 0.2712 3.2571 0.0011 0.0455 
TLR2 20841.62 0.9854 0.3071 3.2087 0.0013 0.049 
TM9SF2 12249.12 0.4823 0.1103 4.3725 0 0.0078 
TM9SF4 5997.882 0.3939 0.1125 3.5022 0.0005 0.0298 
TMED5 6579.794 0.3991 0.1134 3.5195 0.0004 0.0294 
TMED7 11970.08 0.3397 0.0866 3.9224 0.0001 0.017 
TMED9 9185.515 0.3538 0.0963 3.6725 0.0002 0.023 
TMEM104 5814.546 0.6047 0.1743 3.4697 0.0005 0.0306 
TMEM131 5680.992 0.418 0.13 3.2158 0.0013 0.049 
TMEM132A 1846.728 0.559 0.1466 3.8121 0.0001 0.0181 
TMEM164 5159.286 0.3324 0.0935 3.5565 0.0004 0.028 
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TMEM19 3011.849 0.3331 0.0831 4.0065 0.0001 0.0152 
TMEM2 2768.403 0.6281 0.1834 3.4245 0.0006 0.034 
TMEM30A 12706 0.3364 0.0803 4.19 0 0.0113 
TMEM57 2668.674 0.3358 0.0851 3.9436 0.0001 0.0166 
TMEM64 3149 0.5357 0.1522 3.5202 0.0004 0.0294 
TMEM68 1846.48 0.3147 0.0711 4.4237 0 0.0072 
TMX3 6415.346 0.3752 0.0982 3.8206 0.0001 0.0181 
TNF 2685.478 1.4428 0.341 4.2307 0 0.0109 
TNKS2 14357.72 0.3336 0.0993 3.3587 0.0008 0.0376 
TPST2 2584.03 0.3235 0.0839 3.8558 0.0001 0.0175 
TRAM1 9466.617 0.3325 0.0973 3.4161 0.0006 0.0346 
TRAPPC2 973.6465 -0.3002 0.0765 -3.925 0.0001 0.017 
TRMU 463.9333 -0.3944 0.1055 -3.7385 0.0002 0.0199 
TTC13 2953.259 0.3059 0.0932 3.2816 0.001 0.0438 
TTYH3 16065.18 0.5298 0.1571 3.3721 0.0007 0.0373 
TWSG1 5048.738 0.5117 0.1137 4.5015 0 0.0072 
TXNDC11 1764.228 0.3478 0.0969 3.5884 0.0003 0.0269 
TXNL4B 553.3604 -0.3406 0.0978 -3.4839 0.0005 0.0302 
UBE2D1 1866.279 -0.3456 0.1019 -3.3901 0.0007 0.0367 
UGGT1 7733.067 0.64 0.1442 4.4394 0 0.0072 
UGT1A7C 1764.872 0.7477 0.2239 3.3396 0.0008 0.0389 
UTP11L 1867.103 -0.3373 0.0844 -3.9945 0.0001 0.0154 
VMP1 5199.738 -0.6321 0.1419 -4.4534 0 0.0072 
VPS45 1440.364 -0.2842 0.0782 -3.6335 0.0003 0.0246 
VPS4A 3608.722 -0.1682 0.0436 -3.8547 0.0001 0.0175 
WBP1L 5235.345 0.2787 0.0724 3.8495 0.0001 0.0175 
WDFY4 5028.03 0.7778 0.2403 3.237 0.0012 0.047 
XRCC4 755.597 -0.3033 0.0646 -4.6974 0 0.0041 
XXYLT1 1692.086 0.4572 0.1106 4.1329 0 0.0124 
XYLT2 2935.113 0.7188 0.1401 5.1315 0 0.0012 
ZBTB25 543.4528 -0.275 0.0782 -3.5165 0.0004 0.0294 
ZBTB8OS 1140.782 -0.335 0.0982 -3.4119 0.0006 0.035 
ZDHHC20 6570.417 0.4712 0.1171 4.0226 0.0001 0.0152 
ZDHHC7 2457.302 0.2314 0.0653 3.544 0.0004 0.0286 
ZFP330 1910.027 -0.2463 0.0732 -3.3626 0.0008 0.0376 
ZFP386 1470.418 -0.3234 0.0932 -3.4689 0.0005 0.0306 
ZFP706 8249.081 -0.1659 0.0466 -3.5643 0.0004 0.028 
ZFP94 169.5686 -0.6248 0.1686 -3.7065 0.0002 0.0215 
ZFYVE19 966.4367 -0.2197 0.0606 -3.623 0.0003 0.025 
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Table 5. Experiment 1 astrocyte differential gene expression 
Gene Base mean 
Fold 
change 
(log2 ) Lfcse Stat p-value 
Adjusted 
p-value 
42800 7872.051 0.4196 0.128 3.2775 0.001 0.0439 
0610009B22RIK 895.9714 -0.5822 0.1536 -3.7903 0.0002 0.0186 
1110012L19RIK 775.7164 -0.3949 0.1032 -3.8264 0.0001 0.0181 
1110034G24RIK 275.4704 -0.5444 0.1447 -3.763 0.0002 0.0199 
1110059G10RIK 891.831 -0.4886 0.1303 -3.7496 0.0002 0.0199 
1190007I07RIK 227.7795 -0.4425 0.138 -3.206 0.0013 0.049 
2510039O18RIK 4894.173 0.3569 0.0877 4.0718 0 0.0134 
2610306M01RIK 180.2548 -0.6463 0.1774 -3.6437 0.0003 0.0242 
2700089E24RIK 3287.711 -0.2679 0.0836 -3.2062 0.0013 0.049 
2810008D09RIK 279.8897 -1.0949 0.2506 -4.3694 0 0.0078 
3830406C13RIK 1653.929 -0.3361 0.0953 -3.5261 0.0004 0.0294 
4930486L24RIK 165.288 0.8332 0.2098 3.9715 0.0001 0.0158 
9330151L19RIK 217.7894 -0.862 0.194 -4.4441 0 0.0072 






Table 6.  Experiment 1 Microglia Differential Gene Expression 
Gene Base mean 
Fold 
change 
(log2) Lfcse Stat p-value 
Adjusted 
p-value 
A730017C20RIK 73.0021 2.4393 0.5876 4.1512 0 0.0097 
ABLIM1 3743.775 1.3256 0.3745 3.5399 0.0004 0.0412 
ACE2 125.0611 3.6259 0.7301 4.9662 0 0.0014 
ADAMTS14 342.6756 1.239 0.3253 3.8084 0.0001 0.0228 
ADCY1 1073.887 1.4615 0.3905 3.7428 0.0002 0.0271 
ADRB1 863.2682 1.0133 0.249 4.0704 0 0.0118 
ALDH1A2 1173.402 2.7949 0.6767 4.1302 0 0.0101 
ALDH1A7 46.8158 3.4469 0.9661 3.5678 0.0004 0.0392 
ANGPT1 1463.155 2.0042 0.561 3.5724 0.0004 0.0388 
AP3B2 418.1542 1.3198 0.3812 3.4623 0.0005 0.0479 
ARMC5 2066.559 0.3121 0.0715 4.3628 0 0.0062 
BACE2 3868.033 1.7252 0.4666 3.6974 0.0002 0.0295 
BC031361 143.995 1.0786 0.2864 3.7656 0.0002 0.0259 
BC064078 836.2855 1.485 0.3879 3.8282 0.0001 0.0219 
BHLHE22 26.841 2.4867 0.7162 3.4723 0.0005 0.0475 
BICC1 1583.676 1.7668 0.4277 4.1306 0 0.0101 
BMP6 3613.874 1.5421 0.4049 3.8087 0.0001 0.0228 
CACNA1E 84.031 2.371 0.6477 3.6607 0.0003 0.0313 
CACNA2D1 713.522 1.4391 0.3084 4.667 0 0.0028 
CAMK4 314.8504 1.2966 0.3493 3.7117 0.0002 0.0288 
CAMKV 33.3433 4.7324 0.8144 5.8105 0 0.0001 
CCDC80 3533.582 1.9989 0.4335 4.6108 0 0.003 
CCDC85A 453.6419 1.4551 0.3972 3.663 0.0002 0.0312 
CD200 1725.909 1.3493 0.3877 3.4801 0.0005 0.0467 
CDH23 29.1038 0.9503 0.269 3.5329 0.0004 0.042 
CDH4 1414.445 1.2305 0.3526 3.4898 0.0005 0.0458 
CDK5R2 9.4923 2.7579 0.7234 3.8126 0.0001 0.0228 
CHST8 34.784 4.1442 0.9803 4.2275 0 0.008 
CNKSR2 68.5533 1.6299 0.4669 3.4911 0.0005 0.0458 
COL12A1 7295.101 1.7611 0.4582 3.8432 0.0001 0.0209 
COL22A1 513.6226 2.423 0.5553 4.3634 0 0.0062 
COL26A1 527.9782 2.6675 0.5678 4.6976 0 0.0027 
COL4A1 17129.36 2.1169 0.4823 4.3894 0 0.0061 
COL4A2 9102.346 2.0022 0.4842 4.1351 0 0.0101 
COL4A6 5300.096 1.8328 0.4487 4.0842 0 0.0113 
COL5A1 4609.233 1.6091 0.4599 3.499 0.0005 0.0452 
COL6A3 905.7634 2.4516 0.5791 4.2335 0 0.008 
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Table 6.  Experiment 1 Microglia Differential Gene Expression 
Gene Base mean 
Fold 
change 
(log2) Lfcse Stat p-value 
Adjusted 
p-value 
CRTAC1 65.4142 1.9043 0.5231 3.6404 0.0003 0.0326 
CYBRD1 5355.732 1.8173 0.5096 3.5662 0.0004 0.0392 
DAB1 1427.766 1.2953 0.3403 3.8069 0.0001 0.0228 
DBPHT2 63.6344 2.0597 0.5793 3.5556 0.0004 0.0399 
DDN 37.4809 1.8147 0.515 3.5238 0.0004 0.0429 
DENND5B 550.3831 0.6637 0.1774 3.7425 0.0002 0.0271 
DIO2 393.1914 2.4419 0.5804 4.2073 0 0.0084 
DUSP8 791.159 1.2719 0.343 3.7077 0.0002 0.0288 
EDA 179.3621 1.5301 0.3979 3.8453 0.0001 0.0209 
EFNA5 639.1167 1.7303 0.3556 4.8653 0 0.0019 
EGFR 1100.873 1.8237 0.3994 4.5664 0 0.0033 
F3 7337.277 1.249 0.3387 3.6876 0.0002 0.0302 
FADS3 1402.469 0.6138 0.1653 3.7127 0.0002 0.0288 
FAIM2 58.2132 2.3503 0.637 3.6897 0.0002 0.0302 
FAM167A 3059.392 1.407 0.3381 4.162 0 0.0096 
FAM189B 646.888 0.6988 0.153 4.5687 0 0.0033 
FAM26E 424.2522 1.3924 0.4001 3.4799 0.0005 0.0467 
FBLN7 752.5122 1.6441 0.4553 3.611 0.0003 0.0351 
FGF12 352.9938 1.5167 0.4382 3.4613 0.0005 0.0479 
FGF7 170.4306 1.8167 0.5244 3.4645 0.0005 0.0479 
FHDC1 1054.209 1.3042 0.3468 3.7604 0.0002 0.0259 
FNDC1 381.6169 2.2269 0.5596 3.9794 0.0001 0.0154 
FOXF2 132.2251 2.8214 0.6298 4.4802 0 0.0046 
FRMD6 2981.72 0.7892 0.212 3.7232 0.0002 0.028 
GLI1 511.8623 1.611 0.4287 3.758 0.0002 0.0259 
GM12992 77.1153 0.7027 0.1886 3.7268 0.0002 0.028 
GM15698 7563.887 1.8977 0.5158 3.6788 0.0002 0.031 
GM17359 50.6792 1.5755 0.3756 4.1941 0 0.0088 
GM2027 6.5144 2.6555 0.7655 3.4689 0.0005 0.0478 
GM4532 13.0828 -1.4243 0.3982 -3.5772 0.0003 0.0386 
GM5124 15.7992 1.9001 0.5001 3.7994 0.0001 0.0232 
GPR115 5.0011 3.0438 0.8302 3.6662 0.0002 0.0312 
GPR123 1009.71 2.21 0.462 4.7835 0 0.0024 
GPR153 348.9549 1.5166 0.4234 3.5824 0.0003 0.0383 
GPR173 459.5778 1.3409 0.3697 3.6265 0.0003 0.0334 
GREM2 14.813 4.4003 1.0705 4.1103 0 0.0108 
GRIN1 51.0595 2.118 0.4872 4.3477 0 0.0062 
GULP1 1445.241 1.3358 0.3636 3.6734 0.0002 0.0312 
HAPLN1 145.9553 3.3711 0.6302 5.3493 0 0.0005 
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Table 6.  Experiment 1 Microglia Differential Gene Expression 
Gene Base mean 
Fold 
change 
(log2) Lfcse Stat p-value 
Adjusted 
p-value 
HECW1 4.0287 4.3915 1.0389 4.2272 0 0.008 
HIC1 397.7564 1.8703 0.5153 3.6293 0.0003 0.0333 
HPCAL4 137.7397 2.461 0.6885 3.5743 0.0004 0.0388 
ID2 13952.38 0.847 0.2269 3.7323 0.0002 0.028 
IGFBP3 14309.82 1.3288 0.3534 3.76 0.0002 0.0259 
IGFBP5 108788.4 1.5185 0.4174 3.6376 0.0003 0.0327 
IGFBP7 1673.65 2.4178 0.4908 4.9263 0 0.0016 
IGSF1 1511.518 2.1669 0.5554 3.9014 0.0001 0.0185 
INMT 530.03 3.0929 0.7407 4.1758 0 0.0093 
IP6K3 7.6019 2.4873 0.7069 3.5184 0.0004 0.0431 
ITIH3 3789.471 2.1965 0.4675 4.6983 0 0.0027 
ITIH5 5848.005 2.1224 0.5328 3.9832 0.0001 0.0154 
JPH2 350.3937 1.68 0.4095 4.1029 0 0.011 
KANK4 650.0364 2.5025 0.4743 5.2765 0 0.0005 
KCNE1L 769.3375 2.3287 0.5429 4.2896 0 0.0072 
KCNF1 159.135 1.7872 0.5119 3.4911 0.0005 0.0458 
KCNK2 3606.003 1.474 0.4163 3.5408 0.0004 0.0412 
KCNK7 27.1935 1.4609 0.3308 4.4165 0 0.0056 
KCNS1 124.2714 2.7718 0.7442 3.7244 0.0002 0.028 
LAMA2 1052.258 2.1097 0.4457 4.7335 0 0.0026 
LHFP 4927.776 1.5246 0.3863 3.9471 0.0001 0.0169 
LMO7 319.6524 1.7141 0.3702 4.6298 0 0.0029 
LMOD1 1682.484 1.9051 0.4069 4.6817 0 0.0028 
LTBP2 2521.688 1.8347 0.471 3.8957 0.0001 0.0188 
LUM 774.5171 2.9597 0.6558 4.5131 0 0.0041 
MAL2 281.4064 1.6398 0.4581 3.5798 0.0003 0.0385 
MATN4 101.4181 3.3148 0.7219 4.592 0 0.0032 
MEDAG 295.0378 2.0529 0.5307 3.868 0.0001 0.0201 
MEG3 8219.089 1.8175 0.4438 4.0949 0 0.0111 
MEGF10 1784.407 2.0407 0.4747 4.299 0 0.0072 
MFAP2 757.3667 1.4198 0.4059 3.4974 0.0005 0.0452 
MFAP4 605.2943 2.4484 0.5626 4.3517 0 0.0062 
MFAP5 75.2295 3.0096 0.7667 3.9256 0.0001 0.0174 
MFSD2A 2798.267 1.8943 0.4953 3.8244 0.0001 0.0221 
MME 1437.59 1.8741 0.4307 4.3515 0 0.0062 
MPPED1 15.2467 3.0099 0.7564 3.9794 0.0001 0.0154 
NDP 575.1154 2.2861 0.5745 3.9793 0.0001 0.0154 
NECAB1 19.1154 3.4042 0.7944 4.285 0 0.0072 
NID1 5254.111 1.9638 0.53 3.705 0.0002 0.0289 
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Table 6.  Experiment 1 Microglia Differential Gene Expression 
Gene Base mean 
Fold 
change 
(log2) Lfcse Stat p-value 
Adjusted 
p-value 
NPAS4 360.8875 2.4508 0.4824 5.0802 0 0.0009 
NPPC 202.085 2.9561 0.5346 5.5296 0 0.0003 
NPTX2 67.2354 1.9961 0.5482 3.641 0.0003 0.0326 
NPVF 672.9517 2.798 0.6884 4.0645 0 0.0118 
NPY1R 235.8728 3.0075 0.866 3.4728 0.0005 0.0475 
NRGN 14.3936 2.6798 0.7303 3.6692 0.0002 0.0312 
NTM 460.9907 1.9355 0.5312 3.6438 0.0003 0.0326 
NTN4 2999.298 1.4727 0.4172 3.5298 0.0004 0.0423 
NTNG1 116.8852 1.811 0.5154 3.5136 0.0004 0.0433 
OGN 5942.034 1.8519 0.4292 4.315 0 0.007 
PAK6 289.0081 1.4641 0.4039 3.6253 0.0003 0.0334 
PCDH1 553.0089 1.0854 0.3089 3.5141 0.0004 0.0433 
PDE1A 897.0164 1.6789 0.4568 3.6752 0.0002 0.0312 
PDGFRB 1975.468 1.7586 0.3775 4.6582 0 0.0028 
PI15 529.5914 2.7179 0.7067 3.8461 0.0001 0.0209 
PIPOX 1848.177 1.7458 0.4414 3.9549 0.0001 0.0167 
PLAGL1 3735.54 1.7658 0.3394 5.2028 0 0.0006 
PLAT 5775.338 1.7744 0.4488 3.9535 0.0001 0.0167 
PRKD1 1082.668 1.5227 0.3609 4.2196 0 0.0082 
PROM1 3218.514 1.9088 0.4475 4.2651 0 0.0076 
PRRT1 128.6237 1.5306 0.4058 3.7715 0.0002 0.0258 
PRSS12 81.3551 2.2701 0.6023 3.7688 0.0002 0.0258 
PTCH2 94.411 1.7266 0.4814 3.5868 0.0003 0.0379 
PTPN13 3659.421 1.452 0.3964 3.6631 0.0002 0.0312 
PTPRD 1356.39 1.1504 0.3085 3.7285 0.0002 0.028 
RAB40C 1836.967 0.3117 0.0804 3.8793 0.0001 0.0198 
RADIL 304.4651 1.4409 0.4061 3.5486 0.0004 0.0403 
RASGEF1B 5144.28 0.8031 0.2263 3.5491 0.0004 0.0403 
RASGEF1C 98.3201 2.1637 0.554 3.9054 0.0001 0.0184 
RBM24 436.4542 1.8386 0.5013 3.6676 0.0002 0.0312 
RBMS3 1011.575 1.3152 0.3168 4.1509 0 0.0097 
RHOB 29397.12 0.7138 0.1712 4.1707 0 0.0094 
RIAN 4132.306 1.4999 0.3816 3.9306 0.0001 0.0174 
RND3 4150.046 1.3451 0.3158 4.2587 0 0.0076 
RYR2 60.0668 2.5052 0.6157 4.0688 0 0.0118 
SAMD5 560.3396 1.6204 0.4117 3.9357 0.0001 0.0173 
SCG3 10611.28 1.533 0.4433 3.4583 0.0005 0.0482 
SCHIP1 212.4639 2.4022 0.4627 5.1922 0 0.0006 
SCN2A1 155.519 2.2688 0.4768 4.7583 0 0.0025 
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Table 6.  Experiment 1 Microglia Differential Gene Expression 
Gene Base mean 
Fold 
change 
(log2) Lfcse Stat p-value 
Adjusted 
p-value 
SCN2B 55.3216 2.0877 0.5316 3.9268 0.0001 0.0174 
SEMA3C 2350.5 1.7006 0.4403 3.8627 0.0001 0.0203 
SGIP1 747.9939 1.3553 0.3887 3.4868 0.0005 0.046 
SH2D5 28.1419 1.0218 0.2875 3.5548 0.0004 0.0399 
SH3RF2 106.1537 2.5558 0.5955 4.2916 0 0.0072 
SH3RF3 230.5073 1.7665 0.4506 3.9199 0.0001 0.0176 
SLC12A8 180.874 1.8909 0.4881 3.874 0.0001 0.02 
SLC26A8 30.7562 1.5972 0.4151 3.8478 0.0001 0.0209 
SLC44A3 85.0588 2.3914 0.5844 4.0919 0 0.0111 
SLC6A11 288.2325 2.7971 0.7692 3.6361 0.0003 0.0327 
SLCO1A5 860.0803 2.4542 0.5133 4.7813 0 0.0024 
SNPH 677.4294 1.694 0.484 3.5002 0.0005 0.0452 
SPARC 98824.16 1.3061 0.3771 3.4637 0.0005 0.0479 
SPATA33 118.2393 1.8868 0.5445 3.465 0.0005 0.0479 
SPHKAP 28.5643 2.4048 0.6216 3.8685 0.0001 0.0201 
SPRN 6.8803 3.1424 0.892 3.5229 0.0004 0.0429 
SSTR2 437.354 1.8371 0.5329 3.4475 0.0006 0.0499 
SUCNR1 279.6469 1.8587 0.528 3.5201 0.0004 0.043 
SVEP1 335.2602 2.5874 0.6975 3.7096 0.0002 0.0288 
SYNPO 2929.554 1.3996 0.3299 4.2422 0 0.008 
SYNPO2 1740.815 1.6004 0.4494 3.5611 0.0004 0.0397 
TAGLN3 525.0871 1.9767 0.5417 3.6494 0.0003 0.0322 
TENM3 3389.799 1.8332 0.41 4.4718 0 0.0046 
THY1 1068.467 2.3795 0.5128 4.6406 0 0.0029 
TMEM179 26.5128 2.4349 0.6097 3.9939 0.0001 0.0153 
TMEM200A 630.7292 1.9441 0.4448 4.3707 0 0.0062 
TMEM59L 32.472 2.897 0.6798 4.2618 0 0.0076 
TRANK1 23.8336 2.5346 0.6275 4.0391 0.0001 0.0128 
TSHR 403.0675 2.6772 0.6052 4.4234 0 0.0056 
UNC13C 15.0141 4.0948 1.0124 4.0445 0.0001 0.0127 
WFIKKN1 170.5624 1.0498 0.287 3.6586 0.0003 0.0313 
WISP1 314.8719 2.1519 0.5574 3.8604 0.0001 0.0203 
WNT10B 5.0584 3.8566 1.0749 3.5879 0.0003 0.0379 
WSCD2 397.5781 1.29 0.3278 3.9348 0.0001 0.0173 











(log2) Lfcse Stat p-value 
Adjusted 
p-value 
ADAMTSL4 2538.0 -0.2108 0.0589 -3.5787 0.0003 0.0415 
AGRN 17294.6 -0.1554 0.0421 -3.6928 0.0002 0.0303 
AKR1C14 10696.2 -0.2663 0.0683 -3.8996 0.0001 0.0223 
AKTIP 6115.7 -0.2078 0.0599 -3.4682 0.0005 0.0491 
ALX3 141.3 0.5246 0.1439 3.6458 0.0003 0.0352 
APLP2 31875.3 -0.1221 0.0293 -4.1670 0.0000 0.0130 
ARL8A 14719.7 -0.1581 0.0385 -4.1106 0.0000 0.0154 
ATXN10 12340.1 -0.0679 0.0174 -3.9065 0.0001 0.0220 
BC064078 1416.6 -0.3596 0.1041 -3.4544 0.0006 0.0492 
BICC1 3089.1 0.2460 0.0643 3.8242 0.0001 0.0236 
BOK 434.8 0.3643 0.0982 3.7094 0.0002 0.0286 
BSN 179.3 0.3669 0.1040 3.5294 0.0004 0.0431 
CACNA1B 77.4 0.5112 0.1178 4.3391 0.0000 0.0095 
CACNA1C 914.7 0.4540 0.1214 3.7388 0.0002 0.0284 
CACNG7 2441.4 -0.1693 0.0421 -4.0216 0.0001 0.0184 
CACNG8 433.8 -0.2442 0.0697 -3.5046 0.0005 0.0451 
CAPS2 275.7 -0.3205 0.0903 -3.5498 0.0004 0.0426 
CCDC126 394.2 -0.1658 0.0481 -3.4472 0.0006 0.0492 
CCDC141 1506.8 -0.2253 0.0632 -3.5671 0.0004 0.0421 
CD40 54.0 0.5085 0.1456 3.4921 0.0005 0.0464 
CD81 32753.2 -0.1466 0.0363 -4.0377 0.0001 0.0176 
CDH4 2923.0 -0.3445 0.0977 -3.5260 0.0004 0.0431 
CDHR1 314.7 0.5312 0.1431 3.7127 0.0002 0.0286 
CELSR3 164.7 0.4905 0.1423 3.4473 0.0006 0.0492 
CERS4 4719.8 -0.2956 0.0635 -4.6542 0.0000 0.0043 
CHAMP1 2360.5 -0.1189 0.0330 -3.6073 0.0003 0.0384 
CHCHD1 1117.8 0.1670 0.0450 3.7116 0.0002 0.0286 
CHIL1 1053.1 -0.4952 0.1433 -3.4565 0.0005 0.0492 
CHMP5 5993.5 -0.1431 0.0414 -3.4550 0.0006 0.0492 
CHST15 724.5 0.4786 0.1122 4.2640 0.0000 0.0110 
CLEC4A1 123.7 0.5149 0.1416 3.6363 0.0003 0.0356 
CLEC4A2 107.5 0.7710 0.1244 6.1958 0.0000 0.0000 
CLEC4N 171.7 0.5154 0.1359 3.7923 0.0001 0.0246 
CMKLR1 539.9 0.4286 0.0873 4.9097 0.0000 0.0020 
CNTNAP2 612.2 -0.5059 0.1263 -4.0055 0.0001 0.0184 
COBLL1 2102.6 -0.2700 0.0765 -3.5284 0.0004 0.0431 
COL15A1 478.8 0.4973 0.1439 3.4546 0.0006 0.0492 
COL23A1 482.1 0.5310 0.1309 4.0559 0.0000 0.0171 
COL26A1 1013.6 0.5142 0.1335 3.8521 0.0001 0.0228 
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(log2) Lfcse Stat p-value 
Adjusted 
p-value 
COL27A1 479.3 0.3712 0.0963 3.8536 0.0001 0.0228 
COL4A3 446.3 -0.4538 0.1217 -3.7296 0.0002 0.0284 
COL7A1 1928.3 0.5805 0.1455 3.9907 0.0001 0.0184 
CPM 146.8 0.5113 0.1455 3.5141 0.0004 0.0444 
CSNK1G1 1366.5 0.2024 0.0473 4.2764 0.0000 0.0110 
CTSC 6152.1 0.3523 0.0882 3.9960 0.0001 0.0184 
CYFIP2 4281.5 -0.2306 0.0564 -4.0893 0.0000 0.0157 
CYTIP 42.6 0.5106 0.1445 3.5339 0.0004 0.0431 
DEFB1 100.8 -0.6499 0.1440 -4.5145 0.0000 0.0071 
DLX6OS1 269.8 0.5513 0.1434 3.8437 0.0001 0.0228 
DUSP6 4744.9 -0.2355 0.0590 -3.9921 0.0001 0.0184 
E130308A19RIK 601.0 0.1679 0.0428 3.9202 0.0001 0.0214 
EFNA2 146.6 0.4061 0.1094 3.7108 0.0002 0.0286 
EMILIN2 911.6 0.5495 0.1429 3.8450 0.0001 0.0228 
EPAS1 5275.8 -0.3102 0.0620 -5.0017 0.0000 0.0020 
EPDR1 5425.4 -0.0991 0.0279 -3.5519 0.0004 0.0426 
EPHA7 519.6 0.4954 0.1345 3.6830 0.0002 0.0312 
ESYT3 40.7 0.5641 0.1453 3.8826 0.0001 0.0227 
FAM124A 2038.4 -0.2355 0.0571 -4.1248 0.0000 0.0148 
FAM19A5 4434.7 -0.1890 0.0517 -3.6577 0.0003 0.0342 
FGFR3 4699.6 -0.1688 0.0474 -3.5599 0.0004 0.0426 
FGFRL1 9790.8 -0.3023 0.0694 -4.3529 0.0000 0.0095 
FOXF2 218.7 0.5413 0.1450 3.7325 0.0002 0.0284 
FRZB 155.6 0.5098 0.1454 3.5058 0.0005 0.0451 
G6PC3 2092.0 -0.1180 0.0301 -3.9150 0.0001 0.0216 
GAD2 81.3 0.5442 0.1423 3.8258 0.0001 0.0236 
GALNT18 590.3 -0.3980 0.0954 -4.1722 0.0000 0.0130 
GARNL3 638.8 -0.2059 0.0580 -3.5504 0.0004 0.0426 
GLDC 4609.9 -0.3468 0.0865 -4.0114 0.0001 0.0184 
GM15698 12532.5 0.4908 0.1150 4.2693 0.0000 0.0110 
GM5803 18.5 0.4624 0.1282 3.6067 0.0003 0.0384 
GNAO1 17281.1 -0.2914 0.0769 -3.7909 0.0002 0.0246 
GNG11 362.0 0.5124 0.1328 3.8573 0.0001 0.0228 
GPC6 6233.2 0.3637 0.1055 3.4473 0.0006 0.0492 
GPD1 1071.3 -0.2818 0.0757 -3.7207 0.0002 0.0286 
GPD2 4763.0 -0.2486 0.0648 -3.8380 0.0001 0.0228 
GRIN2A 11.8 0.5877 0.1452 4.0465 0.0001 0.0173 
GRINA 9790.2 -0.1974 0.0514 -3.8376 0.0001 0.0228 
GSTM1 36668.6 -0.3687 0.0987 -3.7355 0.0002 0.0284 
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(log2) Lfcse Stat p-value 
Adjusted 
p-value 
HIGD2A 2799.8 -0.1666 0.0479 -3.4764 0.0005 0.0486 
IFNAR1 4812.4 0.1343 0.0379 3.5417 0.0004 0.0426 
IGFBP5 226472.7 -0.3154 0.0903 -3.4930 0.0005 0.0464 
IGLON5 1361.6 -0.1644 0.0455 -3.6121 0.0003 0.0382 
IL1RN 142.5 0.4960 0.1437 3.4523 0.0006 0.0492 
IRAK3 181.0 0.5474 0.1303 4.1998 0.0000 0.0126 
JAKMIP3 124.9 -0.4445 0.1148 -3.8716 0.0001 0.0227 
JAZF1 1645.1 -0.1930 0.0532 -3.6281 0.0003 0.0362 
KANK1 4046.8 -0.2763 0.0797 -3.4675 0.0005 0.0491 
KCNMB4 162.1 0.3742 0.1059 3.5328 0.0004 0.0431 
KCNQ1OT1 93.4 0.4336 0.1224 3.5419 0.0004 0.0426 
KCTD12 5405.9 0.3573 0.0807 4.4272 0.0000 0.0076 
KDM4C 2162.0 -0.1187 0.0282 -4.2116 0.0000 0.0123 
KIFC3 4200.3 -0.2007 0.0490 -4.0974 0.0000 0.0157 
LAMB2 21107.1 -0.1640 0.0472 -3.4727 0.0005 0.0487 
LAMC3 175.5 0.5670 0.1441 3.9335 0.0001 0.0206 
LEF1 121.8 0.5127 0.1454 3.5271 0.0004 0.0431 
LEPREL1 2358.9 -0.2864 0.0803 -3.5672 0.0004 0.0421 
LRP10 7715.3 -0.1010 0.0260 -3.8815 0.0001 0.0227 
MAN1B1 5441.2 -0.0606 0.0163 -3.7115 0.0002 0.0286 
MBTD1 2287.8 0.1653 0.0389 4.2509 0.0000 0.0110 
MDK 1080.0 0.4954 0.1395 3.5518 0.0004 0.0426 
MEDAG 588.5 0.4339 0.0975 4.4522 0.0000 0.0071 
MGAT4A 1015.1 0.2478 0.0618 4.0116 0.0001 0.0184 
MRGPRF 123.6 0.5628 0.1412 3.9872 0.0001 0.0184 
MSC 27.8 0.4991 0.1444 3.4555 0.0005 0.0492 
MYL6B 542.5 -0.3410 0.0764 -4.4622 0.0000 0.0071 
MYO1E 8312.6 -0.2066 0.0505 -4.0940 0.0000 0.0157 
NACC2 22214.8 -0.2159 0.0558 -3.8692 0.0001 0.0227 
NDUFA7 2877.9 -0.0991 0.0250 -3.9576 0.0001 0.0195 
NDUFB2 1117.8 0.1495 0.0398 3.7530 0.0002 0.0271 
NKX6-1 67.4 0.4883 0.1411 3.4594 0.0005 0.0492 
NNMT 104.6 0.4927 0.1237 3.9833 0.0001 0.0184 
NREP 5184.4 0.5528 0.1131 4.8883 0.0000 0.0020 
PANX2 121.5 -0.4230 0.1199 -3.5292 0.0004 0.0431 
PCDHGB2 493.3 -0.2881 0.0744 -3.8698 0.0001 0.0227 
PCX 6520.2 -0.2591 0.0710 -3.6490 0.0003 0.0351 
PDE4A 848.2 -0.3251 0.0892 -3.6441 0.0003 0.0352 
PEA15A 196585.1 -0.2511 0.0663 -3.7893 0.0002 0.0246 
168 
 






(log2) Lfcse Stat p-value 
Adjusted 
p-value 
PHLPP1 6378.6 -0.2590 0.0647 -4.0027 0.0001 0.0184 
PLA1A 172.4 0.5006 0.1428 3.5055 0.0005 0.0451 
PNLIP 9.4 -0.6958 0.1399 -4.9726 0.0000 0.0020 
PPP2R2A 3913.3 -0.0797 0.0184 -4.3212 0.0000 0.0099 
PRDM16 2783.1 -0.2847 0.0647 -4.3965 0.0000 0.0084 
PRSS16 13.1 0.5189 0.1453 3.5706 0.0004 0.0421 
PTN 10305.8 0.4129 0.0978 4.2217 0.0000 0.0121 
RAB4A 1014.0 -0.1020 0.0292 -3.4940 0.0005 0.0464 
RARRES1 124.5 0.4382 0.1243 3.5249 0.0004 0.0431 
RASGRP2 175.1 -0.3719 0.1068 -3.4817 0.0005 0.0480 
RBFOX1 81.3 0.5307 0.1413 3.7549 0.0002 0.0271 
RBFOX2 4559.8 0.2638 0.0745 3.5418 0.0004 0.0426 
REL 232.4 0.3591 0.0942 3.8129 0.0001 0.0239 
RGS3 2422.6 -0.3820 0.1107 -3.4505 0.0006 0.0492 
RNF141 1177.7 -0.1580 0.0420 -3.7594 0.0002 0.0271 
ROBO1 1887.5 0.5103 0.1219 4.1855 0.0000 0.0129 
RPL31-PS12 44.9 0.4148 0.1076 3.8536 0.0001 0.0228 
SALL3 2132.3 -0.2193 0.0567 -3.8688 0.0001 0.0227 
SAP18 2004.9 -0.1943 0.0494 -3.9344 0.0001 0.0206 
SCAP 7705.7 -0.1274 0.0308 -4.1320 0.0000 0.0147 
SEMA3F 1288.3 -0.3209 0.0882 -3.6396 0.0003 0.0355 
SEMA6A 4697.9 0.1583 0.0458 3.4562 0.0005 0.0492 
SH3BGR 153.8 -0.3012 0.0807 -3.7304 0.0002 0.0284 
SKP1A 23642.2 -0.1850 0.0516 -3.5883 0.0003 0.0404 
SLC26A1 48.4 -0.3820 0.0961 -3.9745 0.0001 0.0188 
SLC30A7 2647.7 0.1568 0.0436 3.5946 0.0003 0.0399 
SLC32A1 14.4 0.5455 0.1452 3.7583 0.0002 0.0271 
SMIM4 382.0 -0.1992 0.0525 -3.7951 0.0001 0.0246 
SNAP47 5834.3 -0.1601 0.0369 -4.3416 0.0000 0.0095 
SNED1 663.1 0.4276 0.1202 3.5573 0.0004 0.0426 
SNX33 3464.6 -0.2165 0.0567 -3.8197 0.0001 0.0236 
SOCS2 637.1 0.3515 0.0983 3.5753 0.0003 0.0417 
SORL1 10447.0 -0.3368 0.0882 -3.8184 0.0001 0.0236 
SP2 1308.5 -0.1165 0.0302 -3.8548 0.0001 0.0228 
SP9 115.4 0.5201 0.1450 3.5875 0.0003 0.0404 
SPRY2 3582.5 -0.3162 0.0624 -5.0708 0.0000 0.0020 
SPRY4 2025.5 -0.3680 0.0750 -4.9066 0.0000 0.0020 
SRPK2 6690.9 -0.1612 0.0356 -4.5317 0.0000 0.0071 
SRPX2 75.8 0.5605 0.1424 3.9355 0.0001 0.0206 
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(log2) Lfcse Stat p-value 
Adjusted 
p-value 
SYNE3 257.7 0.4415 0.0983 4.4897 0.0000 0.0071 
SYNPO2 3508.3 -0.1901 0.0512 -3.7143 0.0002 0.0286 
TCEAL3 1988.7 -0.3411 0.0989 -3.4495 0.0006 0.0492 
TECR 6406.3 -0.1113 0.0274 -4.0600 0.0000 0.0171 
TENM2 31.4 0.6047 0.1422 4.2516 0.0000 0.0110 
TGFBI 4078.8 0.4913 0.1414 3.4746 0.0005 0.0487 
TMEM200B 52.3 0.6192 0.1454 4.2586 0.0000 0.0110 
TMEM56 1951.4 -0.2445 0.0616 -3.9698 0.0001 0.0189 
TMX2 5585.2 -0.0603 0.0170 -3.5534 0.0004 0.0426 
TNFRSF19 2983.9 0.4133 0.1110 3.7241 0.0002 0.0286 
TPRGL 6440.3 -0.1308 0.0337 -3.8764 0.0001 0.0227 
TSPAN7 16870.1 -0.3066 0.0865 -3.5436 0.0004 0.0426 
UNC13C 30.3 0.5732 0.1230 4.6586 0.0000 0.0043 
VASH2 249.8 0.5535 0.1238 4.4723 0.0000 0.0071 
VAV2 1312.1 0.1960 0.0504 3.8882 0.0001 0.0227 
VEPH1 124.6 -0.3908 0.1027 -3.8041 0.0001 0.0242 
VSTM2A 350.0 0.5980 0.1335 4.4801 0.0000 0.0071 
WBP2 8936.0 -0.1475 0.0384 -3.8385 0.0001 0.0228 
WNK4 185.5 0.5142 0.1451 3.5442 0.0004 0.0426 
WNT4 490.4 0.6603 0.1406 4.6976 0.0000 0.0042 
WNT6 36.5 0.5891 0.1453 4.0537 0.0001 0.0171 
ZBTB8A 209.6 0.3039 0.0803 3.7819 0.0002 0.0251 
ZC3HAV1L 304.7 0.4134 0.0872 4.7415 0.0000 0.0038 
ZFP282 847.1 0.1945 0.0391 4.9754 0.0000 0.0020 
ZFP536 154.1 0.5005 0.1197 4.1812 0.0000 0.0129 
ZIC4 704.2 0.4792 0.1258 3.8100 0.0001 0.0239 
2900026A02RIK 2962.6 -0.1480 0.0408 -3.6291 0.0003 0.0362 





Table 8. Experiment 2 Microglia Differential Gene Expression 
Gene Base mean 
Fold 
change 
(log2) Lfcse Stat p-value 
Adjusted 
p-value 
A3GALT2 18.9 0.5820 0.1658 3.5106 0.0004 0.0271 
ABCA7 2545.8 -0.2382 0.0648 -3.6781 0.0002 0.0200 
ABCB7 2884.3 -0.2114 0.0493 -4.2841 0.0000 0.0043 
ABHD17A 1884.6 0.1379 0.0335 4.1158 0.0000 0.0070 
ACBD3 3949.3 -0.1982 0.0584 -3.3944 0.0007 0.0343 
ACBD6 999.9 0.2136 0.0531 4.0245 0.0001 0.0086 
ACTR8 987.0 -0.2850 0.0655 -4.3535 0.0000 0.0035 
ADRB1 60.9 0.6680 0.1487 4.4922 0.0000 0.0024 
AGGF1 2817.1 -0.0919 0.0259 -3.5547 0.0004 0.0249 
AGL 1831.5 -0.1882 0.0418 -4.5056 0.0000 0.0024 
AHCYL1 5504.4 -0.1490 0.0415 -3.5909 0.0003 0.0240 
AHSA2 1219.0 -0.1856 0.0474 -3.9174 0.0001 0.0113 
AI314180 4233.0 -0.1797 0.0380 -4.7270 0.0000 0.0012 
AIFM1 1790.2 -0.1948 0.0604 -3.2265 0.0013 0.0475 
AKT1S1 1465.0 0.1829 0.0509 3.5947 0.0003 0.0239 
ALKBH6 552.3 0.2434 0.0500 4.8690 0.0000 0.0007 
ANAPC4 2273.0 -0.1482 0.0462 -3.2108 0.0013 0.0491 
ANKRD26 474.0 -0.3034 0.0929 -3.2648 0.0011 0.0445 
ANXA3 16718.3 -0.2183 0.0436 -5.0045 0.0000 0.0007 
AP2B1 9163.2 -0.1202 0.0303 -3.9635 0.0001 0.0100 
APPL1 2157.1 -0.1848 0.0519 -3.5611 0.0004 0.0247 
ARG2 136.4 0.4938 0.1305 3.7832 0.0002 0.0151 
ARHGAP30 10050.0 -0.1900 0.0569 -3.3399 0.0008 0.0388 
ARID5A 805.7 0.6736 0.1654 4.0714 0.0000 0.0079 
ARMC5 1948.8 0.1711 0.0425 4.0315 0.0001 0.0085 
ARX 139.8 0.5682 0.1589 3.5755 0.0003 0.0247 
ASNS 901.8 0.5685 0.1663 3.4187 0.0006 0.0332 
ATF4 15609.4 0.5663 0.1568 3.6106 0.0003 0.0234 
ATF5 850.0 0.3319 0.0917 3.6207 0.0003 0.0226 
ATM 1270.0 -0.3023 0.0841 -3.5950 0.0003 0.0239 
ATP11B 2630.8 -0.1929 0.0319 -6.0579 0.0000 0.0000 
ATP2C1 5053.2 -0.1703 0.0434 -3.9209 0.0001 0.0112 
ATP5D 5532.3 0.1839 0.0537 3.4282 0.0006 0.0328 
ATP5G2 6991.2 0.1458 0.0397 3.6668 0.0002 0.0205 
ATR 1108.8 -0.2275 0.0610 -3.7327 0.0002 0.0170 
ATRX 4915.7 -0.2703 0.0705 -3.8359 0.0001 0.0132 
B930041F14RIK 235.0 0.2746 0.0782 3.5104 0.0004 0.0271 
BBC3 681.5 0.6168 0.1657 3.7221 0.0002 0.0176 
BC005537 26016.8 -0.2069 0.0515 -4.0174 0.0001 0.0088 
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Table 8. Experiment 2 Microglia Differential Gene Expression 
Gene Base mean 
Fold 
change 
(log2) Lfcse Stat p-value 
Adjusted 
p-value 
BDP1 1652.6 -0.2172 0.0593 -3.6628 0.0002 0.0206 
BICD2 3447.1 -0.2860 0.0576 -4.9681 0.0000 0.0007 
BRD7 3352.7 -0.2130 0.0646 -3.2955 0.0010 0.0418 
CAAP1 453.2 -0.1562 0.0405 -3.8577 0.0001 0.0129 
CAMKK2 1968.5 -0.2019 0.0598 -3.3779 0.0007 0.0356 
CAMSAP1 2026.4 -0.2315 0.0702 -3.2972 0.0010 0.0416 
CCDC171 57.9 -0.4177 0.1205 -3.4651 0.0005 0.0297 
CCDC82 1197.1 -0.2623 0.0707 -3.7082 0.0002 0.0182 
CCDC91 683.3 -0.2335 0.0599 -3.8954 0.0001 0.0119 
CCRN4L 690.4 0.4473 0.1286 3.4798 0.0005 0.0285 
CCSER2 1505.4 -0.1712 0.0489 -3.5045 0.0005 0.0272 
CD180 19226.6 -0.1979 0.0599 -3.3031 0.0010 0.0412 
CD2AP 4584.6 -0.1698 0.0381 -4.4579 0.0000 0.0027 
CDK20 954.5 0.4402 0.1321 3.3325 0.0009 0.0392 
CELF1 5028.4 -0.2329 0.0680 -3.4223 0.0006 0.0331 
CENPF 1689.4 -0.4361 0.1226 -3.5572 0.0004 0.0247 
CEP170 3018.9 -0.3309 0.0724 -4.5726 0.0000 0.0020 
CEP250 3769.8 -0.2159 0.0588 -3.6703 0.0002 0.0204 
CEP290 558.2 -0.3549 0.0704 -5.0446 0.0000 0.0006 
CEPT1 2694.5 -0.2738 0.0822 -3.3325 0.0009 0.0392 
CHAC1 375.6 0.4781 0.1194 4.0055 0.0001 0.0090 
CHML 819.7 -0.1835 0.0503 -3.6473 0.0003 0.0213 
CHORDC1 3205.7 -0.1779 0.0528 -3.3710 0.0007 0.0360 
CIART 191.5 0.6441 0.1658 3.8843 0.0001 0.0122 
CIRBP 884.0 0.4909 0.1348 3.6432 0.0003 0.0215 
CKLF 878.6 -0.1929 0.0539 -3.5800 0.0003 0.0247 
CLDN12 226.9 0.5192 0.1388 3.7391 0.0002 0.0169 
CLOCK 1925.8 -0.1613 0.0502 -3.2123 0.0013 0.0491 
CMAS 2381.3 -0.1481 0.0459 -3.2291 0.0012 0.0475 
CNTRL 1752.9 -0.2540 0.0738 -3.4417 0.0006 0.0314 
COPB1 7858.4 -0.1342 0.0308 -4.3654 0.0000 0.0034 
CPM 15.8 0.5212 0.1573 3.3136 0.0009 0.0405 
CRTC1 595.4 0.3019 0.0761 3.9682 0.0001 0.0099 
CSPP1 567.6 -0.3052 0.0939 -3.2485 0.0012 0.0459 
CTTNBP2NL 6958.5 -0.3567 0.1077 -3.3121 0.0009 0.0405 
CUL2 2220.9 -0.1573 0.0390 -4.0362 0.0001 0.0085 
CUL4A 3224.0 -0.1136 0.0355 -3.2004 0.0014 0.0499 
CYTIP 324.1 0.5826 0.1663 3.5034 0.0005 0.0272 
D330050I16RIK 42.2 0.4375 0.1092 4.0052 0.0001 0.0090 
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Table 8. Experiment 2 Microglia Differential Gene Expression 
Gene Base mean 
Fold 
change 
(log2) Lfcse Stat p-value 
Adjusted 
p-value 
DDA1 2010.9 0.1586 0.0447 3.5497 0.0004 0.0249 
DDIT3 1068.8 0.5555 0.1662 3.3432 0.0008 0.0385 
DDIT4 131.4 0.6213 0.1648 3.7711 0.0002 0.0155 
DDX19B 963.6 -0.1638 0.0494 -3.3157 0.0009 0.0405 
DDX23 3607.0 -0.0938 0.0289 -3.2475 0.0012 0.0460 
DENND2C 909.4 -0.4120 0.1041 -3.9569 0.0001 0.0100 
DICER1 2972.9 -0.2462 0.0572 -4.3063 0.0000 0.0041 
DIRAS2 19.1 0.6227 0.1663 3.7442 0.0002 0.0167 
DOCK10 4503.9 -0.2689 0.0654 -4.1145 0.0000 0.0070 
DOCK8 13878.9 -0.2310 0.0649 -3.5584 0.0004 0.0247 
DOK7 11.2 0.4577 0.1330 3.4405 0.0006 0.0314 
DPP8 5875.1 -0.1682 0.0479 -3.5142 0.0004 0.0271 
DRD1A 22.6 0.7531 0.1655 4.5503 0.0000 0.0022 
DROSHA 1843.4 0.1028 0.0314 3.2779 0.0010 0.0433 
DSEL 619.2 -0.1620 0.0399 -4.0555 0.0001 0.0081 
DUSP14 83.6 0.7880 0.1635 4.8184 0.0000 0.0009 
DUSP8 284.4 0.7448 0.1663 4.4783 0.0000 0.0025 
ECHDC1 1144.1 -0.1755 0.0368 -4.7699 0.0000 0.0011 
EFTUD1 761.0 -0.1461 0.0450 -3.2455 0.0012 0.0460 
EHBP1L1 5589.8 -0.2064 0.0641 -3.2199 0.0013 0.0484 
EIF3K 4849.2 0.1605 0.0434 3.7014 0.0002 0.0186 
EIF5B 7453.8 -0.1569 0.0287 -5.4630 0.0000 0.0001 
EPC1 2254.3 0.4761 0.1354 3.5158 0.0004 0.0271 
EPHA2 328.5 -0.6557 0.1553 -4.2220 0.0000 0.0054 
ERCC1 464.0 0.2185 0.0550 3.9717 0.0001 0.0099 
ESYT2 2031.5 -0.1948 0.0447 -4.3551 0.0000 0.0035 
EXOC1 2373.2 -0.2029 0.0458 -4.4308 0.0000 0.0028 
EYA4 821.1 -0.4711 0.1280 -3.6806 0.0002 0.0199 
FADS3 292.2 0.4571 0.1084 4.2180 0.0000 0.0054 
FAM167B 176.1 -0.4790 0.1316 -3.6388 0.0003 0.0217 
FAM199X 634.7 -0.2334 0.0468 -4.9888 0.0000 0.0007 
FAM73A 1064.8 -0.1725 0.0515 -3.3482 0.0008 0.0380 
FAM78A 900.8 -0.3538 0.1046 -3.3812 0.0007 0.0356 
FAM83F 11.0 0.4484 0.1375 3.2609 0.0011 0.0449 
FAR1 5045.1 -0.2230 0.0625 -3.5654 0.0004 0.0247 
FAU 16130.8 0.1832 0.0508 3.6066 0.0003 0.0235 
FGFR1OP 1085.7 -0.2306 0.0696 -3.3122 0.0009 0.0405 
FLT1 142.9 -0.7126 0.1659 -4.2964 0.0000 0.0042 
FRAT2 104.3 0.5118 0.1566 3.2671 0.0011 0.0445 
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Table 8. Experiment 2 Microglia Differential Gene Expression 
Gene Base mean 
Fold 
change 
(log2) Lfcse Stat p-value 
Adjusted 
p-value 
FRYL 2109.3 -0.2712 0.0810 -3.3480 0.0008 0.0380 
G3BP2 9195.7 -0.1219 0.0246 -4.9594 0.0000 0.0007 
GADD45B 523.8 0.5519 0.1658 3.3286 0.0009 0.0395 
GBF1 2490.3 -0.2348 0.0545 -4.3061 0.0000 0.0041 
GLCCI1 488.7 0.5603 0.1573 3.5619 0.0004 0.0247 
GM10638 14.2 0.5864 0.1617 3.6274 0.0003 0.0222 
GM14322 156.8 -0.4838 0.1219 -3.9690 0.0001 0.0099 
GM15708 47.8 0.4116 0.1142 3.6043 0.0003 0.0235 
GM3414 204.0 -0.3630 0.0949 -3.8270 0.0001 0.0134 
GM4285 93.1 0.3706 0.1090 3.3988 0.0007 0.0341 
GM6498 24.1 -0.5170 0.1393 -3.7114 0.0002 0.0182 
GMCL1 822.0 -0.1879 0.0493 -3.8092 0.0001 0.0141 
GOPC 1518.3 -0.2004 0.0560 -3.5768 0.0003 0.0247 
GPR19 190.5 0.3217 0.0949 3.3888 0.0007 0.0349 
H2AFJ 1262.9 0.1766 0.0523 3.3751 0.0007 0.0358 
HCFC2 765.3 -0.2675 0.0749 -3.5722 0.0004 0.0247 
HIATL1 3922.6 -0.1322 0.0413 -3.2011 0.0014 0.0499 
HK2 2828.2 -0.3479 0.1029 -3.3829 0.0007 0.0355 
HNRNPUL2 10451.4 -0.1543 0.0340 -4.5395 0.0000 0.0022 
HOOK3 3705.1 -0.2809 0.0665 -4.2250 0.0000 0.0054 
HPS3 2519.4 -0.2673 0.0824 -3.2422 0.0012 0.0463 
HSD17B4 7442.0 -0.2042 0.0549 -3.7220 0.0002 0.0176 
IBTK 2278.9 -0.2340 0.0659 -3.5528 0.0004 0.0249 
IK 6794.4 -0.1887 0.0468 -4.0277 0.0001 0.0086 
IKBIP 815.4 -0.2344 0.0551 -4.2533 0.0000 0.0049 
IREB2 4470.8 -0.1319 0.0397 -3.3235 0.0009 0.0400 
IRS2 1638.5 0.5601 0.1606 3.4872 0.0005 0.0282 
ITPRIPL2 5828.5 -0.2513 0.0565 -4.4484 0.0000 0.0027 
IWS1 2531.5 -0.1715 0.0424 -4.0464 0.0001 0.0083 
JMY 1320.4 0.5016 0.1530 3.2794 0.0010 0.0432 
KANSL1 5409.4 0.3860 0.1133 3.4080 0.0007 0.0338 
KDM4C 1407.6 -0.2410 0.0723 -3.3343 0.0009 0.0392 
KLHL20 915.7 -0.2869 0.0783 -3.6641 0.0002 0.0206 
KLHL35 20.7 0.7122 0.1593 4.4699 0.0000 0.0026 
KRCC1 3159.2 -0.2766 0.0657 -4.2105 0.0000 0.0054 
LACTB2 1078.1 -0.2627 0.0564 -4.6568 0.0000 0.0015 
LCORL 1008.2 -0.1966 0.0582 -3.3804 0.0007 0.0356 
LNPEP 2834.1 -0.2984 0.0816 -3.6577 0.0003 0.0207 
LPGAT1 4876.4 -0.1767 0.0433 -4.0794 0.0000 0.0077 
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Table 8. Experiment 2 Microglia Differential Gene Expression 
Gene Base mean 
Fold 
change 
(log2) Lfcse Stat p-value 
Adjusted 
p-value 
LRRK2 313.3 -0.3093 0.0805 -3.8410 0.0001 0.0132 
LTN1 2692.0 -0.2063 0.0439 -4.6951 0.0000 0.0014 
MAFK 1307.0 0.4336 0.1273 3.4053 0.0007 0.0338 
MANBAL 1164.1 0.1948 0.0596 3.2665 0.0011 0.0445 
MBD1 1934.6 0.2669 0.0812 3.2879 0.0010 0.0424 
MCM3AP 1783.6 -0.1997 0.0451 -4.4272 0.0000 0.0028 
MCRS1 1908.1 0.1938 0.0602 3.2189 0.0013 0.0484 
MDM2 8869.8 0.5307 0.1656 3.2054 0.0013 0.0497 
MED1 2008.7 -0.1112 0.0338 -3.2876 0.0010 0.0424 
MED16 1677.0 0.2095 0.0598 3.5063 0.0005 0.0272 
MED25 2180.0 0.1665 0.0296 5.6301 0.0000 0.0001 
MFN1 1796.6 -0.1268 0.0281 -4.5134 0.0000 0.0024 
MIA3 4051.5 -0.1894 0.0456 -4.1549 0.0000 0.0062 
MKLN1 3059.5 -0.1881 0.0379 -4.9621 0.0000 0.0007 
MORC3 4464.5 -0.3390 0.0960 -3.5311 0.0004 0.0262 
MOSPD3 947.6 0.1607 0.0398 4.0401 0.0001 0.0084 
MPHOSPH8 1217.0 -0.3371 0.0668 -5.0491 0.0000 0.0006 
MT1 10115.1 0.4713 0.1192 3.9544 0.0001 0.0100 
MT2 3038.4 0.5639 0.1657 3.4028 0.0007 0.0338 
MTMR6 7181.9 -0.2036 0.0577 -3.5263 0.0004 0.0265 
MXD1 629.8 0.5299 0.1534 3.4546 0.0006 0.0304 
NAA30 1291.2 -0.1559 0.0483 -3.2266 0.0013 0.0475 
NAIP6 395.2 -0.3904 0.1157 -3.3727 0.0007 0.0359 
NDUFA7 2045.0 0.1810 0.0540 3.3512 0.0008 0.0378 
NEMF 1943.0 -0.1862 0.0339 -5.4920 0.0000 0.0001 
NINL 841.1 -0.2887 0.0891 -3.2386 0.0012 0.0463 
NKAP 1275.1 -0.2039 0.0522 -3.9073 0.0001 0.0115 
NLRP1A 425.3 -0.3091 0.0902 -3.4265 0.0006 0.0328 
NPEPPS 5192.0 -0.2558 0.0666 -3.8388 0.0001 0.0132 
NR1D1 273.5 0.5888 0.1645 3.5799 0.0003 0.0247 
OPA1 3778.9 -0.1791 0.0376 -4.7612 0.0000 0.0011 
P4HA1 7052.0 -0.2586 0.0588 -4.3981 0.0000 0.0030 
PANK2 1821.3 -0.2802 0.0869 -3.2265 0.0013 0.0475 
PBRM1 4726.8 -0.2308 0.0471 -4.9040 0.0000 0.0007 
PCIF1 1772.6 0.1818 0.0396 4.5889 0.0000 0.0019 
PCM1 3399.0 -0.2493 0.0652 -3.8219 0.0001 0.0136 
PCNT 1767.0 -0.1997 0.0569 -3.5117 0.0004 0.0271 
PEX14 1275.7 0.1927 0.0577 3.3379 0.0008 0.0390 
PGLS 2630.7 0.1637 0.0505 3.2408 0.0012 0.0463 
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Table 8. Experiment 2 Microglia Differential Gene Expression 
Gene Base mean 
Fold 
change 
(log2) Lfcse Stat p-value 
Adjusted 
p-value 
PIGT 5806.1 0.1205 0.0340 3.5500 0.0004 0.0249 
PIM3 593.8 0.3185 0.0995 3.2005 0.0014 0.0499 
PJA2 3308.2 -0.2935 0.0828 -3.5464 0.0004 0.0251 
PLCXD2 362.1 0.6025 0.1625 3.7078 0.0002 0.0182 
PLEKHA2 4626.2 -0.2821 0.0712 -3.9607 0.0001 0.0100 
POLR2I 610.2 0.2306 0.0650 3.5509 0.0004 0.0249 
POU3F1 25.3 0.6062 0.1661 3.6500 0.0003 0.0213 
PPIG 4992.1 -0.1408 0.0385 -3.6602 0.0003 0.0207 
PPIP5K2 2901.8 -0.1386 0.0360 -3.8511 0.0001 0.0129 
PPM1B 2281.1 -0.1345 0.0313 -4.2919 0.0000 0.0042 
PPP1R32 17.1 0.5391 0.1653 3.2609 0.0011 0.0449 
PRCC 1722.5 0.2032 0.0622 3.2648 0.0011 0.0445 
PRKD3 3941.6 -0.1444 0.0430 -3.3576 0.0008 0.0372 
PRKDC 643.1 -0.3680 0.0907 -4.0561 0.0000 0.0081 
PROS1 5055.9 -0.2530 0.0786 -3.2176 0.0013 0.0484 
PRPF38B 3041.9 -0.2152 0.0514 -4.1858 0.0000 0.0059 
PRPF4B 3678.2 -0.1361 0.0382 -3.5658 0.0004 0.0247 
PRR3 466.1 0.2994 0.0711 4.2099 0.0000 0.0054 
PRRC1 2338.1 -0.1761 0.0500 -3.5225 0.0004 0.0268 
PSME4 4651.0 -0.1743 0.0401 -4.3509 0.0000 0.0035 
PSMF1 1640.7 0.2727 0.0714 3.8190 0.0001 0.0137 
PTBP3 22203.0 -0.1389 0.0390 -3.5608 0.0004 0.0247 
PTPRC 12970.4 -0.1783 0.0489 -3.6459 0.0003 0.0213 
PTPRE 2343.5 -0.2013 0.0600 -3.3561 0.0008 0.0373 
RAB11B 5346.6 0.1345 0.0382 3.5176 0.0004 0.0271 
RAB14 16198.8 -0.1740 0.0497 -3.4988 0.0005 0.0274 
RAB3GAP1 2769.7 -0.1897 0.0564 -3.3604 0.0008 0.0369 
RALGAPB 2983.1 -0.2352 0.0522 -4.5029 0.0000 0.0024 
RAP1GDS1 10200.3 -0.1031 0.0318 -3.2394 0.0012 0.0463 
RAP2A 14651.6 -0.2315 0.0695 -3.3336 0.0009 0.0392 
RBM15B 1149.5 0.1948 0.0590 3.3008 0.0010 0.0414 
RBM25 5363.1 -0.1752 0.0460 -3.8075 0.0001 0.0141 
RBM26 1467.0 -0.2981 0.0675 -4.4151 0.0000 0.0029 
RBM42 2703.8 0.1705 0.0498 3.4258 0.0006 0.0328 
RBM4B 284.2 0.2952 0.0842 3.5076 0.0005 0.0272 
RBPMS2 23.6 0.5138 0.1512 3.3970 0.0007 0.0341 
RHOD 291.0 0.5092 0.1571 3.2415 0.0012 0.0463 
RIN1 65.7 0.5197 0.1383 3.7575 0.0002 0.0161 
RLF 1713.8 -0.1889 0.0573 -3.2979 0.0010 0.0416 
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Gene Base mean 
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Adjusted 
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RNF113A1 69.7 0.5669 0.1571 3.6086 0.0003 0.0234 
RNF170 1134.9 -0.1716 0.0519 -3.3049 0.0009 0.0411 
RNF20 2551.1 -0.1274 0.0214 -5.9566 0.0000 0.0000 
RNF220 2692.3 0.1469 0.0372 3.9454 0.0001 0.0102 
ROCK2 4415.6 -0.2061 0.0367 -5.6203 0.0000 0.0001 
RPL10A 14543.3 0.1959 0.0562 3.4828 0.0005 0.0284 
RPL18A 21153.7 0.2392 0.0538 4.4471 0.0000 0.0027 
RPL23A 11958.4 0.1714 0.0491 3.4885 0.0005 0.0282 
RPL28 14100.4 0.2233 0.0535 4.1764 0.0000 0.0060 
RPL29 5126.6 0.2484 0.0597 4.1587 0.0000 0.0062 
RPL36 6392.9 0.2275 0.0636 3.5747 0.0004 0.0247 
RPL41 20083.8 0.2197 0.0646 3.4024 0.0007 0.0338 
RPS15 16405.0 0.2576 0.0558 4.6133 0.0000 0.0018 
RPS20 15239.4 0.1832 0.0536 3.4197 0.0006 0.0332 
RPS5 17877.2 0.2077 0.0603 3.4439 0.0006 0.0314 
RRM2B 581.6 -0.1970 0.0607 -3.2465 0.0012 0.0460 
RSBN1 814.1 -0.2526 0.0750 -3.3680 0.0008 0.0361 
RSBN1L 2244.1 -0.1894 0.0429 -4.4129 0.0000 0.0029 
SAP30BP 1309.6 0.2500 0.0714 3.5017 0.0005 0.0273 
SCAND1 1232.3 0.2979 0.0399 7.4693 0.0000 0.0000 
SEC23A 2231.2 -0.1312 0.0404 -3.2502 0.0012 0.0458 
SESN2 1179.7 0.6301 0.1656 3.8047 0.0001 0.0142 
SETD3 5514.8 -0.1340 0.0384 -3.4896 0.0005 0.0282 
SETX 2821.4 -0.2555 0.0524 -4.8779 0.0000 0.0007 
SF3A2 2690.2 0.2959 0.0857 3.4537 0.0006 0.0304 
SGMS2 91.9 0.5648 0.1660 3.4020 0.0007 0.0338 
SHPRH 1196.8 -0.3742 0.1048 -3.5714 0.0004 0.0247 
SIKE1 1494.0 -0.1824 0.0447 -4.0795 0.0000 0.0077 
SLC25A17 1538.2 0.1199 0.0350 3.4214 0.0006 0.0331 
SLC25A53 62.5 0.3871 0.1083 3.5737 0.0004 0.0247 
SLC35A3 3109.8 -0.1654 0.0499 -3.3144 0.0009 0.0405 
SLC4A7 1805.6 -0.3777 0.0771 -4.8974 0.0000 0.0007 
SLC7A5 2094.4 0.5310 0.1650 3.2185 0.0013 0.0484 
SLC9A6 1350.5 -0.1572 0.0408 -3.8529 0.0001 0.0129 
SLCO4A1 244.6 -0.5276 0.1611 -3.2742 0.0011 0.0437 
SLMAP 3785.4 -0.1744 0.0376 -4.6329 0.0000 0.0017 
SMCHD1 3735.9 -0.2014 0.0628 -3.2089 0.0013 0.0493 
SMG9 1904.1 0.3303 0.0978 3.3776 0.0007 0.0356 
SMIM15 3767.8 -0.2393 0.0722 -3.3147 0.0009 0.0405 
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SNAPC2 800.5 0.1719 0.0483 3.5613 0.0004 0.0247 
SOGA1 4987.0 -0.3742 0.0802 -4.6681 0.0000 0.0015 
SP1 4197.5 -0.2523 0.0769 -3.2833 0.0010 0.0428 
SP9 103.5 0.5032 0.1546 3.2536 0.0011 0.0458 
SPPL2A 8627.3 -0.1626 0.0453 -3.5914 0.0003 0.0240 
SPPL2B 1134.5 0.1555 0.0442 3.5187 0.0004 0.0271 
SPRED1 9411.1 -0.2011 0.0538 -3.7386 0.0002 0.0169 
SPTBN1 5214.9 -0.1930 0.0603 -3.2021 0.0014 0.0499 
SRP54A 580.8 -0.1465 0.0388 -3.7720 0.0002 0.0155 
STAG2 5332.5 -0.1409 0.0336 -4.1958 0.0000 0.0057 
STX7 12355.2 -0.1411 0.0357 -3.9571 0.0001 0.0100 
SWT1 371.1 -0.3224 0.0944 -3.4152 0.0006 0.0335 
SYPL 8007.0 -0.1475 0.0448 -3.2890 0.0010 0.0424 
SYS1 1668.6 0.1753 0.0490 3.5779 0.0003 0.0247 
SYT12 10.3 0.5776 0.1657 3.4857 0.0005 0.0282 
TAF1 2375.4 -0.1943 0.0394 -4.9331 0.0000 0.0007 
TAF1C 656.0 0.2632 0.0647 4.0691 0.0000 0.0079 
TBC1D8B 905.7 -0.2487 0.0658 -3.7772 0.0002 0.0154 
TEP1 3184.6 -0.3459 0.0732 -4.7235 0.0000 0.0012 
THADA 890.2 -0.1834 0.0558 -3.2858 0.0010 0.0426 
THOC2 3254.1 -0.1948 0.0487 -3.9977 0.0001 0.0091 
THUMPD3 1306.5 -0.2526 0.0671 -3.7637 0.0002 0.0159 
TIAM2 229.1 0.5362 0.1616 3.3188 0.0009 0.0404 
TJAP1 1016.1 0.2847 0.0731 3.8919 0.0001 0.0120 
TLR3 844.5 -0.3379 0.0899 -3.7578 0.0002 0.0161 
TMED8 2057.7 -0.1910 0.0592 -3.2261 0.0013 0.0475 
TMEM158 169.1 0.5635 0.1553 3.6287 0.0003 0.0222 
TMEM164 5260.5 -0.1367 0.0401 -3.4099 0.0006 0.0338 
TMEM199 1085.7 -0.2277 0.0669 -3.4066 0.0007 0.0338 
TMEM245 1314.1 -0.2278 0.0701 -3.2519 0.0011 0.0458 
TMEM259 3388.2 0.1320 0.0317 4.1617 0.0000 0.0062 
TMEM30A 10613.4 -0.1481 0.0422 -3.5057 0.0005 0.0272 
TMEM55B 4131.6 0.2618 0.0741 3.5352 0.0004 0.0260 
TMEM68 1828.5 -0.1970 0.0496 -3.9680 0.0001 0.0099 
TMF1 3882.0 -0.3462 0.0764 -4.5333 0.0000 0.0022 
TMUB1 343.7 0.1793 0.0552 3.2500 0.0012 0.0458 
TMX3 5573.2 -0.1445 0.0393 -3.6811 0.0002 0.0199 
TNFAIP6 28.6 0.5461 0.1535 3.5580 0.0004 0.0247 
TOP1 7011.0 -0.1570 0.0409 -3.8357 0.0001 0.0132 
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TPR 9536.8 -0.1946 0.0540 -3.6040 0.0003 0.0235 
TRIB3 289.9 0.5221 0.1322 3.9501 0.0001 0.0101 
TRIM23 634.7 -0.2176 0.0628 -3.4673 0.0005 0.0296 
TRIP11 1537.8 -0.3139 0.0826 -3.8002 0.0001 0.0143 
TRIP4 1338.4 -0.1845 0.0541 -3.4112 0.0006 0.0338 
TROVE2 1251.7 -0.1982 0.0597 -3.3178 0.0009 0.0404 
TTC37 902.7 -0.2926 0.0712 -4.1097 0.0000 0.0070 
UAP1 1632.1 -0.2625 0.0633 -4.1455 0.0000 0.0063 
UBA3 2868.3 -0.1615 0.0430 -3.7550 0.0002 0.0161 
UBALD1 1671.0 0.2901 0.0843 3.4422 0.0006 0.0314 
UBB 6584.5 0.3693 0.1140 3.2383 0.0012 0.0463 
UBE3A 2353.9 -0.2248 0.0582 -3.8653 0.0001 0.0127 
UEVLD 1097.4 -0.3178 0.0943 -3.3685 0.0008 0.0361 
UFL1 1578.5 -0.2804 0.0862 -3.2518 0.0011 0.0458 
UIMC1 1305.6 -0.2348 0.0600 -3.9135 0.0001 0.0114 
USP12 3255.2 -0.2066 0.0585 -3.5319 0.0004 0.0262 
USP2 1263.9 0.2587 0.0528 4.9015 0.0000 0.0007 
USP25 4348.5 -0.1227 0.0375 -3.2705 0.0011 0.0442 
USP42 526.1 -0.3139 0.0809 -3.8810 0.0001 0.0122 
USP45 1555.1 -0.2181 0.0545 -4.0007 0.0001 0.0091 
USP9X 7816.3 -0.1951 0.0607 -3.2168 0.0013 0.0484 
UTP3 2510.7 -0.1840 0.0573 -3.2103 0.0013 0.0491 
VPS13A 874.6 -0.3750 0.0697 -5.3807 0.0000 0.0001 
VPS13C 6226.6 -0.4661 0.1216 -3.8321 0.0001 0.0132 
VPS37A 2018.2 -0.2077 0.0583 -3.5628 0.0004 0.0247 
VSIG4 101.7 -0.5245 0.1611 -3.2563 0.0011 0.0455 
WAPAL 4614.6 -0.1410 0.0408 -3.4602 0.0005 0.0300 
WDR37 1497.6 -0.1514 0.0473 -3.2021 0.0014 0.0499 
WDR83OS 1737.5 0.2104 0.0641 3.2825 0.0010 0.0428 
XIAP 4600.3 -0.1983 0.0539 -3.6761 0.0002 0.0200 
XKR8 253.4 -0.2792 0.0802 -3.4811 0.0005 0.0285 
YLPM1 2199.8 -0.2242 0.0659 -3.4029 0.0007 0.0338 
YTHDC2 687.0 -0.3399 0.0882 -3.8530 0.0001 0.0129 
YY1 3485.8 -0.1233 0.0297 -4.1535 0.0000 0.0062 
ZBTB2 2097.9 0.5256 0.1506 3.4912 0.0005 0.0281 
ZBTB41 958.1 -0.1708 0.0491 -3.4765 0.0005 0.0287 
ZC3H13 1752.6 -0.1857 0.0448 -4.1475 0.0000 0.0063 
ZCCHC7 543.1 -0.3132 0.0808 -3.8756 0.0001 0.0123 
ZDHHC4 788.2 0.1564 0.0431 3.6288 0.0003 0.0222 
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ZFML 2576.7 -0.2874 0.0688 -4.1748 0.0000 0.0060 
ZFP143 941.4 -0.2461 0.0630 -3.9056 0.0001 0.0115 
ZFP318 1184.0 -0.2559 0.0753 -3.3968 0.0007 0.0341 
ZFP518B 563.0 -0.2352 0.0706 -3.3308 0.0009 0.0394 
ZFP52 598.5 -0.4250 0.1124 -3.7831 0.0002 0.0151 
ZFP597 601.9 -0.4043 0.1169 -3.4586 0.0005 0.0301 
ZFP628 1199.2 0.3423 0.0882 3.8787 0.0001 0.0122 
ZFP7 157.0 -0.3553 0.0925 -3.8412 0.0001 0.0132 
ZFP771 373.9 0.2167 0.0565 3.8337 0.0001 0.0132 
ZFP777 698.3 0.2538 0.0768 3.3055 0.0009 0.0411 
ZFP871 3033.3 -0.2739 0.0754 -3.6345 0.0003 0.0219 
ZFP930 247.0 -0.2787 0.0828 -3.3681 0.0008 0.0361 
ZFP956 135.3 -0.2831 0.0852 -3.3211 0.0009 0.0402 
ZFPL1 940.7 0.1538 0.0455 3.3785 0.0007 0.0356 
ZFYVE16 1321.2 -0.3688 0.0957 -3.8540 0.0001 0.0129 
ZKSCAN8 353.9 -0.3741 0.1156 -3.2349 0.0012 0.0467 
ZMIZ2 4745.3 0.2161 0.0634 3.4084 0.0007 0.0338 
ZRANB2 3119.4 -0.2091 0.0560 -3.7359 0.0002 0.0169 
0610010K14RIK 1528.9 0.1573 0.0442 3.5625 0.0004 0.0247 
1700066M21RIK 565.6 -0.2805 0.0690 -4.0629 0.0000 0.0080 
1810011O10RIK 171.1 -0.6053 0.1561 -3.8786 0.0001 0.0122 
2410006H16RIK 690.0 0.4070 0.1131 3.5978 0.0003 0.0239 
2510009E07RIK 9556.5 -0.3395 0.0826 -4.1100 0.0000 0.0070 
3000002C10RIK 133.2 0.4163 0.1202 3.4642 0.0005 0.0297 
3930402G23RIK 14.1 0.5671 0.1614 3.5136 0.0004 0.0271 
4931440P22RIK 66.5 0.3813 0.1155 3.3027 0.0010 0.0412 
5830417I10RIK 411.6 -0.2755 0.0850 -3.2401 0.0012 0.0463 
8430427H17RIK 832.4 -0.4101 0.1234 -3.3234 0.0009 0.0400 
9130221H12RIK 215.7 -0.2762 0.0839 -3.2936 0.0010 0.0419 





Figure 28. Cellular adhesion and signaling ontologies are over-represented in 
differential gene expression of astrocyte cultures.  Differentially expressed gene lists 
were subjected for statistical overrepresentation in four gene ontology groups: A) 
Biological process – slim, B) Pathway, C) Reactome Pathway, and D) Protein 
Classification.  Results represent gene expression changes with over/under-representation 
in notated ontologies with a p-value of less than 0.05.  Results indicate there are a number 
of gene expression changes that play a role in cell signaling and adherence.  All 
expression changes are overrepresented by their group signifying there are more genes in 
these categories in the differentially expressed gene list than would be expected based on 




Figure 29. Comprehensive biological process ontology identifies additional 
developmental ontologies in astrocyte cultures.  Differentially expressed gene lists 
were subjected for statistical overrepresentation in Biological process – complete.  The 
complete biological process ontology accounts for all ontologies and more genes in each 
ontology than the slim biological process ontology.  Results represent gene expression 
changes with over/under-representation and with a p-value of less than 0.05.  Results 
indicate there are a number of gene expression changes that play a role in cell signaling 
and adherence.  There are also several gene expression changes in developmental 
categories.  All gene expression changes are overrepresented by their group signifying 
there are more genes in these categories in the differentially expressed gene list than 
would be expected based on the number of genes in the list. 
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Table 9.  Experiment 2 Astrocyte Differential Gene Expression Gene Ontology 










PANTHER GO-SLIM BIOLOGICAL PROCESS       
CELL-CELL ADHESION (GO:0016337) 310 18 2.5 + 7.2 2.68E-08 
CELL ADHESION (GO:0007155) 486 19 3.92 + 4.85 4.85E-06 
BIOLOGICAL ADHESION (GO:0022610) 486 19 3.92 + 4.85 4.85E-06 
NERVOUS SYSTEM DEVELOPMENT (GO:0007399) 668 19 5.39 + 3.53 5.78E-04 
SYSTEM DEVELOPMENT (GO:0048731) 1084 23 8.74 + 2.63 5.83E-03 
DEVELOPMENTAL PROCESS (GO:0032502) 2027 37 16.35 + 2.26 5.00E-04 
SIGNAL TRANSDUCTION (GO:0007165) 2728 46 22 + 2.09 1.91E-04 
CELL COMMUNICATION (GO:0007154) 3008 49 24.26 + 2.02 2.03E-04 
UNCLASSIFIED (UNCLASSIFIED) 9053 53 73 - 0.73 0.00E+00        
GO BIOLOGICAL PROCESS COMPLETE       
HEXOSE BIOSYNTHETIC PROCESS (GO:0019319) 28 5 0.23 + 22.14 3.22E-02 
CELL ADHESION (GO:0007155) 747 21 6.02 + 3.49 6.87E-03 
BIOLOGICAL ADHESION (GO:0022610) 757 21 6.1 + 3.44 8.47E-03 
NEGATIVE REGULATION OF SIGNAL TRANSDUCTION 
(GO:0009968) 
1048 24 8.45 + 2.84 3.77E-02 
REGULATION OF SIGNAL TRANSDUCTION 
(GO:0009966) 
2432 43 19.61 + 2.19 4.85E-03 
REGULATION OF SIGNALING (GO:0023051) 2778 48 22.4 + 2.14 1.70E-03 
REGULATION OF DEVELOPMENTAL PROCESS 
(GO:0050793) 
2331 40 18.8 + 2.13 2.80E-02 
REGULATION OF CELL COMMUNICATION 
(GO:0010646) 
2756 47 22.22 + 2.11 3.48E-03 
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GO BIOLOGICAL PROCESS COMPLETE CONT.       
REGULATION OF MULTICELLULAR ORGANISMAL 
PROCESS (GO:0051239) 
2711 44 21.86 + 2.01 3.41E-02 
SYSTEM DEVELOPMENT (GO:0048731) 3909 61 31.52 + 1.94 7.77E-04 
MULTICELLULAR ORGANISM DEVELOPMENT 
(GO:0007275) 
4474 65 36.08 + 1.8 3.49E-03 
SINGLE-MULTICELLULAR ORGANISM PROCESS 
(GO:0044707) 
5145 74 41.49 + 1.78 4.53E-04 
ANATOMICAL STRUCTURE DEVELOPMENT 
(GO:0048856) 
4796 66 38.67 + 1.71 1.97E-02 
DEVELOPMENTAL PROCESS (GO:0032502) 5119 68 41.28 + 1.65 4.52E-02 
SINGLE-ORGANISM PROCESS (GO:0044699) 12063 133 97.27 + 1.37 2.82E-04 
UNCLASSIFIED (UNCLASSIFIED) 1777 4 14.33 - 0.28 0.00E+00 
 
      
PANTHER PROTEIN CLASS 
      
CELL ADHESION MOLECULE (PC00069) 496 14 4 + 3.5 1.18E-02 
SIGNALING MOLECULE (PC00207) 1079 21 8.7 + 2.41 3.73E-02 
UNCLASSIFIED (UNCLASSIFIED) 10995 64 88.66 - 0.72 0.00E+00 
 
      
PANTHER PATHWAYS 
      
CADHERIN SIGNALING PATHWAY (P00012) 154 7 1.24 + 5.64 4.49E-02 
UNCLASSIFIED (UNCLASSIFIED) 19715 134 158.98 - 0.84 0.00E+00 
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COLLAGEN BIOSYNTHESIS AND MODIFYING ENZYMES 
(R-MMU-1650814) 
62 7 0.5 + 14 1.34E-03 
COLLAGEN FORMATION (R-MMU-1474290) 89 7 0.72 + 9.75 1.40E-02 
UNCLASSIFIED (UNCLASSIFIED) 14500 90 116.93 - 0.77 0.00E+00 




Figure 30. Immune function and stimulation response ontologies are over-1 
represented in differential gene expression of microglia cultures.  Differentially 2 
expressed gene lists were subjected for statistical overrepresentation in two gene 3 
ontology groups: A) Biological process – slim and B) Reactome Pathway.  Results 4 
represent gene ontologies with over/under-representation with a p-value of less than 0.05.  5 
Results indicate there are a number of gene groups that play a role in immune function 6 
and stimulation response.  Gene expression changes are under-represented in biological 7 
process and over-represented in reactome pathway ontologies.  No gene expression 8 




Figure 31. Comprehensive biological process ontology identifies numerous 11 
metabolic ontologies in microglia culture differential gene expression.  Differentially  12 
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Figure 31 cont.  expressed gene lists were subjected for statistical overrepresentation in 13 
Biological process – complete.  Results represent gene expression changes with 14 
over/under-representation in ontologies and with a p-value of less than 0.05.  Results 15 
indicate there are a number of gene expression changes that play a role in transcription 16 
and metabolic and catabolic processes.  Most expression changes are overrepresented 17 




Table 10.  Experiment 2 Microglia Differential Gene Expression Gene Ontology 










PANTHER GO-SLIM BIOLOGICAL PROCESS       
UNCLASSIFIED (UNCLASSIFIED) 9053 174 150.46 + 1.16 0.00E+00 
BIOLOGICAL REGULATION (GO:0065007) 3021 26 50.21 - 0.52 1.23E-02 
RESPONSE TO STIMULUS (GO:0050896) 3345 28 55.6 - 0.5 2.40E-03 
REGULATION OF BIOLOGICAL PROCESS 
(GO:0050789) 
2647 16 43.99 - 0.36 8.37E-05 
SYSTEM PROCESS (GO:0003008) 1992 12 33.11 - 0.36 2.89E-03 
DEVELOPMENTAL PROCESS (GO:0032502) 2027 11 33.69 - 0.33 6.10E-04 
SINGLE-MULTICELLULAR ORGANISM PROCESS 
(GO:0044707) 
2527 13 42 - 0.31 1.14E-05 
NEUROLOGICAL SYSTEM PROCESS 
(GO:0050877) 
1770 9 29.42 - 0.31 1.41E-03 
MULTICELLULAR ORGANISMAL PROCESS 
(GO:0032501) 
2628 13 43.68 - 0.3 3.00E-06 
IMMUNE SYSTEM PROCESS (GO:0002376) 1354 4 22.5 - < 0.2 3.21E-04 
SYSTEM DEVELOPMENT (GO:0048731) 1084 3 18.02 - < 0.2 3.04E-03 
SENSORY PERCEPTION (GO:0007600) 1283 2 21.32 - < 0.2 1.95E-05 
IMMUNE RESPONSE (GO:0006955) 800 1 13.3 - < 0.2 4.69E-03        
GO BIOLOGICAL PROCESS COMPLETE       
RNA SPLICING (GO:0008380) 304 18 5.05 + 3.56 4.19E-02 
UBIQUITIN-DEPENDENT PROTEIN CATABOLIC 
PROCESS (GO:0006511) 
396 21 6.58 + 3.19 3.74E-02 
MODIFICATION-DEPENDENT PROTEIN 
CATABOLIC PROCESS (GO:0019941) 
403 21 6.7 + 3.14 4.86E-02 
189 
 
Table 10.  Experiment 2 Microglia Differential Gene Expression Gene Ontology 










GO BIOLOGICAL PROCESS COMPLETE CONT.       
MRNA METABOLIC PROCESS (GO:0016071) 488 24 8.11 + 2.96 2.78E-02 
PROTEOLYSIS INVOLVED IN CELLULAR 
PROTEIN CATABOLIC PROCESS (GO:0051603) 
468 23 7.78 + 2.96 4.51E-02 
REGULATION OF CELLULAR PROTEIN 
LOCALIZATION (GO:1903827) 
570 28 9.47 + 2.96 4.29E-03 
PROTEIN CATABOLIC PROCESS (GO:0030163) 531 25 8.83 + 2.83 3.67E-02 
CELLULAR MACROMOLECULE CATABOLIC 
PROCESS (GO:0044265) 
630 28 10.47 + 2.67 2.87E-02 
MACROMOLECULE CATABOLIC PROCESS 
(GO:0009057) 
711 31 11.82 + 2.62 1.26E-02 
REGULATION OF CELL CYCLE (GO:0051726) 862 34 14.33 + 2.37 3.37E-02 
REGULATION OF PROTEIN LOCALIZATION 
(GO:0032880) 
996 37 16.55 + 2.24 4.78E-02 
CELLULAR PROTEIN METABOLIC PROCESS 
(GO:0044267) 
2662 86 44.24 + 1.94 9.19E-06 
RNA METABOLIC PROCESS (GO:0016070) 2642 85 43.91 + 1.94 1.44E-05 
GENE EXPRESSION (GO:0010467) 2942 94 48.9 + 1.92 2.07E-06 
NEGATIVE REGULATION OF 
MACROMOLECULE METABOLIC PROCESS 
(GO:0010605) 
2206 69 36.66 + 1.88 2.06E-03 
NUCLEIC ACID METABOLIC PROCESS 
(GO:0090304) 
3070 96 51.02 + 1.88 3.93E-06 
NEGATIVE REGULATION OF NITROGEN 
COMPOUND METABOLIC PROCESS 
(GO:0051172) 
2079 65 34.55 + 1.88 5.03E-03 
CELLULAR NITROGEN COMPOUND 
BIOSYNTHETIC PROCESS (GO:0044271) 
2568 80 42.68 + 1.87 2.06E-04 
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GO BIOLOGICAL PROCESS COMPLETE CONT.       
NEGATIVE REGULATION OF CELLULAR 
METABOLIC PROCESS (GO:0031324) 
2229 69 37.05 + 1.86 3.02E-03 
CELLULAR NITROGEN COMPOUND 
METABOLIC PROCESS (GO:0034641) 
4053 125 67.36 + 1.86 5.44E-09 
NEGATIVE REGULATION OF METABOLIC 
PROCESS (GO:0009892) 
2446 75 40.65 + 1.84 1.20E-03 
NUCLEOBASE-CONTAINING COMPOUND 
METABOLIC PROCESS (GO:0006139) 
3522 107 58.54 + 1.83 1.38E-06 
CELLULAR MACROMOLECULE METABOLIC 
PROCESS (GO:0044260) 
5333 161 88.64 + 1.82 1.09E-12 
CELLULAR PROTEIN MODIFICATION PROCESS 
(GO:0006464) 
2156 65 35.83 + 1.81 1.73E-02 
PROTEIN MODIFICATION PROCESS 
(GO:0036211) 
2156 65 35.83 + 1.81 1.73E-02 
HETEROCYCLE METABOLIC PROCESS 
(GO:0046483) 
3648 108 60.63 + 1.78 4.91E-06 
NUCLEOBASE-CONTAINING COMPOUND 
BIOSYNTHETIC PROCESS (GO:0034654) 
2133 63 35.45 + 1.78 4.92E-02 
CELLULAR AROMATIC COMPOUND 
METABOLIC PROCESS (GO:0006725) 
3702 109 61.53 + 1.77 5.40E-06 
ORGANELLE ORGANIZATION (GO:0006996) 2674 78 44.44 + 1.76 4.68E-03 
ORGANIC CYCLIC COMPOUND METABOLIC 
PROCESS (GO:1901360) 
3890 111 64.65 + 1.72 2.15E-05 
CELLULAR MACROMOLECULE BIOSYNTHETIC 
PROCESS (GO:0034645) 
2652 75 44.08 + 1.7 2.57E-02 
MACROMOLECULE BIOSYNTHETIC PROCESS 
(GO:0009059) 
2690 76 44.71 + 1.7 2.25E-02 
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GO BIOLOGICAL PROCESS COMPLETE CONT.       
REGULATION OF GENE EXPRESSION 
(GO:0010468) 
3786 106 62.92 + 1.68 1.63E-04 
CELLULAR METABOLIC PROCESS 
(GO:0044237) 
7037 196 116.96 + 1.68 1.40E-13 
MACROMOLECULE METABOLIC PROCESS 
(GO:0043170) 
6040 168 100.39 + 1.67 3.71E-10 
REGULATION OF CELLULAR 
MACROMOLECULE BIOSYNTHETIC PROCESS 
(GO:2000112) 
3429 95 56.99 + 1.67 1.97E-03 
PROTEIN METABOLIC PROCESS (GO:0019538) 3396 94 56.44 + 1.67 2.44E-03 
REGULATION OF NUCLEOBASE-CONTAINING 
COMPOUND METABOLIC PROCESS 
(GO:0019219) 
3558 98 59.14 + 1.66 1.55E-03 
ORGANIC SUBSTANCE BIOSYNTHETIC 
PROCESS (GO:1901576) 
3455 93 57.42 + 1.62 9.96E-03 
REGULATION OF MACROMOLECULE 
BIOSYNTHETIC PROCESS (GO:0010556) 
3533 95 58.72 + 1.62 7.64E-03 
NITROGEN COMPOUND METABOLIC PROCESS 
(GO:0006807) 
6709 180 111.51 + 1.61 6.09E-10 
BIOSYNTHETIC PROCESS (GO:0009058) 3519 94 58.49 + 1.61 1.19E-02 
CELLULAR BIOSYNTHETIC PROCESS 
(GO:0044249) 
3372 90 56.04 + 1.61 2.25E-02 
REGULATION OF CELLULAR BIOSYNTHETIC 
PROCESS (GO:0031326) 
3717 99 61.78 + 1.6 6.33E-03 
REGULATION OF MACROMOLECULE 
METABOLIC PROCESS (GO:0060255) 
5221 139 86.77 + 1.6 7.40E-06 
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GO BIOLOGICAL PROCESS COMPLETE CONT.       
NEGATIVE REGULATION OF CELLULAR 
PROCESS (GO:0048523) 
4158 110 69.11 + 1.59 1.59E-03 
REGULATION OF NITROGEN COMPOUND 
METABOLIC PROCESS (GO:0051171) 
5070 134 84.27 + 1.59 3.01E-05 
REGULATION OF CELLULAR METABOLIC 
PROCESS (GO:0031323) 
5302 140 88.12 + 1.59 1.09E-05 
REGULATION OF PRIMARY METABOLIC 
PROCESS (GO:0080090) 
5196 137 86.36 + 1.59 2.07E-05 
REGULATION OF METABOLIC PROCESS 
(GO:0019222) 
5657 149 94.02 + 1.58 2.43E-06 
PRIMARY METABOLIC PROCESS (GO:0044238) 7292 192 121.2 + 1.58 2.20E-10 
REGULATION OF BIOSYNTHETIC PROCESS 
(GO:0009889) 
3772 99 62.69 + 1.58 1.24E-02 
NEGATIVE REGULATION OF BIOLOGICAL 
PROCESS (GO:0048519) 
4545 118 75.54 + 1.56 1.24E-03 
ORGANONITROGEN COMPOUND METABOLIC 
PROCESS (GO:1901564) 
4214 109 70.04 + 1.56 5.76E-03 
ORGANIC SUBSTANCE METABOLIC PROCESS 
(GO:0071704) 
7618 197 126.61 + 1.56 4.47E-10 
METABOLIC PROCESS (GO:0008152) 8101 205 134.64 + 1.52 7.13E-10 
REGULATION OF CELLULAR PROCESS 
(GO:0050794) 
10161 212 168.88 + 1.26 3.89E-02 
REGULATION OF BIOLOGICAL PROCESS 
(GO:0050789) 
10723 223 178.22 + 1.25 1.70E-02 
BIOLOGICAL REGULATION (GO:0065007) 11220 230 186.48 + 1.23 3.01E-02 
CELLULAR PROCESS (GO:0009987) 13608 278 226.17 + 1.23 7.83E-05 
UNCLASSIFIED (UNCLASSIFIED) 1777 15 29.53 - 0.51 0.00E+00 
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GO BIOLOGICAL PROCESS COMPLETE CONT.       
NEUROLOGICAL SYSTEM PROCESS 
(GO:0050877) 
2107 9 35.02 - 0.26 5.56E-04 
G-PROTEIN COUPLED RECEPTOR SIGNALING 
PATHWAY (GO:0007186) 
1805 6 30 - 0.2 4.27E-04 
SENSORY PERCEPTION (GO:0007600) 1761 4 29.27 - < 0.2 2.29E-05        
PANTHER PROTEIN CLASS       
UNCLASSIFIED (UNCLASSIFIED) 10995 186 182.74 + 1.02 0.00E+00        
PANTHER PATHWAYS       
UNCLASSIFIED (UNCLASSIFIED) 19715 329 327.67 + 1 0.00E+00        
REACTOME PATHWAYS       
FORMATION OF A POOL OF FREE 40S 
SUBUNITS (R-MMU-72689) 
92 10 1.53 + 6.54 6.55E-03 
SRP-DEPENDENT COTRANSLATIONAL 
PROTEIN TARGETING TO MEMBRANE (R-
MMU-1799339) 
83 9 1.38 + 6.52 2.00E-02 
GTP HYDROLYSIS AND JOINING OF THE 60S 
RIBOSOMAL SUBUNIT (R-MMU-72706) 
103 11 1.71 + 6.43 2.59E-03 
NONSENSE MEDIATED DECAY (NMD) 
INDEPENDENT OF THE EXON JUNCTION 
COMPLEX (EJC) (R-MMU-975956) 
85 9 1.41 + 6.37 2.41E-02 
CAP-DEPENDENT TRANSLATION INITIATION 
(R-MMU-72737) 
109 11 1.81 + 6.07 4.42E-03 
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REACTOME PATHWAYS CONT.       
EUKARYOTIC TRANSLATION INITIATION (R-
MMU-72613) 
110 11 1.83 + 6.02 4.81E-03 
L13A-MEDIATED TRANSLATIONAL SILENCING 
OF CERULOPLASMIN EXPRESSION (R-MMU-
156827) 
102 10 1.7 + 5.9 1.59E-02 
NONSENSE MEDIATED DECAY (NMD) 
ENHANCED BY THE EXON JUNCTION 
COMPLEX (EJC) (R-MMU-975957) 
104 10 1.73 + 5.79 1.87E-02 
NONSENSE-MEDIATED DECAY (NMD) (R-
MMU-927802) 
104 10 1.73 + 5.79 1.87E-02 
TRANSLATION (R-MMU-72766) 126 11 2.09 + 5.25 1.70E-02 
GENE EXPRESSION (R-MMU-74160) 1088 43 18.08 + 2.38 2.74E-04 





Figure 32.  Astrocyte and microglia cultures have different predicted responses in 
activation of pathways.  Differentially expressed gene lists were subjected to Ingenuity 
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Figure 32 cont.  Pathway Analysis and results are displayed in bar chart format for 
astrocytes (A) and microglia (B).  Bar charts for ingenuity pathway analysis display p-
value (top horizontal axis) in length of the bar.  Color of the bar indicates the predicted 
activation of the pathway based upon z-score (calculations incorporate differential gene 
expression) to be activated (orange), no change (white), deactivated (blue) or no activity 
pattern detected (gray).  The ratio line (orange line with square points) indicates the ratio 







Figure 33.  Ingenuity pathway analysis identifies some potential proto-oncogenic 
pathways in Paraquat exposed astrocyte cultures.  Graphs represent expansion of 
pathways impacted by changes in gene expression identified in ingenuity pathway 
analysis.  A) Wnt/b catenin signaling, p-value: 5.01 x 10-4; B) Role of Wnt/Gsk-b in the 
pathogenesis of influenza, p-value:  3.98 x 10-4; C) Human embryonic stem cell 
pluripotency, p-value:  6.46 x 10-3, and D) Glioblastoma multiforme signaling, p-value:  
4.17 x 10-2 are expanded for hits in differentially expressed genes of selected ontologies.  
Expanded ontologies have implications in cancer development and progression.  
Individual genes within the expanded lists, such as Lef1, Wnt 4 and Ppp2r2a have altered 




Figure 34.  Ingenuity pathway analysis identifies some glial scarring and disrupted 
cellular signaling pathways in Paraquat exposed astrocyte cultures.  Represented 
here are pathways identified by ingenuity pathway analysis that identify genes and 
pathways indicative of glial scarring as well as disrupted cell signaling.  A)  Hepatic 
fibrosis/hepatic stellate cell activation, p-value: 2.09 x 10-5; B) Axonal guidance   
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Figure 34 Cont.  signaling, p-value:  3.39 x 10-4; C) NF-kB signaling, p-value:  1.66 x 
10-2, D) Dopamine-DARRP32 feedback in cAMP signaling, p-value:  1.07 x 10-2 and E) 
Glycerol-3-phosphate shuttle, p-value:  3.98 x 10-4 are expanded for hits in differentially 





Figure 35.  Several DNA damage response genes and pathways are down regulated 
in Paraquat exposed microglia cultures.  Selected IPA pathway ontologies were 
expanded to identify constituents differentially expressed in pup microglia cultures from 
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Figure 35 cont.  maternal Paraquat exposure.  A) p53 signaling, p-value: 1.12 x 10-5; B) 
GADD45 signaling, p-value:  3.24 x 10-3; C) ATM signaling, p-value:  8.91 x 10-3, D) 
Protein ubiquination pathway, p-value:  8.32 x 10-4 and E) eIF2 signaling, p-value:  1.02 
x 10-7.  Pathways and gene constituents indicate a general decrease in expression of DNA 





Figure 36.  Several cell proliferation and apoptosis pathways and genes are 
dysregulated in Paraquat exposed microglia cultures.  Selected IPA pathway  
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Figure 36 cont.  ontologies were expanded to identify constituents differentially 
expressed in pup microglia cultures from maternal Paraquat exposure.  A) mTOR 
signaling, p-value: 3.63 x 10-3; B) AMPK signaling, p-value:  3.39 x 10-3; C) Molecular 
mechanisms in cancer, p-value:  3.80 x 10-2, D) Hereditary breast cancer signaling, p-
value:  2.00 x 10-3 and E) Nitric oxide signaling in the cardiovascular system, p-value:  
9.55 x 10-3.  Pathways and gene constituents indicate dysregulated proliferation and cell 





Figure 37.  In utero Paraquat exposure alters RNA splicing in astrocyte and 
microglia cultures.   Paired end RNA sequencing data was subjected to Multivariate 
Analysis for Transcript Splicing for A) astrocyte and B) microglia cultures.  Data are 
represented as junction counts only and junction counts with reads on target, which 
indicate read events that span the junction (junction counts only) and read events which 
span the junction and additionally are inferred from reads on exons involved in 
alternative splicing events (junction counts with reads on target).  Astrocyte cultures 
exhibited fewer alternative splicing events than that of microglia cultures, with most 
alternative splicing events being skipped exons.  Microglia also exhibit mostly skipped 
exon events.  Each culture type also has alternative splicing events in each event 
category.  SE:  Skipped Exon; MXE:  Mutually Exclusive Exons; A5SS:  Alternative 5’ 





Figure 38.  As an example, tensin 1 in astrocytes is alternatively spliced in in utero 
Paraquat exposure.  Sashimi plots of tensin 1 gene for astrocyte culture alternative 
splicing data.  A) Junction reads only; B) Junction reads with on target reads of tensin 1 
in astrocyte cultures show cultures from maternal Paraquat exposure have preference for 
longer transcript of tensin 1.  Some samples in control show preferential selection for 





We set out to establish an early development environmental toxicant model to 
evaluate if a window of opportunity exists for epigenetic remodeling events that may 
drive future disease events.  Our data reflects many of the technical difficulties in 
establishing such a model.  We found that primary cells can have changes in DNA 
methylation through long term culture.  These culture induced changes are important to 
the field as previous investigations have only noted changes in pluripotent cells [267, 
269, 270, 284].  Identifying these changes may offer insight into the in vitro fertilization 
and therapeutic cell expansion fields.  We propose future investigations that may help to 
identify how these changes occur.   
We also report that different cells respond differently to an environmental 
toxicant in both in vitro and in vivo models. While we were only able to test two 
parameters in our in vitro models, we were able to note differences dependent on cell 
type.  This was corroborated in the in vivo model as two distinct cell types had unique 
gene expression profiles in response to Paraquat exposure even though both cell types 
came from the same animal.  Differential cell response to toxicants is important to 
understand when evaluating pharmacological effects; the heterogeneous population needs 
to be considered in understanding specific mechanisms.  We also report that an 
immortalized cell line has a more robust response to a toxicant than the primary 
counterpart.  This highlights the importance of studying primary cell cultures.  Our work 
lays the groundwork for future studies evaluating the effect of toxicants in brain cells and 
continued work in evaluating Paraquat in primary cell types. 
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Finally we report significant and persistent changes in gene expression of neonate 
glial cells.  Despite the absence of Paraquat in the tissues at the time of measurement, 
there are subtle changes that we interpret to have a potential impact driving future 
oncogenic events.  We also begin to address the effect of a toxicant after differentiation 
from a pluripotent state.  This work may help to define the boundaries of the window of 
opportunity for epigenetic remodeling if identifying a senescent or apoptotic cell 
population.  This is important in the field of oncology in identifying from which 
population of cells the low mutational load cancers arise.  This may also help to define 
the idea that environmental toxicants play a significant role in the development of 
disease.  We can also begin to identify that segments of the population are at risk of 
neural disease due to environmental exposure.   
We highlighted that primary cells undergo epigenetic changes induced by culture.  
We also presented data that astrocyte cultures respond differently to Paraquat exposure in 
as little as on culture event.  Some of the in vitro work was based upon cultures that had 
been passaged at least once which should be repeated with fresh primary cultures to 
confirm the data we have found.  We reported a batch effect in gene expression of in vitro 
astrocyte cultures, which could be due to different culture states, and repeating RNA 
sequencing would be of significant value if the culturing conditions can be controlled 
sufficiently.  Additionally this data should be sequenced paired-end to evaluate 
alternative splicing events in a differentiated cell type.   
We also reported differences in the two in vivo Paraquat exposure experiments.  
We outlined the differences previously, but the underrepresentation of ages in Paraquat 
treated animals prevents us from fully evaluating the first study.  Having controlled for 
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the age of the animals in the second study prevented a repeat of skewed representation, 
but also prevented us from evaluating differences in age during pregnancy.  We were also 
unable to evaluate the differences in littermates during maternal Paraquat exposure.  The 
finding that littermates are not affected equally may be of significance becoming a 
missed opportunity.  Additionally, by pooling the pups and not sexing the animals we 
also missed an opportunity to identify gender differences in our study.  Finally having 
only just established the model in our lab, we were unable to identify how much we could 
assess in a single experiment.  One critical piece of information that would direct future 
epigenetic studies is the accessibility of chromatin.  With this data we would be able to 
define regions of interest and identify epigenetic targets that may play a significant role in 
that region.   
Future Directions 
Our study has yielded significant results but leaves room for further investigation.  
We have highlighted future directions in each individual model, but there are additional 
directions we could assess.  One key factor that we may have identified in our model 
system is that maternal age in pregnancy may play a significant role in the impact of 
toxicant exposure.  Studying the difference in maternal age in addition to environmental 
exposure may identify potential risk factors in developing a cancerous or 
neurodegenerative phenotype.  Developed countries are facing advanced maternal age in 
bearing children, studying the effect in maternal age will have significant societal reward 
[391, 392].   
Another area that we did not address were other tissues.  We proposed that the 
astrocyte cultures may be more protected by the blood brain barrier thereby limiting their 
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exposure compared to microglia which may play a role in the differential gene 
expression.  However, if this is true we might expect to find similar gene expression 
patterns in other unprotected cell types.  We did not evaluate other tissues or cell types to 
this effect.  Understanding the dichotomy between the unique tissue types may further 
advance our understanding of the impact of environmental toxicants in disease.  This 
would also help to define the idea that different cells respond differently and what the 
difference in the cells is that defines their response.   
The final future direction we will address here is the impact of additional 
toxicants in developmental exposure.  Paraquat is not unique in its ability to inhibit 
mitochondrial function nor to produce reactive oxygen species.  Our in vitro data indicate 
that at low concentrations, Paraquat had little impact on mitochondrial function and 
reactive oxygen species response was undetectable.  By expanding the toxicant library we 
may be able to define the biological process that is most impacted by environmental 
toxicant exposure providing an avenue for future therapeutics.  Addressing different 
toxicants may also define if each toxicant is unique in its own right or if there are classes 
of toxicants that can drive epigenetic remodeling events.   
In using Paraquat as a model toxicant we offer a glimpse into developmental 
changes that have potential to drive future disease states.  We also offer a straightforward 
model to address unanswered questions in environmental exposures and potentially 
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